April 2–6, 2008 Gaylord Texan, Dallas, Texas Spring `08 Clinical

Transcription

Spring ’08 Clinical Meetings
April 2–6, 2008
Gaylord Texan, Dallas, Texas
A[[fkfm_jÂ;;F JC
<_dZekjêmj^[DWj_edWbA_Zd[o<ekdZWj_edÊi
A_Zd[o;Whbo;lWbkWj_edFhe]hWcYedj_dk[i
je[nfWdZ$$$
@::E^hi]ZaVg\ZhiYZiZXi^dcegd\gVb^ci]Z
JcîZYHiViZh[dg`^YcZnY^hZVhZ#
BdgZi]Vc&%%!%%%eVgi^XêVcih
@::E^h[daadl^c\"jelî]eVgi^XêVcihdkZg
VcZmiZcYZYeZg^dYd[i^bZ#
<adWVaZmeVch^dcd[@::E^hjcYZglVn#
B[Whdceh[WXekjA;;F
m^_b[oekWh[Wjj^[Yed\[h[dY[$
&# K^hijhVii]ZC@;Wddi],&.[dgi]ZaViZhi^c[dgbVi^dc#
'#?d^cjh[dgV[gZZ8B:7gZV`[VhiHnbedh^jb^c<gVeZk^cZ8
dcHVijgYVn!6egâ*!'%%-[gdb+/%%VbÄ-/%%Vb/
Æ8]gdc^X@^YcZn9^hZVhZ>ciZgkZci^dch/
>begdk^c\8@9VcY8K9DjiXdbZh#Ç
(# K^Zli]ZaViZhi@::EYViVWZ^c\egZhZciZY^c&&edhiZgh
Yjg^c\i]ZedhiZghZhh^dc#Add`[dgedhiZgcjbWZgh/)*!*(!
+)!,*!,,!,-!'%*!',%!'-'!'-(VcY'-.#
NdjXVcVahdk^hîa[[fedb_d[$eh][dgi]ZaViZhi@::E^c[dgbVi^dcVcYVhX]ZYjaZd[
hXgZZc^c\hVXgdhhi]ZJ#H#
www.keeponline.org
'%%-CVi^dcVa@^YcZn;djcYVi^dc!>cX#6aag^\]ihgZhZgkZY#%'"(*"),(6
Your Partner in
Transplantation
At Astellas, we are committed to uncovering
new possibilities in immunology through
broad scale research aimed at new product
development.
Through the transference and sharing of
scientific knowledge, we work in partnership
with healthcare professionals like you to
positively impact patient care.
Our goal remains clear:
Enhance the practice of transplantation.
It is our passion and our priority.
© 2007 Astellas Pharma US, Inc. PRG00266-MK-R0-12/06
Quality Dialysis
Experience dialysis in the comfort of your home!
QUALITY DIALYSIS has been providing Staff-Assisted
Home Dialysis services to Texas for over thirteen years.
Founded in 1993, the founder’s goal and mission has always
been to educate patients and their families about chronic kidney
disease, and provide professional, quality services to clients in
the home. Our wellness team consist of experienced social
workers, renal dietitians, registered nurses, and bio-medical
technicians under the direct supervision of Nephrologist.
Quality Dialysis offers home dialysis services
in the Central, Southwestern and Northeastern regions of Texas.
We consider it our privilege and your choice to provide home
dialysis services to you.
890 East Travis
La Grange, TX 78945
979-968-3800
4007 Greenbriar Drive, Suite E
Stafford, TX 77477
281-491-4009
1034 Shady Trail, Suite 112
Dallas, TX 75229
214-295-7344
www.gethomedialysis.com
By Author
Cindy Barclay
That Damn Dialysis
A Must Read !!!
This book answers a myriad of questions about chronic
kidney disease and dialysis. The answers are expertly woven
into the humerous heartfelt journey of 50 year old Cledus B.
Washington. If you have questions, this book has answers !
Visit Booth #636
www.claybarpublishing.com
www.gethomedialysis.com 1-888-491-9533
Association of Mineral Metabolism,
Vitamin D Therapy, and Calcimimetics on
Chronic Kidney Disease Patient Survival
A CME-CERTIFIED SYMPOSIUM at the NKF 2008 Spring Clinical Meetings
Wednesday, April 2, 2008
7:30 PM – 9:30 PM
Gaylord Texan
Dallas, Texas
Grapevine Ballroom D
PROGRAM OVERVIEW
FACULTY
This symposium will provide an overview of recent evidence on altered mineral
metabolism occurring in chronic kidney disease and therapeutic regimens that
restore mineral homeostasis in chronic kidney disease patients. The session will
also discuss the impact of altered mineral metabolism on cardiovascular risk
factors and maximizing therapy to improve survival. Current information will
focus on important differences between nonselective and selective vitamin D
receptor activator therapy, that not only include suppression of parathyroid
hormone and regulation of calcium balance, but also examine nonclassical
actions of vitamin D receptor activators and how they impact cardiovascular and
bone health. In addition, the session will provide an understanding of
calcimimetic use in treating secondary hyperparathyroidism in chronic kidney
disease patients, and the impact of calcimimetics on risk factors and survival.
LEARNING OBJECTIVES
Myles Wolf, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School; Renal Unit
Massachusetts General Hospital
Boston, Massachusetts
Stuart Sprague, DO
Chief, Division of Nephrology and
Hypertension, Evanston
Northwestern Healthcare
Professor of Medicine
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Daniel Coyne, MD
Division of Renal Diseases
Director, Hemodialysis
Chromalloy American Kidney Center
Director, Outpatient Renal Clinics
Co-Director, Renal Fellowship
Training Program
Washington University
School of Medicine
Division of Renal Diseases
St. Louis, Missouri
• Understand the impact of disordered mineral metabolism on risk factors and
survival in chronic kidney disease patients.
• Discuss the differences between nonselective and selective vitamin D receptor
activators and how their use impact survival in chronic kidney disease
patients.
AGENDA
• Review the mechanism of action of calcimimetic therapy, its role in therapy of
secondary hyperparathyroidism, and long-term benefits on risk factors and
survival in chronic kidney disease.
TARGET AUDIENCE: This CME-certified symposium is directed towards
nephrologists and clinicians who treat patients with chronic kidney disease.
8:00 PM Welcome and Introduction
HOW YOU WILL LEARN: This CME activity will be a live symposium consisting
of lectures with panel audience participation
8:05 PM “Associations of Mineral Metabolism with Patient Survival”
Daniel Coyne, MD
ACCREDITATION STATEMENT: The National Kidney Foundation is accredited
by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
8:30 PM “Impact of Vitamin D therapy on Patient Survival”
DESIGNATION STATEMENT: The National Kidney Foundation designates this
educational activity for a maximum of 1.5 AMA PRA Category 1 Credit TM.
Physicians should only claim credit commensurate with the extent of their
participation in the activity.
The National Kidney Foundation is an approved provider of continuing nursing
education by the New York State Nurses Association, which is accredited as an
approver of continuing nursing education by the American Nurses Credentialing
Center’s Commission on Accreditation.
This program is pending approval with the American Academy of Nurse Practitioners.
DECLARATION OF DISCLOSURE: It is the policy of the National Kidney
Foundation to ensure balance, independence, objectivity, and scientific rigor in
all CME activities. Faculty participating in this activity are required to disclose
to the audience any relationship they may have with the commercial supporters
of this activity or with any other commercial organizations whose products or
devices may be mentioned in their presentations.
UNLABELED / INVESTIGATIONAL USE DECLARATION: During their
presentations, faculty may discuss an unlabeled use or an investigational use
not approved for a commercial product. Each faculty member is required to
disclose this information to the audience when referring to an unlabeled or
investigational use.
7:30 PM Registration
8:55 PM “Does Direct Modulation of the Calcium Sensor Affect
Patient Survival?”
Stuart Sprague, DO
9:20 PM Q&A / Discussion
REGISTRATION: You must be registered for the NKF 2008 Spring Clinical
Meetings to attend this symposia and receive credit.
DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do not
recommend the use of any pharmaceutical, diagnostic test, or device outside of the
labeled indications as approved by the FDA. Please refer to the official prescribing
information for each product for approved indications, contraindications, and
warnings.
Supported by an unrestricted
medical educational
grant from Abbott.
Sponsored by the
National Kidney
Foundation
A Symposium and Breakfast during the
National Kidney Foundation 2008 Spring Clinical Meetings
The Impact of Glycemic Control in Patients
with Diabetes and Chronic Kidney Disease
Thursday, April 3, 2008 | 6:00 AM – 8:00 AM | The Gaylord Texan | Grapevine Ballroom B | Grapevine, Texas
Program Purpose
Diabetes is currently the fifth leading cause of death in the United States
and is associated with significant morbidity due to associated
macrovascular and microvascular complications, particularly chronic
kidney disease (CKD). In both diabetes and CKD there is evidence that
identifying individuals early in the disease continuum can reduce
morbidity and mortality. Yet experts estimate that fewer than 1 in 4
patients with diabetes receive the minimum annual testing in preventive
care for blood glucose and lipid levels. Management of diabetes in
patients with CKD may be complicated as many medications may require
dosage adjustment or may be contraindicated, thus it is essential to have
understanding of the most effective treatment approaches for achieving
tight glycemic control in these patients. Patient compliance is essential
for an impact on patient outcome to be realized. This symposium will
address considerations in managing patients with CKD and diabetes.
Specifically the impact of strict glycemic control on outcome and
strategies for enhancing patient compliance with these complicated
medical regimens will be discussed.
Program Objectives
At the conclusion of this program participants should:
• Describe optimal glycemic targets and the impact of glycemic control
on outcomes in different stages of CKD
• Develop an optimal clinical management plan of diabetes in patients
with different stages of CKD
• Simplify the complex medication regimens in patients with CKD and
diabetes in order to improve compliance
Symposium Registration
• Pre-registration for this symposium is not required.
We recommend arriving at the symposium early. Seating is limited and
will be available on a first come, first serve basis.
• You must be registered for the NKF 2008 Spring Clinical Meetings to
attend this symposium and
receive credit.
Agenda
6:00 AM Registration and Breakfast
6:30 AM Welcome and Introduction
Martin J. Abrahamson, MD
Medical Director and Senior Vice President
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA
6:40 AM Glycemic Control in Patients with CKD
Mark S. Roberts, MD, MPP
Professor of Medicine, Health Policy and Management
and Industrial Engineering
Chief, Section of Decision Sciences and Clinical Systems Modeling
Department of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA
7:00 AM How Low Should You Go?
7:20 AM When and How to Use Insulin in Patients with
Chronic Renal Failure
Arturo R. Rolla, MD
Endocrinologist, Beth Israel Deaconess Medical Center
Associate Clinical Professor of Medicine
Harvard Medical School and Tufts University School of Medicine
Boston, MA
7:40 AM Case Studies / Panel Discussion / Question and Answer Session
All Faculty
8:00 AM Closing Remarks
Target Audience
Nephrology professionals
Educational Method
This CME activity will be a live symposium consisting of lectures and panel
discussion with audience participation.
Accreditation
The National Kidney Foundation is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for
physicians.
Designation
The National Kidney Foundation designates this educational activity for a
maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only
claim credit commensurate with the extent of their participation in the activity.
education by the New York State Nurses Association, which is accredited as
an approver of continuing nursing education by the American Nurses
Credentialing Center's Commission on Accreditation.
This program is pending approval with the American Academy of Nurse
Practitioners.
Declaration of Disclosure
It is the policy of the National Kidney Foundation to ensure balance,
independence, objectivity, and scientific rigor in all CME activities. Faculty
participating in this activity are required to disclose to the audience any
relationship that they may have with the commercial supporters of this activity
or with any other commercial organizations whose products or devices may
be mentioned in their presentations.
Unlabeled/Investigational Use Declaration
During their presentations, faculty may discuss an unlabeled use or an
investigational use not approved for a commercial product. Each faculty
member is required to disclose this information to the audience when
referring to an unlabeled or investigational use.
Disclaimer
The faculty, National Kidney Foundation, and Novo Nordisk do not recommend
the use of any pharmaceutical, diagnostic test, or device outside of the
labeled indications as approved by the FDA. Please refer to the official
prescribing information for each product for approved indications,
contraindications, and warnings.
Supported by an
educational grant from
Sponsored by the National Kidney Foundation
A symposium to be conducted at the National Kidney Foundation
2008 Spring Clinical Meetings
Trends and Challenges in
CKD Progression and Management
in Older Adults
April 3, 2008
6:00 am – 6:30 am: Breakfast & Registration
6:30 am – 8:00 am: Symposium
Grapevine Ballroom Dt(BZMPSE5FYBOt%BMMBT5FYBT
Target Audience
Nephrology professionals
How Will You Learn?
This CME activity will be a live symposium consisting of three lectures and a question and
answer session.
Activity Purpose
This symposium will educate nephrology professionals and PCPs on proper management of
chronic kidney disease (CKD) and will focus on raising awareness of social and medical issues
related to CKD in elderly patients.
Learning Objectives
At the conclusion of the program, participants should:
t 3FDPHOJ[FUIFIJHIQSFWBMFODFBOEJNQBDUPG$,%JOPMEFSBEVMUT
t 6OEFSTUBOEIPXQSPHSFTTJPOPG$,%WBSJFTXJUIBHF
t 6OEFSTUBOEUIFSPMFBOEMJNJUBUJPOTPGHVJEFMJOFTSFMBUJWFUP$,%JOPMEFSBEVMUT
6:30 – 6:35 am Welcome and Introductions
Ann O’Hare, MD – Program Chair
VA Puget Sound Health Care System, Seattle, Washington
6:35 – 7:00 am Natural History and Epidemiology of CKD in the Elderly
Brenda R. Hemmelgarn, MD
6OJWFSTJUZPG$BMHBSZ'PPUIJMMT.FEJDBM$FOUSF$BMHBSZ"MCFSUB$BOBEB
7:00 – 7:25 am Assessment of Kidney Function in the Elderly
Lesley A. Stevens, MD, MS, FRCP
Tufts-New England Medical Center, Boston, Massachusetts
7:25 – 7:50 am Challenges of Managing CKD in the Elderly
Ann O’Hare, MD
VA Puget Sound Health Care System, Seattle, Washington
7:50 – 8:00 am Questions and Answers
Declaration of Disclosure: It is the policy of the
/BUJPOBM,JEOFZ'PVOEBUJPOUPFOTVSFCBMBODF
independence, objectivity, and scientific rigor in
BMM$.&BDUJWJUJFT'BDVMUZQBSUJDJQBUJOHJOUIJT
activity are required to disclose to the audience any
relationship they may have with the commercial
supporters of this activity or with any other
DPNNFSDJBMPSHBOJ[BUJPOTXIPTFQSPEVDUTPSEFWJDFT
may be mentioned in their presentations.
Unlabeled/Investigational Use Declaration:
During their presentations, faculty may discuss an
unlabeled use or an investigational use not approved
for a commercial product. Each faculty member is
required to disclose this information to the audience
when referring to an unlabeled or investigational use.
Accreditation Statement: The National Kidney
'PVOEBUJPOJTBDDSFEJUFECZUIF"DDSFEJUBUJPO
Council for Continuing Medical Education to provide
Designation Statement: The National Kidney
'PVOEBUJPOEFTJHOBUFTUIJTFEVDBUJPOBMBDUJWJUZGPS
a maximum of 1.5 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate
with the extent of their participation in the activity.
5IF/BUJPOBM,JEOFZ'PVOEBUJPOJTBOBQQSPWFE
provider of continuing nursing education by the New
York State Nurses Association, which is accredited as
an approver of continuing nursing education by the
American Nurses Credentialing Centers Commission
on Accreditation.
This program is pending approval with the American
Academy of Nurse Practitioners.
:PVNVTUCFSFHJTUFSFEGPSUIF/,'4QSJOH$MJOJDBM.FFUJOHT
to attend this symposium and receive credit.
Sponsored by the National Kidney
'PVOEBUJPO
Supported by an educational grant from
0SUIP#JPUFDI1SPEVDUT-1
Disclaimer: The faculty, National Kidney
'PVOEBUJPOBOE0SUIP#JPUFDI1SPEVDUT-1EPOPU
recommend the use of any pharmaceutical, diagnostic
test, or device outside of the labeled indications as
BQQSPWFECZUIF'%"1MFBTFSFGFSUPUIFPGGJDJBM
prescribing information for each product for approved
indications, contraindications, and warnings.
Please note that spouses, guests, or children are not
permitted to attend. This is an educational program
for healthcare professionals only.
National Kidney Foundation (NKF) 2008 Spring Clinical Meetings
Dietary Phosphorus and Outcomes in Patients With CKD
Thursday, April 3, 2008
12:00
12:30
PM
PM
– 12:30 PM
– 2:00 PM
Registration and Lunch
Symposium
Gaylord Texan Resort and Convention Center
Grapevine Ballroom C
1501 Gaylord Trail
Grapevine, Texas
EDUCATIONAL OBJECTIVES
ACTIVITY PURPOSE
The purpose of this symposium is to educate nephrologists, fellows,
residents, physician assistants, nurse practitioners, nephrology nurses and
technicians, and renal and clinical dietitians interested in learning about safe
and effective control of phosphorus levels in patients with CKD.
HOW YOU WILL LEARN
The symposium is held in a panel discussion format, incorporating
case-based presentations, didactic lectures, and audience participation using
the audience response system (ARS).
TARGET AUDIENCE
This program is designed for nephrologists, fellows, residents, physician
assistants, nurse practitioners, nephrology nurses and technicians, and renal
and clinical dietitians.
Upon completion of this symposium, participants will be able to:
• Apply dietary restriction techniques to control phosphorus (P) levels in patients with
chronic kidney disease (CKD)
• Evaluate the efficacy of dietary P control and its effect on survival
• Assess the risk of malnutrition associated with dietary P control
• Appropriately implement the use of phosphate binders in controlling hyperphosphatemia
in patients with CKD
PROGRAM AGENDA
12:00
PM
Registration and Lunch
12:30
PM
Welcome and Introduction
Moderator and Program Chair
Chief, Division of Nephrology and
Hypertension
Evanston Northwestern Healthcare
Feinberg School of Medicine
Chicago, Illinois
ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
The National Kidney Foundation is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for
physicians.
The National Kidney Foundation designates this educational activity for a
maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim
credit commensurate with the extent of their participation in the activity.
12:35 PM
Should Phosphorus Be Controlled by
Dietary Restriction or Phosphate Binders
in Patients With CKD?
1:00
PRO: Dietary Phosphorus Control
Improves Survival
PM
This program is pending approval by the American Academy of Nurse
Practitioners.
The National Kidney Foundation is a Continuing Professional
Education (CPE) Accredited Provider with the Commission on Dietetic
Registration (CDR). Registered dietitians (RDs) and dietetic
technicians, registered (DTRs) will receive 1.5 continuing professional
education units (CPEUs) for completion of this program/material.
• Effectiveness of dietary control
• Association of phosphorus with survival
1:25
PM
independence, objectivity, and scientific rigor in all CME activities. Faculty
participating in this activity are required to disclose to the audience any
relationship they may have with the commercial supporters of this activity
or with any other commercial organizations whose products or devices may
CON: Dietary Phosphorus Control
Increases Survival
• Limitations of dietary control
• Effectiveness of phosphate binders
DECLARATION OF DISCLOSURE
UNLABELED/INVESTIGATIONAL USE DECLARATION
Stuart M. Sprague, DO
1:50
PM
Panel Discussion/Q&A
2:00
PM
Adjourn
Daniel W. Coyne, MD
Renal Division
Washington University School of Medicine
St. Louis, Missouri
Kamyar Kalantar-Zadeh, MD, PhD, MPH
Associate Professor of Medicine and
Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Director, Dialysis Expansion Program
and Epidemiology
Harbor–UCLA Medical Center
Los Angeles, California
DISCLAIMER
The faculty, National Kidney Foundation, and Shire Pharmaceuticals do not
recommend the use of any pharmaceutical, diagnostic test, or device outside
of the labeled indications as approved by the FDA. Please refer to the official
prescribing information for each product for approved indications, contraindications, and warnings.
Sponsored by the National Kidney Foundation.
Supported by an unrestricted educational
grant from Shire Pharmaceuticals.
REGISTRATION
To ensure participation, preregistration is strongly recommended by March, 31, 2008.
To register for this symposium, please call the Registration Center at 1-866-890-2945.
On-site registration will begin at 12:00 PM in Grapevine Ballroom C, Gaylord Texan
Resort and Convention Center, Grapevine, Texas. Seating priority will be given to
preregistered attendees; however, walk-ins are encouraged and will be admitted on
a first-come, first-served basis, as space permits.
You must be registered for the NKF 2008 Spring Clinical Meetings to attend this
symposium and receive credit.
Evidence-Based Review of the Management of Hyperphosphatemia
and its Pharmacoeconomic Impact on Patients with Stage 5 CKD:
New Perspectives for Optimal Outcomes in 2008
Held During the National Kidney Foundation 2008 Spring Clinical Meetings
Thursday, April 3, 2008, 7:30 p.m. - 9:30 p.m.
The Gaylord Texan | Grapevine Ballroom C | Grapevine, Texas
PROGRAM PURPOSE
Hyperphosphatemia has been implicated in a myriad of negative consequences including the pathogenesis of
cardiovascular calcification and is independently associated with increased mortality in patients with stage 5 chronic
kidney disease (CKD). Therefore adequate control of phosphate is essential in these patients; however the most
appropriate therapy has been a matter of much debate. This symposium will review recently published studies evaluating
phosphate binder and its impact on efficacy, patient outcomes, and pharmacoeconomics, especially as it relates to
treatment selection and the attainment of KDOQI guidelines for mineral metabolism disorders in the United States.
TARGET AUDIENCE
This program has been designed to meet the learning
objectives of Physicians, Researchers, Fellows,
Residents, and may be beneficial to nurses and
dietitians.
PROGRAM OBJECTIVES
At the conclusion of the program, participants
will be able to:
• Discuss the epidemiology of hyperphosphatemia in
patients with stage 5 CKD
• Summarize the salient findings from recent clinical
trials that investigated the outcomes, including
mortality rates, among patients with stage 5 CKD
who were treated with various phosphate binders
• Understand the recent pharmacoeconomic data for
phosphate binder selection and the impact of
applying the 2003 KDOQI guidelines for bone
metabolism and disease in the United States
Educational Method
This CME activity will be a live symposium consisting of lectures and panel discussion with
audience participation.
Accreditation
The National Kidney Foundation is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
Designation
The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA
PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent
of their participation in the activity.
The National Kidney Foundation is an approved provider of continuing nursing education by the
New York State Nurses Association, which is accredited as an approver of continuing nursing
education by the American Nurses Credentialing Center's Commission on Accreditation.
It is the policy of the National Kidney Foundation to ensure balance, independence, objectivity,
and scientific rigor in all CME activities. Faculty participating in this activity are required to
disclose to the audience any relationship that they may have with the commercial supporters of
this activity or with any other commercial organizations whose products or devices may be
mentioned in their presentations.
During their presentations, faculty may discuss an unlabeled use or an investigational use not
approved for a commercial product. Each faculty member is required to disclose this
information to the audience when referring to an unlabeled or investigational use.
Disclaimer
The faculty, National Kidney Foundation, and Fresenius Medical Care – North America (FMC-NA)
do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the
labeled indications as approved by the FDA. Please refer to the official prescribing information
for each product for approved indications, contraindications, and warnings.
AGENDA AND SPEAKERS:
7:30 p.m. Registration and Dinner
8:00 p.m. Introduction by Program Moderator
Vincent W. Dennis, M.D.
Senior Medical Adviser
Ambulatory Services of America
Brentwood, Tennessee
8:10 p.m. A Review of Recent Clinical Studies of Patients
with Stage 5 CKD: Impact on Clinical Practice
Lynda Szczech, M.D.
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina
8:40 p.m. Phosphate Binder Choice in the Treatment of
Patients with Stage 5 CKD: Health-Economic
Considerations
Wolfgang C. Winkelmayer, M.D., ScD
Cambridge Brigham and Women's Hospital
9:10 p.m. Question and Answer Session
Faculty
9:30 p.m. Closing Remarks
Vincent W. Dennis, M.D.
SYMPOSIUM REGISTRATION
• Pre-registration for this symposium is not required.
We recommend arriving at the symposium early. Seating is limited
and will be available on a first come, first serve basis.
• You must be registered for the NKF 2008 Spring Clinical Meetings
to attend this symposium and receive credit.
Friday
April 4, 2008
Assessing the Role
of Proteinuria in the
Progression of
Chronic Kidney Disease
Gaylord Texan
1501 Gaylord Trail
Grapevine, Texas
Breakfast / Live
Clinical Experts
Roundtable Program: 6:00
AM
Q & A:
7:45
AM
8:00
AM
......................
Adjourn:
...................
ACTIVITY PURPOSE
PANELISTS
To familiarize attendees with the availability of published guidelines for
the management of patients with CKD and to acquire a knowledge
base for implementing these guidelines into clinical practice. As a
result of attending this session, Healthcare First anticipates a change
in attitudes regarding the early detection and aggressive primary and
secondary prevention of disease progression in these patients.
Barry M. Brenner, MD
TARGET AUDIENCE
Daniel C. Batlle, MD
Brigham and Woman's Hospital
David G. Warnock, MD
University of Alabama Birmingham
Birmingham, Alabama
Physicians, fellows, residents, physician's assistants, nurse
practitioners, and nephrology nurses and technicians interested in or
involved with the management of CKD.
Northwestern University Medical School
Chicago, Illinois
LEARNING OBJECTIVES
The National Kidney Foundation is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing
medical education for physicians.
• Review Treatment Guidelines (JNC-7, KDOQI) as they relate to
treatment of CKD with hypertension and proteinuria
• Review the relations between urine protein excretion,
cardiovascular risk and CKD
• Review the therapeutic approaches to hypertension and
proteinuria in CKD
• Develop a conceptual framework for stopping the progression
of CKD: treatment goals for hypertension and proteinuria
AGENDA
• Slide Presentation One – Proteinuria and Progression:
Primary and Secondary Prevention
- Barry M. Brenner, MD
• Slide Presentation Two – Fabry Nephropathy; Proteinuria
Without Hypertension: Targets for Therapy
- David G. Warnock, MD
• Slide Presentation Three – Progression From
Normoalbuminuria to Overt Proteinuria and CKD in Type I
Diabetes: Role of Nocturnal Hypertension
- Daniel C. Batlle, MD
HOW YOU WILL LEARN
This CME activity will be a live symposia consisting of presentations,
panel exchange, and audience participation.
ACCREDITATION
DESIGNATION STATEMENT
The National Kidney Foundation designates this educational activity for
a maximum of 1.5 AMA PRA Category 1 Credits.TM Physicians should
only claim credit commensurate with the extent of their participation in
the activity.
The National Kidney Foundation is an approved provider of continuing
nursing education by the New York State Nurses Association, which is
accredited as an approver of continuing nursing education by the
American Nurses Credentialing Center's Commission on Accreditation.
This program is pending approval with the American Academy of Nurse
Practitioners.
DECLARATION OF DISCLOSURE
independence, objectivity, and scientific rigor in all CME activities.
Faculty participating in this activity are required to disclose to the
audience any relationship they may have with the commercial
supporters of this activity or with any other commercial organizations
whose products or devices may be mentioned in their presentations.
UNLABELED/INVESTIGATIONAL USE DECLARATION
investigational use not approved for a commercial product. Each
faculty member is required to disclose this information to the audience
when referring to an unlabeled or investigational use.
DISCLAIMER
Sponsored by the
National Kidney Foundation.
The faculty, National Kidney Foundation, and Genzyme do not
recommend the use of any pharmaceutical, diagnostic test, or device
outside of the labeled indications as approved by the FDA. Please refer
to the official prescribing information for each product for approved
The National Kidney Foundation and Healthcare First reserve the right
to cancel or modify the activity content, faculty, and activities, if
necessary.
You must be registered for the NKF 2008 Spring Clinical Meetings to
attend this symposia and receive credit.
Supported by an unrestricted medical education grant from
A dinner symposium to be held at the
Friday, April 4, 2008
7:00 PM – 9:00 PM
Program Agenda
Grapevine Ballroom D, Gaylord Texan
Dallas, Texas
7:30 pm – 7:45 pm Chair’s Introduction
7:00 pm – 7:30 pm Registration and Dinner
Mark J. Sarnak, MD, MS
7:45 pm – 8:05 pm Sudden Cardiac Death in Pre-dialysis CKD Patients and
in Patients Undergoing Dialysis
Charles A. Herzog, MD
Professor of Medicine, University of Minnesota
Director, Cardiovascular Special Studies Center
United States Renal Data System
Director, Cardiac Ultrasound Lab, HCMC
8:05 pm – 8:25 pm Calcium and Phosphorus as Cardiovascular Risk Factors
David A. Bushinsky, MD
University of Rochester School of Medicine and Dentistry
Rochester, NY
8:25 pm – 8:45 pm Coronary Artery Disease: Screening and Therapy
Mark J. Sarnak, MD, MS
Tufts University School of Medicine
Boston, MA
8:45 pm – 9:00 pm Questions and Answers
Pre-dialysis and Dialysis
Accreditation Statement(s)
The National Kidney Foundation is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.
The National Kidney Foundation designates
this educational activity for a maximum of 1.5
AMA PRA Category 1 Credit(s)TM. Physicians
should only claim credit commensurate with
the extent of their participation in the activity.
The National Kidney Foundation is an
approved provider of continuing nursing
education by the New York State Nurses
Association, which is accredited as an
approver of continuing nursing education by
the American Nurses Credentialing Centers
Commission on Accreditation.
This program is pending approval with the
American Academy of Nurse Practitioners.
You must be registered for the NKF 2008
Spring Clinical Meetings to attend this
Disclaimer:The faculty, NKF, and Genzyme
do not recommend the use of any
pharmaceutical, diagnostic test, or device
outside of the labeled indications as
approved by the FDA. Please refer to the
official prescribing information for each
product for approved indications,
contraindications, and warnings.
Declaration of Disclosure: It is the policy
of the National Kidney Foundation to ensure
balance, independence, objectivity, and
scientific rigor in all CME activities. Faculty
participating in this activity are required to
disclose to the audience any relationship they
may have with the commercial supporters of
this activity or with any other commercial
organizations whose products or devices may
Unlabeled/Investigational Use
Declaration: During their presentations,
faculty may discuss an unlabeled use or an
investigational use not approved for a
commercial product. Each faculty member is
required to disclose this information to the
audience when referring to an unlabeled or
Activity Purpose
The purpose of this symposium is to examine the link between elevated phosphorus and calcium levels
and the high incidence of cardiovascular (CV) disorders in patients with chronic kidney disease (CKD)
and to discuss how appropriate screening and therapy can help minimize the impact of heart disease in
these patients. CV disorders are a major cause of morbidity and mortality in patients with CKD, and
sudden death is the leading cause of CV mortality in dialysis patients. Early intervention is important to
prolong survival in patients on hemodialysis. Elevated serum phosphorus and calcium concentrations
are associated with increased risk of CV events and death in patients with end-stage renal disease.
Recently published data comparing mortality among CKD patients treated with phosphate binders is of
great interest to practicing nephrologists and renal dietitians. In addition, recent evidence suggests that
routine screening of new dialysis patients for vascular calcification may allow early identification of
those at risk for progressive coronary artery disease (CAD) who would benefit from non-calcium
containing phosphate binders as suggested by the KDOQI guidelines.
This symposium will also explore such issues as the epidemiology of sudden death in dialysis patients,
how different phosphate binders may affect mortality, the proper role of screening for CAD in
asymptomatic CKD patients, and the most appropriate therapy for established CAD in dialysis patients.
Target Audience
Physicians, pharmacists, physician assistants, nephrology nurses, nurse practitioners, dietitians,
nephrology social workers.
How You Will Learn
This CME activity will be a live symposium consisting of lectures with a question-and-answer
session for the audiences.
Learning Objectives
• Learn about the epidemiology of sudden death and possible interventions in dialysis patients
• Learn about the cardiovascular effects of calcium and phosphorus
• Learn about the controversies on coronary artery screening and therapy in CKD
Supported by an educational grant from Genzyme
• Learn about the controversies on peripheral vascular disease in dialysis patients
NKF 2008 SPRING CLINICAL MEETINGS
Optimal Patient Outcomes:
Identification and Treatment of Iron Deficiency
Anemia in Early Chronic Kidney Disease
Friday, April 4, 2008 7:00 PM – 9:00 PM
Gaylord Texan Resort and Convention Center
Grapevine Ballroom C
1501 Gaylord Trail
Grapevine, Texas
Educational Objectives
Activity Purpose
The purpose of this symposium is to educate nephrologists, fellows,
residents, physician assistants, nurse practitioners, nephrology nurses
and technicians, and renal and clinical dietitians interested in learning
about the identification and treatment of iron deficiency in patients
with CKD.
How You Will Learn
The symposium is held in a panel discussion format, incorporating
case-based presentations, didactic lectures, and audience participation
using the audience response system (ARS).
Target Audience
This program is designed for nephrologists, fellows, residents,
physician assistants, nurse practitioners, nephrology nurses and
technicians, and renal and clinical dietitians.
Accreditation and Credit Designation Statements
The National Kidney Foundation is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide
The National Kidney Foundation designates this educational activity for
a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only
claim credit commensurate with the extent of their participation in the
activity.
American Nurses Credentialing Center’s Commission on Accreditation.
This program is pending approval with the American Academy
of Nurse Practitioners.
Education (CPE) Accredited Provider with the Commission on
Dietetic Registration (CDR). Registered dietitians (RDs) and
dietetic technicians, registered (DTRs) will receive 1.5
continuing professional education units (CPEUs) for
completion of this program/material.
independence, objectivity, and scientific rigor in all CME activities.
Faculty participating in this activity are required to disclose to the audience any relationship they may have with the commercial supporters
of this activity or with any other commercial organizations whose
products or devices may be mentioned in their presentations.
Disclaimer
The faculty, National Kidney Foundation, and AMAG Pharmaceuticals,
Inc. do not recommend the use of any pharmaceutical, diagnostic test,
or device outside of the labeled indications as approved by the FDA.
Please refer to the official prescribing information for each product
for approved indications, contraindications, and warnings.
Upon completion of this symposium, participants will be able to:
• Discuss the prevalence of iron deficiency anemia in CKD and
associated complications
• Outline current clinical practice guidelines and examine recent clinical data
regarding patient identification, testing, and treatment goals
• Review current and future therapeutic approaches to the management of
iron deficiency anemia in CKD
Program Agenda
7:00 PM Registration and Dinner
7:30 PM Welcome and Introduction
Anatole Besarab, MD
Moderator and Program Chair
7:40 PM Prevalence and Diagnosis of Anemia in Patients With CKD
Allen R. Nissenson, MD
8:05 PM State of the Art in Treatment of Iron Deficiency Anemia:
Current and Future Directions
Ajay K. Singh, MB, MRCP
8:30 PM Case Review and Panel Discussion
Anatole Besarab, MD
8:50 PM Questions and Answers
9:00 PM
Adjourn
Registration
To ensure participation, preregistration is strongly recommended by March 31, 2008.
To register for this symposium, please call the Registration Center at 1-866-324-9148.
On-site registration will begin at 7:00 PM in Grapevine Ballroom C, Gaylord Texan
Resort and Convention Center, Grapevine, Texas. Seating priority will be given to
preregistered attendees; however, walk-ins are encouraged and will be admitted
on a first-come, first-served basis, as space permits.
You must be registered for the NKF 2008 Spring Clinical Meetings to attend this
Sponsored by the National Kidney Foundation.
Supported by an unrestricted educational
grant from AMAG Pharmaceuticals, Inc.
Exploring the Link Between
Chronic Kidney Disease and
Cardiovascular Disease
A CME-CERTIFIED SYMPOSIUM at the NKF 2008 Spring Clinical Meetings
Saturday, April 5, 2008
6:00 AM – 8:00 AM
Gaylord Texan
Dallas, Texas
PROGRAM OVERVIEW
FACULTY
This symposium examines the association of cardiovascular disease in patients
with chronic kidney disease. Recent data indicates a much higher incidence of
cardiovascular disease and mortality linked to cardiovascular risk factors
observed in chronic kidney disease patients. The session highlights current
epidemiologic data, mechanisms contributing to pathophysiological processes
and cardiovascular risk factors, and therapies that can reduce risk and improve
survival in chronic kidney disease patients. This symposium will review current
therapies for attenuating vascular calcification and bone resorption, provide
insight into classical and non-classical actions of vitamin D analogs, and
management strategies for reducing cardiovascular risk factors associated with
chronic kidney disease.
Louisa Tammy Ho, MD
Division of Nephrology and
Hypertension
Evanston, Illinois
Ravi I. Thadhani, MD, MPH
Director of Clinical Research in
Nephrology
Kamyar Kalantar-Zadeh,MD,PhD
Associate Professor of Medicine and
Pediatrics
Division of Nephrology and
Hypertension
Los Angeles Biomedical Research
Institute
At Harbor–UCLA Medical Center
Torrance, California
LEARNING OBJECTIVES
• Identify cardiovascular risk factors associated with chronic kidney disease.
• Understand the mechanisms that contribute to pathophysiologic processes
and risk factors for chronic kidney disease patients.
AGENDA
• Review current management strategies to reduce vascular calcification and
bone resorption in chronic kidney disease patients.
Saturday, April 5, 2008
6:00 AM Registration
TARGET AUDIENCE: This CME-certified symposium is directed towards
nephrologists and clinicians who treat patients with chronic kidney disease.
6:30 AM Welcome and Introduction
Louisa Tammy Ho, MD
HOW YOU WILL LEARN: This CME activity will be a live symposium consisting
of lectures with panel audience participation
6:35 AM “Exploring the Association Between Cardiovascular
Disease and Chronic Kidney Disease”
Louisa Tammy Ho, MD
ACCREDITATION STATEMENT: The National Kidney Foundation is accredited
DESIGNATION STATEMENT: The National Kidney Foundation designates this
educational activity for a maximum of 1.5 AMA PRA Category 1 Credit TM.
Physicians should only claim credit commensurate with the extent of their
DECLARATION OF DISCLOSURE: It is the policy of the National Kidney
Foundation to ensure balance, independence, objectivity, and scientific rigor in
all CME activities. Faculty participating in this activity are required to disclose
to the audience any relationship they may have with the commercial supporters
of this activity or with any other commercial organizations whose products or
devices may be mentioned in their presentations.
UNLABELED / INVESTIGATIONAL USE DECLARATION: During their
presentations, faculty may discuss an unlabeled use or an investigational use
not approved for a commercial product. Each faculty member is required to
disclose this information to the audience when referring to an unlabeled or
7:00 AM “Mechanisms that Contribute to Altered Cardiovascular
Regulation in Chronic Kidney Disease”
Ravi Thadhani, MD
7:25 AM “Management Strategies for Reducing Cardiovascular Risk
Factors in Chronic Kidney Disease”
Kamyar Kalantar-Zadeh, MD
7:50 AM Q&A / Discussion
REGISTRATION: You must be registered for the NKF 2008 Spring Clinical
Meetings to attend this symposia and receive credit.
DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do not
recommend the use of any pharmaceutical, diagnostic test, or device outside of the
labeled indications as approved by the FDA. Please refer to the official prescribing
information for each product for approved indications, contraindications, and
warnings.
Supported by an unrestricted
medical educational
grant from Abbott.
Sponsored by the
National Kidney
Foundation
Friday, April 4th, 2008
6:00 AM – 8:00 AM � Gaylord Texan � Grapevine Ballroom C
A Breakfast Symposium during the
National Kidney Foundation
2008 Spring Clinical Meetings
Optimizing
Evidence-Based Best Practices
for the Hemodialysis Team
Activity Purpose
Program Objectives
This interactive learning activity is designed to
enhance the performance of dialysis healthcare providers in the use of evidence-based
clinical strategies and best practices to
improve the health and quality of life of
patients on hemodialysis.
� List two factors that have been
demonstrated to contribute to high firstyear mortality among incident End-Stage
Renal Disease (ESRD) patients and may be
modifiable through optimal pre-ESRD care.
� Describe the relationship between the
Fistula First initiative and hemodialysis
central venous catheter use in the
United States.
� Explain the technique for assessing
multiple outcomes targets simultaneously
to improve dialysis patient outcomes.
Target Audience
Program Agenda
The live symposium is designed for nephrology nurses, renal and clinical dietitians, and
nephrology social workers.
Symposium Registration: You must be registered for the NKF 2008
Spring Clinical Meetings to attend this symposium and receive credit. To
register for this symposium, please e-mail your name and e-mail address
or fax number to [email protected]. Onsite registration will be
available just prior to the symposium at our registration desk outside of
Grapevine Ballroom C, starting at 6:00 AM on Friday, April 4, 2008.
How You Will Learn: This CME/CE symposium will incorporate an
interactive multi-disciplinary panel discussion of patient cases as well as
an audience response system (ARS) to include audience participation in
the panel discussion.
Accreditation Statement: The National Kidney Foundation is accredited
Designation Statement: The National Kidney Foundation designates
this educational activity for a maximum of 1.5 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the
extent of their participation in the activity.
6:00 AM – 6:25 AM
Registration and Buffet Breakfast Available
6:25 AM – 6:30 AM
Welcome and Introductions
Bruce Robinson, MD, MSCE – Moderator
American Nurses Credentialing Center’s Commission on Accreditation.
Vice President – Research
Arbor Research Collaborative for Health, Ann Arbor, Michigan
This program is pending approval with the American Academy of
Nurse Practitioners.
6:30 AM – 7:00 AM
Improving Delivery of Pre-ESRD Care,
Case Discussion
Ronald Pisoni, PhD, MS
Director of Analytical Support – DOPPS
Arbor Research Collaborative for Health, Ann Arbor, Michigan
7:00 AM – 7:30 AM
Has Catheter Use Increased Due to
Fistula First? No! Case Discussion
Lawrence Spergel, MD, FACS
Clinical Chair, Fistula First National Breakthrough Initiative
Director, Dialysis Management Medical Group
San Francisco, California
7:30 AM – 8:00 AM
Managing Multiple Targets for Best Patient
Outcomes, Case Discussion
David Mendelssohn, MD, FRCPC
Chief and Physician Director, Department of Nephrology
Humber River Regional Hospital and University of Toronto
Toronto, Canada
Education (CPE) Accredited Provider with the Commission on
Dietetic Registration (CDR). Registered dietitians (RDs) and
dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion
of this program/material.
Declaration of Disclosure: It is the policy of the National Kidney
Foundation to ensure balance, independence, objectivity, and scientific
rigor in all CME activities. Faculty participating in this activity are required
to disclose to the audience any relationship they may have with the commercial supporters of this activity or with any other commercial organizations whose products or devices may be mentioned in their presentations.
Unlabeled/Investigational Use Declaration: During their presentations,
faculty may discuss an unlabeled use or an investigational use not
approved for a commercial product. Each faculty member is required to
disclose this information to the audience when referring to an unlabeled
or investigational use.
Disclaimer: The faculty, National Kidney Foundation, and Amgen do not
recommend the use of any pharmaceutical, diagnostic test, or device
outside of the labeled indications as approved by the FDA. Please refer to
the official prescribing information for each product for approved indications, contraindications, and warnings.
Supported by an educational grant from AMGEN
Join Us for a Breakfast Symposium
Saturday, April 5, 2008 from 6:00 am–8:00 am in Grapevine C.
Chronic Kidney Disease Interventions:
IMPROVING CKD AND CVD OUTCOMES
I.
KEEP overview and social conceptions of kidney disease: myths vs. realities
II. Glycemic control in kidney disease
I]ZAVg\Zhi8@9
9ZiZXi^dcEgd\gVb
III. Interventions and CVD interactions in diabetics with proteinuria
IV. Impact of blood pressure control in CKD
1. Provide update on the NKF’s Kidney
Early Evaluation Program (KEEP), a
community-based screening initiative
to identify those at increased risk for
kidney disease.
2. Present current views and misconceptions regarding the management
and treatment of kidney disease.
3. Poor glycemic control and blood pressure are the leading causes of kidney
failure and significantly contribute to
7YYh[Z_jWj_ed0
© 2008 National Kidney Foundation, Inc. All Rights Reserved.
ǩ
HOW YOU WILL LEARN: This CME activity will
be a live symposium consisting of lectures with
panel audience participation.
ǩ
ACCREDITATION STATEMENT: The National
Kidney Foundation is accredited by the Accreditation Council for Continuing Medical
Education
to provide continuing medical education for
physicians.
ǩ
DESIGNATION STATEMENT: The National
Kidney Foundation designates this educational
activity for a maximum of&#*6B6EG68Vi"
Z\dgn&8gZYîh# Physicians should only
claim credit commensurate with the extent of
their participation in the activity.
ǩ
DECLARATION OF DISCLOSURE: It is the
policy of the National Kidney Foundation to
ensure balance, independence, objectivity, and
scientific rigor in all CME activities. Faculty
participating in this activity are required to
disclose to the audience any relationship they
may have with the commercial supporters
of this activity or with any other commercial
organizations whose products or devices may
ǩ
UNLABELED/INVESTIGATIONAL USE DEC�
LARATION: During their presentations, faculty
may discuss an unlabeled use or an investigational use not approved for a commercial
product. Each faculty member is required to
disclose this information to the audience when
ǩ
02-35-284A
DISCLAIMER: The faculty and National Kidney
Foundation do not recommend the use of any
pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by
the FDA. Please refer to the official prescribing
information for each product for approved
heart disease. Best practice recommendations impact both CKD and
CVD outcomes.
4. Decribe how global risk reduction can
be applied to both renal and cardiovascular systems.
5. Utilize NKF’s KEEP cohort and other
cohorts to demonstrate opportunities
for improvement in the detection and
management of CKD.
Faculty:
Allan J. Collins, MD, FACP
President, National Kidney
Foundation
University of Minnesota
Minneapolis, MN
Peter A. McCullough, MD,
MPH, FACC, FACP, FAHA, FCCP
Vice Chair, NKF KEEP Steering
Committee
Consulting Cardiologist and Chief
Division of Nutrition and Preventive
Medicine
William Beaumont Hospital
Health Center
Royal Oak, MI
Sponsored by
Samy I. McFarlane, MD, MPH,
FACP, FACE
Chief, Division of Endocrinology, Diabetes
and Hypertension
State University of New York
Health Science Center at Brooklyn
Brooklyn, NY
George Bakris, MD
Chair, NKF KEEP Steering
Committee
Director, Hypertensive Diseases Center
Section of Endocrinology,
Diabetes & Metabolism
University of Chicago –
Pritzker School of Medicine
Chicago, IL
KEEP is supported by
Primary Sponsor
Associate Sponsors
Contributing Sponsors
Additional support provided by H^ZbZchBZY^XVaHdaji^dch9^V\cdhi^Xh!A^[ZhXVc!>cX#!6WWdiCjigî^dc!
DXZVcHegVn8gVcWZgg^Zh!>cX#
Dear
Colleague
Welcome to the NKF 2008 Spring Clinical Meetings!
On behalf of the National Kidney Foundation and the Program Committee, it is our pleasure to welcome you to
the NKF 2008 Spring Clinical Meetings. This year’s conference was designed to provide a balanced curriculum
that will meet the needs of the kidney healthcare team to stay current in advances in renal disease.
We hope you find that the next few days provide you with stimulating and useful updates. Please be sure to
complete the evaluations so we can continue to improve the meeting.
Have a great meeting!
FPO
Micheal Allon, MD
Program Chair
CM08
FPO
Beth Piraino, MD
Program Co-Chair
CM08
Continuing Medical Education (CME) Program Mission Statement
The mission of the National Kidney Foundation (NKF) Continuing Medical Education Program is to provide education for academic as well as private
practitioners in nephrology and related disciplines. These education activities are offered to regional, national and international audiences.
Purpose:
To provide all members of the kidney healthcare community with current, state-of-the-art science information on prevention, diagnosis and treatment
of kidney and urinary tract diseases in order to improve the care of individuals with chronic kidney disease (CKD) and those at risk for developing it.
Content Area:
Topics are selected based on physician gaps in knowledge regarding the care and treatment of individuals with kidney disease. KDOQI evidence-based
guidelines and the latest peer-reviewed clinical science provide the foundation for developing much of the content as well as professional interests,
expert opinions, literature reviews and needs assessment data from patients and caregivers that identify gaps in quality of care relative to physician
implementation of the science.
Target Audiences:
Practicing physicians, residents, and fellows in nephrology, internal medicine, cardiology, endocrinology, family practice, physician assistants, nurse
practitioners and other specialties who care for individuals who are at increased risk for, or affected by, CKD.
Types of Activities:
Live activities include conferences, symposia, courses, hands-on workshops, audience response sessions, and debates. Enduring materials include
monographs, videotapes, CD-ROM, web-based, PDA/Pocket PC software and audiotape. Adult learning principles and critical thinking strategies are
incorporated into all education activities by ensuring that participants are given an opportunity to explore new applications and or strategies.
Expected Results:
Improve physician practice patterns in order to maximize the quality of care given to patients and improve patient outcomes. This will be accomplished
by providing comprehensive educational activities that are current, largely based on evidence-based practice guidelines and expert opinion and by offering a variety of learning formats to meet the diverse needs of our participants. Results will be evidenced by post testing and reviewing responses from
activity evaluations that ask if participants plan to make any changes in their practice as a result of this activity and to identify these changes. Following our annual Spring Clinical Meeting, participants will be sent additional web-based evaluation questions which include if they are willing to provide
contact information for follow-up. Telephone surveys will then be conducted three to six months following an activity with those who have agreed to
follow-up contact.
Spring Clinical Meetings ’08
What’s Inside…
17
CM08 Program Committee
18
NKF Leadership
19
NKF Distinguished Lectures and Awards
27
NKF Professional Council Awards
28
Contributors
31
Exhibit Hall/Poster Information
32
General Information
32
Program Objectives
34
Corporate Partners
36
Corporate Supported Symposia
37
Disclosure Information
Program Tracks:
42
Physician
63
Advanced Practitioner
72
Nephrology Nurse and Technician
82
Renal and Clinical Dietitian
94
Nephrology Social Worker
100 Clinical Conversations Lunches
102 Exhibit Hall Map and Listings
113 Research Grant Recipients
114 Hotel Map
115 Faculty
Program
Committee
Michael Allon, MD
Andrea DeKam, LMSW
Ivan D. Maya, MD
Program Chair
Nephrology Social Worker Program Co-Chair
University of Alabama
University of Michigan Dialysis
Birmingham, AL
Birmingham, AL
Livonia, MI
Beth Piraino, MD
Peter B. DeOreo, MD, FACP
Montefiore Medical Center
Program Co-Chair
Centers For Dialysis Care
Albert Einstein College of Medicine
University of Pittsburgh
Shaker Heights, OH
Bronx, NY
Pittsburgh, PA
Michele H. Mokrzycki, MD, MS
Marrianne Hutton, RD, CDE
Ann O’Hare, MD
Sharon Adler, MD
Renal & Clinical Dietitian
University of Washington
UCLA Medical Center
Program Co-Chair
Seattle, WA
Torrance, CA
Fresenius Medical Care North America
Carolyn Atkins, RN, BS, CCTC
Santa Rosa, CA
Program Chair
Harbor-University of California
Children’s Medical Center
Torrance, CA
Dallas, TX
Pamela S. Kent, MS, RD, CSR, LD
Milagros D. Samaniego, MD
University of Wisconsin
Madison, WI
Evanston, IL
Joanne M. Bargman, MD, FRCPC
Renal & Clinical Dietitian Program Chair
Toronto General Hospital
Genzyme Renal
Toronto, Ontario, Canada
Vermilion, OH
Nephrology Social Worker Program Chair
Srinivasan Beddhu, MD
Bobbie Knotek, RN, BSN, CNN, LPHQ
Rochester, MN
University of Utah Health Sciences Center
Salt Lake City, UT
Program Co-Chair
Laurie E. Benton, RN, PA-C, BS, MPAS
Advanced Practitioner Program Co-Chair
ESRD Network of Texas, Inc.
Dallas, TX
Scott & White Hospital
Julia Lewis, MD
Temple, TX
Vanderbilt University Medical Center
Jeffrey Berns, MD
Nashville, TN
University of Pennsylvania School of Medicine
Charmaine Lok, MD
Philadelphia, PA
Michael J. Choi, MD
Johns Hopkins University School of Medicine
Barbara Weis Malone, BSN, RN, CFNP
Baltimore, MD
Advanced Practitioner Program Co-Chair
Stephanie Stewart, LICSW
Mayo Clinic
Maria Taylor, PharmD
Birmingham, AL
Miguel Vazquez, MD
University of Texas-Southwestern
Dallas, TX
Ex-Officio
Joseph Vassalotti, MD
University of Colorado Health
Sciences Center
Golden, CO
p.17
Leadership
President
Over its 58-year history, the NKF has grown to
become the preeminent voluntary health care
organization dedicated to improving outcomes
for people covering the entire spectrum of
chronic kidney and urologic diseases.
The Foundation has made tremendous advances
in its mission through the visionary leadership
of the National Presidents and Chairmen.
Chairman
2006–2008
Past Presidents
Tom McDonough
2008–2010
Past Chairmen
David Warnock, MD
2004–2006
Charles B. Fruit
2005–2007
Brian J.G. Pereira, MD
2002–2004
Fred L. Brown, MBA, FACHE
2003–2005
William F. Keane, MD
2000–2002
Andrew Baur
2001–2003
Joel D. Kopple, MD
1998–2000
Frederick A. Herbert
1999–2001
Garabed Eknoyan, MD
1996–1998
Joseph L. Brand
1997–1999
Alan R. Hull, MD
1994–1996
Wendy Brown, MD
1995–1997
Neil A. Kurtzman, MD
1992–1994
A. Bruce Bowden
1993–1995
Shaul G. Massry, MD
1990–1992
Donald R. Wilson
1991–1993
Saulo Klahr, MD
1988–1990
Charles E. Westcott
1989–1991
The mission of the National Kidney Foundation
Richard J. Glassock, MD
1986–1988
William P. Hunter, Jr.
1987–1989
is to prevent kidney and urinary tract
Robert W. Schrier, MD
1984–1986
diseases, improve the health and well-being
David A. Ogden, MD
1982–1984
The Honorable
John N. Kirkendall
1985–1987
of individuals and families affected by these
Richard M. Freeman, MD
1980–1982
John Hoag
1983–1985
diseases and increase the availability of all
Stuart A. Kleit, MD
1978–1980
E. Burns McLindon
1981–1983
organs for transplantation.
Arvin Weinstein, MD
1976–1978
Oliver W. Porter
1979–1981
James C. Hunt, MD
1973–1976
Harold D. Schwartz
1977–1979
E. Lovell Becker
1970–1973
Jack C. Kent
1975–1977
George E. Schreiner
1968–1970
Jordan E. Ringel
1973–1975
George Lingua
1967–1968
William J. Jones, MD
1966–1967
Wallace W. McCrory, MD
1964–1966
Daniel P. Richman, MD
1960–1964
William A. Wargo
1959–1960
Henry Kessler, MD
1954–1959
Mrs. John E. Tedford
1952–1954
Mrs. Ada U. DeBold
(Founder)
1950–1952
p.18
The office of Chairman was created in 1973.
Distinguished
Lectures and Awards
The Shaul G. Massry Distinguished Lecture
The Donald W. Seldin Award
This lectureship was established to honor Dr. Shaul G. Massry for his
The Donald W. Seldin Award was established to recognize excellence
scientific achievements and his contributions to the kidney health
in clinical nephrology in the tradition of one of the foremost teachers
care community and the National Kidney Foundation. The 2008
and researchers in the field, Dr. Donald W. Seldin. The 2008 award
honored lecturer is Tom Greene, PhD. Dr. Greene will be presenting
recipient is Thomas D. DuBose, Jr., MD.
“Randomized and Observational Studies in Nephrology: How Strong
Dr. DuBose is the Tinsley R.
Is the Evidence?” on Thursday, April 3rd.
Harrison Professor and Chair of
After receiving his PhD in
Internal Medicine and Professor
statistics from Cornell, Dr. Greene
of Physiology and Pharmacology
served as an Assistant Profes-
at Wake Forest University School
sor of Statistics at the University
of Medicine. His training in Inter-
of Kentucky from 1985 to 1989.
nal Medicine was accomplished
He moved to the Department of
Tom Greene, PhD
Statistics and Epidemiology at the
Cleveland Clinic Foundation in
clinical fellowship in Nephrology was completed at the University of
1991, where Dr. Greene joined the
Texas Southwestern Medical Center under Drs. Juha P. Kokko and
department’s Data Coordinating Center for multi-center clinical trials.
Dr. Greene’s close relationship with the field of nephrology began soon
thereafter, and in 1993 Dr. Greene became the lead statistician for the
data analyses of the Modification of Diet in Renal Disease Study. This
work provided Dr. Greene the opportunity to interact closely with many
researchers in the field. In subsequent years, Dr. Greene and his
colleagues at the Cleveland Clinic Foundation coordinated other major
clinical trials in nephrology, including the Hemodialysis Study, the
African American Study of Kidney Disease, the Dialysis Access Consortium, the Focal Segmental Glomerulosis Study, and the Frequent
Dialysis Network. Collaborations in association with these studies
led to methodological research into clinical trial designs, outcome
measures in kidney disease, kinetic modeling, and estimation of renal
function. Dr. Greene is continuing his collaborations in nephrology
after moving to the University of Utah in 2006.
Past Shaul G. Massry Distinguished Lecture Recipients
2007Eberhard Ritz, MD
2006Giuseppe Remuzzi, MD, FRCP
2005Edmund J. Lewis, MD
2004
Hans-Henrik Parving, MD, DMSc
2003Robert Alpern, MD
2002
Joseph V. Bonventre, MD, PhD
2001Andrzej S. Krolewski, MD, PhD
2000Richard J. Glassock, MD
1999Giuseppe Bianchi, MD
1998
Josephine Briggs, MD
1997Gary E. Striker, MD
1996Alfred Michael, MD
at Parkland Memorial Hospital
Thomas D. DuBose, Jr., MD
in Dallas, Texas. A research and
Donald W. Seldin.
Dr. DuBose was initially appointed Assistant Professor of Medicine at
the University of Texas Health Science Center at Dallas, Southwestern
Medical School and was subsequently recruited to the University
of Texas Medical Branch, Galveston where he became Professor of
Medicine and of Physiology and Biophysics, and served as Chief of the
Division of Nephrology. From 1991–1999, Dr. DuBose was Professor
of Internal Medicine and of Integrative Biology, Pharmacology, and
Physiology and Director of the Division of Renal Diseases and Hypertension at the University of Texas Medical School–Houston, where he
also served as Vice Chair of Internal Medicine. Prior to being recruited
to Wake Forest University School of Medicine, Dr. DuBose served as
the Peter T. Bohan Professor and Chair of the Department of Internal
Medicine at the University of Kansas, School of Medicine.
The overall goal of investigation by his laboratory is to illuminate
factors involved in the molecular regulation of tubule transporters
responsible for urinary acidification and potassium homeostasis.
Several translational studies from this group have explained the
pathophysiological basis of classical distal renal tubular acidosis with
hypokalemia (Type 1) and the generalized distal nephron defect resulting in Type 4 RTA with hyperkalemia. He and his co-workers have
advanced a new model of urinary acidification which has placed the
regulation of ammonia production and transport as pivotal for acidbase homeostasis and have elucidated the consequences of abnormal
potassium balance on acidosis and alkalosis, respectively. Current
studies have identified the contribution of the colonic H+, K+-ATPase
to the maintenance of metabolic alkalosis. This investigator has been
funded continually by the NIH since 1981.
p.19
Dr. DuBose served as President of the American Society of Nephrology,
David M. Hume Memorial Award
2005–2006 and was an elected member of Council for seven years. At
The David M. Hume Award was created in memory of one of the the ASN he was most closely identified with development of the Public
National Kidney Foundation’s most distinguished members. The
Policy Board, and served as Chair of the ASN Grants Program. In the
Hume Award is the highest honor given to a distinguished scientist-
latter position, he expanded the scope and size of the awards available
clinician in the field of kidney and urologic diseases. It is bestowed
for academic career development and innovation among established
upon an individual who exemplifies the high ideals of scholarship
investigators. The initiative of his presidency was to encourage nephrol-
and humanitarianism in an outstanding manner. The 2008 award
ogists, primary care physicians, and federal funding agencies to work
recipient is Lawrence Hunsicker, MD.
in partnership and to recognize that chronic kidney disease is a public
Dr. Hunsicker is Professor of
health issue requiring a coordinated response. He helped organize a
Internal Medicine and Medical
multi-society task force involving all kidney organizations to be more
Director of Organ Transplantation
effective in educating the public and funding agencies on placing
at the University of Iowa, College
chronic kidney disease within existing programs in cardiovascular
diseases and diabetes.
of Medicine. His research interests
Dr. DuBose has held several leadership positions in the American
transplantation medicine, the
include progressive kidney disease,
Heart Association Council on the Kidney in Cardiovascular Disease and
design and performance of clinical
was Chair 2002–2004. In 2005, Dr. DuBose received the Distinguished
Lawrence Hunsicker, MD
Science Award from the AHA.
national medical databases. In 1979 he founded with Dr. Edmund Lewis
DuBose is an author of 147 published papers and chapters in textbooks.
Along with Dr. Lee Hamm, he co-edited the text: Acid-Base and
Electrolyte Disorders. The second edition of this textbook is scheduled
to be published in 2008.
Past Donald W. Seldin Award Recipients
2007L. Lee Hamm, MD, FACP
2006
Heine Murer, MD and Bernard Rossier, MD
2005Roland C. Blantz, MD
2004Gerhard H. Giebisch, MD
2003
William M. Bennett, MD
2002 Professor Carl Erik Mogensen
2001
Friedrich K. Port, MD, MS, FACP
2000
Tilman B. Drüeke, MD
1999
Shaul G. Massry, MD
1998Alan R. Hull, MD
1997
Thomas F. Parker, III, MD
1996
Floyd C. Rector, MD
1995
1994
Manuel Martinez-Maldonado
p.20
trials, and the analysis of large
the Collaborative Study Group (CSG), which has demonstrated a striking
benefit from blockade of the renin-angiotensin system in patients with
diabetic kidney disease. This group is now studying the efficacy of
sulodexide in diabetic kidney disease. Dr. Hunsicker was also one of
the PIs in the Modification of Diet in Renal Disease Study. Dr. Hunsicker
played major roles in the design of the data registries of the United
Network for Organ Sharing (UNOS) and the United States Renal Data
System (USRDS). He was also the Principal Investigator for the Economic
Special Studies Center of the USRDS.
Dr. Hunsicker was one of the founders and later President of the
American Society of Transplantation and in 2000 was awarded their
Roche Lifetime Achievement Award. He has been President of the
National Kidney Foundation of Iowa and Regional President of the
National Kidney Foundation. He has served as President of UNOS
and was also the first Medical Advisor to the American Organ Procurement Organization. He served from 2001 to 2004 on the initial
HHS Secretary’s Advisory Committee on Organ Transplantation. He
has been a member and chair of many NIH Study Sections and is
presently a member of the FDA Advisory Committee on Antivirals.
Past David M. Hume Memorial Award Recipients
The Garabed Eknoyan Award
2007
William G. Couser, MD
The Garabed Eknoyan Award was created to recognize an individual
2006
Frank Delmonico, MD
who has promoted the mission of the National Kidney Foundation in
2005Roland C. Blantz, MD
Making Lives Better for people with kidney disease through excep-
2004
John Stewart Cameron, MD
tional contributions to key initiatives of NKF such as the Kidney Disease
2003
Franklin H. Epstein, MD
Outcomes Quality Initiative (KDOQI) or clinical research in the field of
kidney disease. The 2008 award recipient is Adeera Levin, MD, FRCPC.
2002
2001
William E. Mitch, MD
2000
[No Award]
1999
Neil A. Kurtzman, MD
1998
Jared J. Grantham, MD
1997
Thomas E. Andreoli, MD
Dr. Levin is currently a Clinical
Professor of Medicine at the
University of British Columbia
(BC), Co-director of the Clinical
Investigator Program at UBC. She
1996Edmund G. Lowrie, MD
1995
Joseph W. Eschbach, MD
1994
Wadi N. Suki, MD
1993
Joel D. Kopple, MD
1992
Saulo Klahr, MD
1991
Professor August Heidland
1990Richard J. Glassock, MD
1989
Professor Priscilla Kincaid-Smith
1988
Shaul G. Massry, MD
1987Robert W. Schrier, MD
1986Robert Heptinstall, MD
1985
Willem J. Jolff, MD
1984
Charles R. Kleeman, MD
1983Robert W. Berliner, MD
1982
Professor Hugh E. de Wardener
1981
Donald W. Seldin, MD
1980George E. Schreiner, MD
1979
is the Executive Director of the
BC Provincial Renal Agency, an
organization which manages and
Adeera Levin, MD, FRCPC
coordinates the care of patients
with kidney disease in the province of BC, and which has developed
and maintained the provincial registry for renal patients.
Dr. Levin is the Past Chair of the Kidney Foundation of Canada Biomedical
Fellowship and Scholarship Committee, and serves as Chair of the
Curriculum Committee for a new innovative program for the training of Canadian clinical scientists in kidney disease (KRESCENT). In
addition she is Chair of the NKF KDOQI clinical Practice Guideline
initiative process, and is on the Board of Directors and Executive committee of the newly formed KDIGO, an international group providing
collaborative structure for outcomes research and guideline development in CKD.
John P. Merrill, MD
Her research and clinical activities focus on chronic kidney disease,
1978
Thomas E. Starzl, MD
co-morbidities associated with CKD, mechanisms of disease, and health
1977
Henry L. Barnett, MD
outcomes research. She is active in mentoring young investigators in
1976
Carl. W. Gottschalk, MD
kidney-related research, and holds numerous grants for clinical studies.
1975
Belding Scribner, MD
1974Robert M. Kark, MD
1973
Jean Hamburger, MD
Dr. Levin has over 135 peer-reviewed publications, numerous book
chapters, and has been guest editor for sections in Current Opinion in
Nephrology and Hypertension for two consecutive years, as well as serving on the editorial board for NDT, JASN and AJKD. She reviews papers
for Circulation, New England Journal of Medicine, Annals of Internal
Medicine, Canadian Family Practice and Kidney International as well.
Dr. Levin was recently awarded a team-planning grant from
Michael Smith to create an active research team, INTEGRATION, to
develop a research strategy for the study of complex patients; and
was also awarded a Provincial Treasury Board administered Health
Innovation Fund grant to develop and assess novel methods of care
p.21
delivery for patients with Diabetes, Kidney Disease and Heart Disease
KDOQI Distinguished Service Award
in the province of BC.
In recognition of their longtime dedication and effectiveness in
Past Garabed Eknoyan Award Recipients
2007
Norbert H. Lameire, MD
2006
Francesco Locatelli, MD
2005
Nathan W. Levin, MD, FACP
2004
Neil R. Powe, MD, MPH, MBA
2003
Bertram L. Kasiske, MD
improving clinical research in the fields of kidney and urologic disease,
the National Kidney Foundation wishes to honor Dr. Lawrence Y.C.
Agodoa, Dr. Paul W. Eggers, and Dr. John W. Kusek with a special
KDOQI Distinguished Service Award. This award was established
to recognize significant contributions in the area of chronic kidney
disease health care and research.
2002Andrew S. Levey, MD
Dr. Agodoa graduated from the
Cornell University College of
Medicine, New York, NY in 1971.
He completed internship and
Joel D. Kopple Award
residency training in Internal
The Joel D. Kopple Award is an annual award honoring an individual who
Medicine at the University of
has made significant contributions to the field of renal nutrition. This
Washington Hospitals in Seattle,
year’s Joel D. Kopple Award recipient is Alison L. Steiber, PhD, RD, LD
who will be speaking on “Dietitian: Powerhouse Behind the Patients.”
Alison Steiber is the Director of
the Coordinated Dietetic Internship/Master’s Degree Program at
Case Western Reserve University in Cleveland, Ohio. Allison
received her Bachelor’s Degree
in Dietetics from Mankato State
Alison Steiber, PhD, RD, LD
University, followed by her Master’s Degree from the University
of Kansas Medical Center. She earned her Doctorate in Nutrition from
Michigan State University. Her dissertation was on carnitine levels
in patients receiving hemodialysis as well as supplementation with
WA, and training in clinical and
Lawrence Y.C. Agodoa, MD, FACP
biomedical research in Nephrology
and Renal Pathology.
He was appointed Chief of the Nephrology Service at the Madigan
Army Medical Center, Tacoma, WA. in 1976. In 1981, he returned to
the University of Washington and completed two years of clinical and
research training in Rheumatology and Immunology. In 1983, he was
assigned to the Walter Reed Army Medical Center as Assistant Chief
of the Nephrology Service and the Nephrology Training Program, and
was appointed to the Faculty of Medicine at the Uniformed Services
University of the Medical Sciences (USUMS), Bethesda, Maryland. In
1985, he was appointed Director of the Military Medical Research
Fellowship at the Walter Reed Army Institute of Research.
carnitine to study the effects on clinical parameters and quality of life.
In 1987, Dr. Agodoa was appointed Director of the Clinical Affairs Pro-
She was the recipient of a CRN National Research Grant in 2004 to
gram in the Division of Kidney, Urologic, and Hematologic Diseases at
conduct the “North American Subjective Global Assessment Valida-
the National Institute of Diabetes, Digestive and Kidney Diseases of
tion Project” which was published recently in the Journal of Renal
the National Institutes of Health (NIH) in Bethesda, Maryland.
Nutrition. Dr. Steiber has published numerous articles, abstracts and
CPE modules and has been a phenomenal force in encouraging and
fostering renal dietitians in research and excellence in practice.
Past Joel D. Kopple Award Recipients
2007
Kamyar Kalantar-Zadeh, MD, PhD, MPH
2006
Mary Pat Kelly, MS, RD, GNP
2005
Jerrilynn D. Burrowes, PhD
2004
Judith Beto, PhD, RD, FADA
2003Linda M. McCann, RD, LD, CSR
2002Linda Moore, RD, LDN
p.22
Presently, he is Professor of Medicine at the Uniformed Services Uni-
John W. Kusek received his PhD
versity of the Health Sciences, F. Edward Hebert School of Medicine,
from the University of Michigan.
and Program Director at the National Institutes of Health. His current
He is currently at the Division of
duties include the following:
Kidney, Urologic and Hematologic
Director, Office of Minority Health Research Coordination at the
Diseases, National Institute of
n
Diabetes and Digestive and Kid-
National Institute of Diabetes and Digestive and Kidney Diseases
ney Diseases (NIDDK), National
(NIDDK), National Institutes of Health.
Director of the Minority Health Program in the Division of Kidney,
Institutes of Health. Prior to
n
Urologic and Hematologic Diseases (DKUHD).
Program Scientist and Coordinator of the multi-center clinical trial,
n
John W. Kusek, PhD
coming to the NIH in 1983 he was
a faculty member in the Department of Epidemiology and Biometry,
The African American Study of Kidney Disease and Hypertension
School of Public Health, University of Illinois at Chicago. For the past
(AASK) Cohort.
18 years he has worked on major clinical research studies in chronic
Co-Project Officer of the ESRD renal database, the United States
n
Renal Data System (USRDS).
entist or Assistant Project Scientist on the following studies of chronic
Dr. Eggers is the Program Director for Kidney and Urology Epidemiology at the National Institute
of Diabetes and Digestive and
Kidney Diseases. He oversees the
United States Renal Data System
(USRDS), the Urologic Diseases
in America (UDA) project, the
Paul W. Eggers, PhD
kidney disease and urologic diseases. He has served as Project Sci-
Boston Area Community Health
(BACH) Study, the Frequent Hemodialysis Network (FHN) Clinical
Trial, the NIDDK data repository, and the RAND Interstitial Cystitis
Epidemiology (RICE) survey. In addition, he oversees a variety of epidemiological grants in the area of kidney and urologic diseases.
Prior to joining NIDDK, Dr. Eggers was Director of the Division of
Beneficiary Research in the Office of Strategic Planning at the Health
Care Financing Administration (HCFA). He worked on research and
evaluation studies at HCFA since 1978. He has conducted studies and
evaluations of Medicare enrollment in HMOs, the Prospective Payment System, Physician Payment Reform, and the hospice benefit.
His major area of expertise is the End Stage Renal Disease Program.
His research on ESRD includes epidemiological studies of mortality
kidney disease: The Modification of Diet in Renal Disease Study, the
African American Study of Kidney Disease and Hypertension, the
Hemodialysis Study, the Dialysis Access Consortium, the Folic Acid for
Vascular Reduction in Renal Transplants, the Chronic Kidney Disease
Epidemiology Collaboration and the Chronic Renal Insufficient Cohort
Study. He has also served as Project Scientist for a large number of
clinical research studies in urology, including the Medical Therapy
of Prostatic Symptoms Trial, the Chronic Prostatitis Collaborative
Research Network, the Interstitial Cystitis Clinical Research Network,
the Urinary Incontinence Research Network, the Minimally Invasive
Surgical Therapy Network, the Complementary and Alternative Medicine for Urological Symptoms trial and the Boston Area Community
Health Survey. He has published over 100 articles on chronic kidney
disease and urology, over 200 abstracts, and several book chapters.
He has received two NIH Director’s Awards, the NIH Award of Merit
and a special achievement award from the NIDDK. He has reviewed
manuscripts for over a dozen leading medical journals.
John W. Kusek is married to Jody, a Senior Investigator for Monitoring
and Evaluation at the World Bank, specializing in HIV/AIDS in Africa. They
have two daughters, Jessica, a lawyer currently serving as a clerk for a
state of Maryland circuit court judge and Jenna, a high school senior.
and morbidity among ESRD beneficiaries, transplantation studies and
cost studies of dialysis and transplantation. He has over 60 publications concerning various issues relating to the Medicare program, and
ESRD in particular.
p.23
CM08 International Distinguished Medal Recipients
Dr. Hoy is Professor of Medicine
The International Distinguished Medal was established in 1990 to
and Director of the Center for
honor the achievement of individuals who have made significant
Chronic Disease at the University
contributions to the field of kidney disease and extended the goals of
of Queensland, Australia. Her
the National Kidney Foundation. The Foundation President presents
work on high-risk populations in
medals each year to recognize the accomplishments of individuals
the USA and Australia has helped
through their clinical work, roles in academia, scientific discoveries
promote expansion of nephrolo-
or volunteer work in organizations similar to the Foundation.
Dr. Charra was born April 19,
1942, in Décazeville, in the central
part of France. He spent his early
youth in France, then in Morocco.
Dr. Charra’s family took summer
vacations at his mother’s home in
Coligny near Switzerland, where
Bernard Charra, MD
he met Marie-Jo his wife-to-be.
He attended medical school in
Montpellier between 1961 and 1968. He married Marie-Jo in 1966. They
lived two years in Seattle where he was a senior fellow in nephrology
under B.H.Scribner with their two first children; Claire, an oncologist,
and Vincent, a professor of history.
gy’s focus beyond ESRD to early
Wendy Hoy, MD
markers of risk and disease,
and the notion of their integration with other chronic diseases. Her
research addresses the epidemiology of renal disease, hypertension,
type 2 diabetes and cardiovascular disease, and determinants of accentuated susceptibility to disease, including intrauterine and early
life events, and their structural markers. It also addresses primary
and secondary prevention, outcomes research, health services and
policy and cost-effectiveness evaluations. She advocates for programs
of systematic surveillance and management of chronic kidney disease
in high risk groups, and has modeled their success in Australian
Aboriginal groups. She advocates for a needs-based system of health
care delivery at the community level, and, working on protocols for
primary pharmacologic prevention. Her awards include: Austin Doyle
Award, High Blood Pressure Research Council of Australia, 1997;
Wyeth Award, Best manuscript in MJA, Australian Medical Association,
The two years spent in Seattle left an indelible impression on Bernard
2000; Wyeth Award, Best manuscript in MJA, Australian Medical
and Marie-Jo. Dr. Charra was strongly influenced in his career by
Association, 2002; Australian Kidney Foundation Clinical Nephrology
B.H. Scribner who became a close friend over the years and corresponded
Award: 2002. Best oral presentation 38th Annual Meeting of the
daily. Dr. Charra joined Dr. Laurent in Tassin near Lyon in 1979 where he
ANZSN, 2002; Australian Kidney Foundation Clinical Nephrology
spent the following 26 years as a nephrologist and ultimately as the
Award: 2004. Best oral presentation 40th Annual Meeting of the
head of the unit. They had two more children, a son Clément, a general
ANASN, 2004; Barry M. Brenner Endowed Lectureship: American
practitioner, and Camille, a designer.
Society of Nephrology, 2006.
Dr. Charra’s favorite motto in life is taken from Reinhold Neibuhr:
“God, grant me the serenity to accept the things I cannot change, courage to change things I can, and the wisdom to know the difference.”
p.24
Michel Jadoul, MD
Professor Michel Jadoul, born in
European Representative of the Council of the Transplantation Soci-
1958, is married and has three
ety. Dr. Vanrenterghem is the Vice-Chairman of the Global Alliance for
children, aged 22, 19 and 15. He
Transplantation. Since 2005 he is a Member of the KDIGO Board. He
completed his medical studies in
has been the principal investigator of several international multi-center
1983 at the Université Catholique
trials on new immunosuppressive agents after kidney transplantation.
de Louvain, Brussels, Belgium.
In 1987 he was the winner of the 20th Eurotransplant Anniversary
He trained in internal medicine
Award. From 1996 till 2001 he was the holder of the Baxter Chair for
and nephrology with Professor
Renal Transplantation.
Charles van Ypersele de Strihou
as his mentor and spent a year in the Academic Hospital in Utrecht
(Professors Dorhout Mees and Koomans) in the Netherlands.
Past International Distinguished Medal Recipients
2007
Mona Al-Rukhaimi, MD, Dubai, United Arab Emirates
He is the head of the Department of Nephrology of the Cliniques
Dick de Zeeuw, MD, PhD, Groningen, The Netherlands
Universitaires Saint Luc since 2003 and Clinical Professor at the
Sayyid Ali Jaffer Naqvi, MD, Karachi, Pakistan
Université Catholique de Louvain. His main clinical research interests
Susumu Takahashi, MD, PhD, Tokyo, Japan
relate to Beta2microglobulin-amyloidosis, hepatitis C in dialysis and,
Christoph Wanner, MD, Wurzburg, Germany
more recently, falls and bone fractures in hemodialysis patients and
cardiovascular complications in kidney transplant recipients. He is
an associate editor of the American Journal of Kidney Diseases and a
member of the Editorial Board of Nephrology Dialysis Transplantation
and Clinical Nephrology. Professor Jadoul is country investigator
with Professor Norbert Lameire for DOPPS in Belgium and cochair with
Professor David Roth of the Kidney Disease Improving Global Outcomes
Hepatitis C in CKD Clinical Practice Guideline Work group.
Yves Vanrenterghem, MD, PhD, received his MD degree in 1973 from
the Catholic University of Leuven,
Belgium. He then undertook a
Research Fellowship at the Queen
Elisabeth Foundation for Medical
Research in Brussels, Belgium.
At present he is affiliated with the
Yves Vanrenterghem, MD, PhD
University Hospital Gasthuisberg
in Leuven, Belgium, where he is Chairman of the Department of
Nephrology and Professor of Medicine. Since 1993 he is a member of
the Board of Eurotransplant International of which he was the President
2006
Jorge Cannata-Andia, MD, Oviedo, Spain
Prakesh Keshaviah, MD, Dehradun, Uttaranchal, India
Gabriel Mircescu, MD, Bucharest, Romania
Yusuke Tsukamoto, MD, Tokyo, Japan
Haiyan Wang, MD, Beijing, China
2005
John Dirks, MD, Toronto, Ontario, Canada
Saraladevi Naicker, MD, Johannesburg, South Africa
Luis Revert, MD, Barcelona, Spain
Wu Chang Yang, MD, Taiwan, China
2004
Peter G. Blake, MB, FRCP, Toronto, Canada
Kai-Uwe Eckardt, MD, Berlin, Germany
S. Adibul Hasan Rizvi, MBBS, FRCS, FRCSE, FCPS, FRCP,
Karachi, Pakistan
Bernardo Rodriguez-Iturbe, MD, Maracaibo, Venezuela
Claudio Ronco, MD, Vicenza, Italy
between 1996 and 2005. Previously he was Treasurer of the European
2003
Society for Organ Transplantation and a member of the Scientific
Georgi Abraham, MD, Chennai, India
Committee of the EDTA Registry. Professor Vanrenterghem is Subject
Shanyan Lin, MD, Shanghai, China
Editor of Nephrology Dialysis and Transplantation (NDT), Associate Editor
Nester Schor, MD, PhD, São Paolo, Brazil
of the American Journal of Transplantation and a member of the
Carmine Zoccali, MD, Reggio, Italy
Editorial Board of Transplantation. Recently he was elected as the
p.25
Past International Distinguished Medal Recipients (continued)
2002
1994
Gavin Becker, MD, Victoria, Australia
Stefan Angielsi, MD, Gdansk, Poland
Francesco Locatelli, MD, Lecco, Italy
Natale G. De Santo, MD, Naples, Italy
Sergio Mezzano, MD, Valdivia, Chile
Professor Miroslaw Mydilk, Kosice, Slovac Republic
Giuseppe Piccoli, MD, Torino, Italy
Wladyslaw Sulowica, MD, PhD, Kracow, Poland
1993
Jamie Herrera-Acosta, MD, Mexico City, Mexico
2001
Jose L. Rodicio, MD, Madrid, Spain
Elvira Emilia Arrizurieta, MD, Buenos Aires, Argentina
Professor Sandor, Sonkodi, Hungary
Hans-Henrick Parving, MD, DMSC, Copenhagen, Denmark
Visith Sitprija, MD, Bangkok, Thailand
Yahya Sagliker, MD, Adana, Turkey
Fernando Valderrababo, MD, PhD, Madrid, Spain
2000
1992
Professor Albert Valek, Czechoslovakia
Professor Mary G. McGeown, Belfast, Ireland
Vittorio Andreucci, MD, PhD, Naples, Italy
Professor Ori Better, Haifa, Israel
Norbert Lameire, MD, PhD, Ghent, Belgium
Professor Rashad Barsoum, Cairo, Egypt
Florian Lang, MD, PhD, Tubingen, Germany
1999
Professor Karl M. Koch, Hannover, Germany
M. Derome Tremblay, France
Jonas Bergstrom, MD, PhD, Huddinge, Sweden
1991
Walter H. Hörl, MD, PhD, Vienna, Austria
Professor Nobuhiro Sugino, Tokyo, Japan
Vincenzo Savica, MD, Messina, Italy
Professor K.S. Chugh, Mumbai, India
Gianfranco Guarnieri, MD, Trieste, Italy
Professor Renee Habib, Paris, France
1998
Professor Rosario Maiorca, Brescia, Italy
Professor Franciszek Kokot, Poland
Professor Sevrin Ringoir, Ghent, Belgium
John Walls, MD, Leicester, England
1990
Shaul M. Shasha, MD, Nahariya, Israel
Professor Kazimierz Baczyk, Poznan, Poland
Professor Jean-Pierre Grunfeld, Paris, France
Professor Vittorio Bonomini, Bologna, Italy
1997
Professor Guido Bellinghieri, Sicily, Italy
Professor Hirotoshi Morii, Osaka, Japan
Professor Momir H. Polenakovic, Skopje, Macedonia
Professor J. Stewart Cameron, London, England
T.T. Durai, MD, Singapore
Professor Henri Jahn, Strasbourgh-Cedex, France
Professor Eberhard Ritz, Heidelberg, Germany
Professor Boleslaw Rutkowski, Gdansk, Poland
1996
Professor Judit Nagy, Pecs, Hungary
Professor Karel Opatrny, Pizen, Czech Republic
Miguel C. Riella, MD, Curitba, Brazil
1995
Maurice Slapak, MD, Hampshire, England
Guy Laurent, MD, Tassin, France
David N. Kerr, MD, London, England
Alexander P. Disney, MD, Adelaide, South Australia
Andrzej Ksiazek, MD, Lublin, Poland
p.26
CM08 NKF Professional
Council Awards
Each year, NKF Professional Councils recognize individuals who have
made outstanding contributions in the field of renal health. It is an
honor to announce some of those individuals who will be formally
recognized at this year’s meeting.
Council on Renal
Nutrition (CRN)
Joel D. Kopple Award
Council of Nephrology
Social Workers (CNSW)
Alison L. Steiber, PhD, RD, LD
Please see page 22 for biographical information.
Susan Knapp Excellence in Education Award
Jane Greene, MS, RD, CSR, LDN
CNSW Lifetime Achievement Award
Patricia McKevitt, ACSW, LCSW
Jane Greene is the Education Coordinator for the Renal Clinic and
is a Renal Dietitian at Vanderbilt University Medical Center. In addition,
Patricia McKevitt is celebrating 35 years in renal health. She began
Jane is a Preceptor for the Dietetic Internship at Vanderbilt University
her career in 1973 — just as Medicare made dialysis available on a
Medical Center for the past 18 years. She is also involved in the
broad scale. Since 1981 she has been the Director of Social Work at
education of her peers and other health care professionals including
Chromalloy American Kidney Center and a Research Associate in
a preceptor for the Adult Acute Care Nurse Practitioner Program and
Medicine, Washington University School of Medicine. She is truly one of the Nephrology Fellowship program. Additionally, Jane participates in
the founders of CNSW, having served as its third Chair as well as many community outreach by providing classes and overseeing educational
other positions. She has also been continually active with NKF and her
materials and care plans for CKD patients through the Vanderbilt
local Chapter as well as the Network Coordinating Council. She serves
Nephrology Clinic. Jane has been an invited speaker at over 40 local,
on the editorial boards of five journals/magazines. She also contrib-
state and national meetings in addition to publishing over a dozen
uted heavily to the CNSW CQI Manual. She has been a leader in Renal
peer-reviewed journal articles. She is active with local and national
social work through presentations and publications from the beginning
CRN activities serving as Regional Representative for Region 2. Jane
of her career. She has served on the National Advisory Board of the
is truly passionate about education and the patients she cares for.
longitudinal, International National Dialysis Outcomes and Practice
Patterns Study (DOPPS). Pat’s career is certainly exemplary.
The 2008 CNSW Merit Award
Judy Caldwell, LMSW, ACSW, DaVita Garden West, Westland, MI
Judy has been a leader for the Michigan CNSW Chapter and has served
on the Program Committee as Chair and Co-Chair for the Annual
Symposium. She has worked with the Discharge Planners Outreach
Program Committee, a special program to increase the communication
between hospitals and the dialysis units. She is also sharing her skills
through mentoring new social workers and those wishing to become
involved in the Michigan NKF and CNSW.
Recognized Renal Dietitian
Marianne Vennegoor, RD, HPC
Marianne Vennegoor is the first dietitian to receive this award outside
of the United States. She studied and earned her degree in Nutrition
and Dietetics in the Netherlands. She also completed a middle management course at Guy’s and St. Thomas’ Hospital where she worked
for 31 years. She has traveled the world as an ambassador for renal
dietitians and has shared her expertise in the United Kingdom, Austria,
France, Czech Republic, Greece, Germany, Italy, Israel, Japan, Mexico,
Philippines, Russia, Estonia, Spain and Sweden. Marianne has been
the contact for the European CRN for the past 14 years. Additionally,
Diane Perry, LISW, Edina Dialysis of DaVita, Edina, MN
she remains active with the International Society of Renal Nutrition and
Diane has been an active member of the Upper Midwest NKF Gift of
Metabolism, the International Congress of Dietetics and the Interna-
Life program promoting and educating patients, families, and staff
tional Society for Peritoneal Dialysis. She is a founding member and
about organ donation and transplantation. She has also helped coordi-
Chair of the Dietetic Subgroup of the European Dialysis and Transplant
nate the local KEEP program, which promotes early detection of CKD.
Nurses Association European Renal Care (EDTNA/ERCA). She is also
Diane worked with State Services for the Blind to implement a books-
Chair of the Education Committee of the International Federation
on-tape program for blind patients.
of Kidney Foundations. Marianne has also been a member of the
p.27
editorial Board for Advances in Renal Replacement Therapy, the
and completed the new orientation manual for new executive
Journal of Renal Nutrition and the Journal of the EDTNA/ERCA.
Committee Members.
2008 CNNT Distinguished Service Award
COuNCil OF NePHrOlOgy
NurSeS aND TeCHNiCiaNS
(CNNT)
KayHall,RN,CNN,BSN
Kay has served as Chair for region 2 for the past four years. in addition to her normal duties as Chair, she has written numerous articles
for RenaLink in regulatory issues and helped the council with issues
related to CMS and survey regulations. She has also co-authored the
orientation manual for new Council Members with Dadi Ding.
The 2008 CNNT Distinguished Service Award
DadiDing,RN,CNN
Dadi has been on the CNNT executive Committee for two terms as
region 3 Chair. She has worked very closely with our two councils
(illinois and iowa) to assist with recertification and communication.
in addition, she and Kay Hall, outgoing region 2 Chair, developed
CM08 Contributors
TheNationalKidneyFoundationgratefullyacknowledgesthesupportofthefollowingorganizations
whohelpedmaketheNKF2008SpringClinicalMeetingspossible:
Primary Contributors:
Meeting Contributors:
Corporate Supported Symposia
additional Conference Materials
abbott
genzyme
and events
Keryx Biopharmaceuticals, inc.
MedComp
aMag Pharmaceuticals, inc.
Novo Nordisk
abbott
amgen
Ortho Biotech Products, l.P.
amgen
Omron
Shire Pharmaceuticals
astellas Pharma uS, inc.
Ortho Biotech Products, l.P.
Bard
Baxter Healthcare
Watson Pharma, inc.
Fresenius Medical Care
Merck
Boehringer ingelheim
genzyme
p.28
What’s In
store?
A Curriculum for CKD
Risk Reduction and Care
store hours:
Thursday
Friday
Saturday
April 3
April 4
April 5
8:00 a.m. – 6:30 p.m.
7:00 a.m. – 6:00 p.m.
7:00 a.m. – 5:00 p.m.
Store is located at Ballroom Foyer in the NKF Registration Area.
Use YoUr coUpon to save
FIve Dollars
on pUrchases oF $25 or more
One COupOn per purChase
Be a part oF oUr
raFFle
DraWIngs
everY DaY
© 2008 National Kidney Foundation, Inc. All rights reserved.
02-10-491A
exhibit
hall
2008 Exhibit Hall and Poster Presentation Hours
Thursday, April 3
6:00pm–7:30pm
Opening Ceremonies and Faculty Reception –
Visit Posters/Exhibits
Friday, April 4
7:00am–8:00am
10:00am–2:00pm
5:30pm–7:00pm
Posters/Exhibits and Continental Breakfast
Posters/Exhibits and Lunch
Networking Reception – Posters/Exhibits
Saturday, April 5
9:00am–1:00pm
Posters/Exhibits and Brunch
Poster Presentations
CMO8 provides an opportunity to meet with over 300 authors to discuss
their research experiences and significant areas of development in chronic kidney
disease. All participants will have an opportunity to view a stimulating selection of
poster presentations in the Exhibit Hall,
starting Thursday, April 3 at 6:00pm and ending Saturday, April 5 at 1:00pm.
Authors available for questions at the Exhibit Hall Opening and Networking Reception
on Thursday.
p.31
General
Information
Meeting Objectives
CME/CEU
Poster Presentations
Participants will learn about new and evolving
Information pertaining to CMEs or CEUs can be
Over 300 abstracts will be presented as poster
concepts related to kidney disease through
found at the beginning of each program track.
presentations. Posters are available for view-
workshops, debates, interactive courses
and traditional didactic sessions. The meetings’ learning objectives are to increase the
participants’ understanding, knowledge and
competency regarding improving patient care
in the following areas:
Methods to preserve hemodialysis access
n
and prevent infectious complications
Acute kidney injury, long-term impact, and
n
strategies for preventing AKI
Causes of secondary hypertension
n
What’s new on nephrogenic systemic fibrosis
n
Understanding the controversies regarding
n
living donors for kidney transplantation
The controversy over the target hemoglobin
CME & CEU Session Tracking
NKF offers an online system for tracking your
CME/CEUs. With an easy swipe of a badge,
attendance at sessions will automatically be
NKF’s Expectation of Presenters
Through the National Kidney Foundation
Evaluations will be distributed at the beginning of each session and collected at the end.
instantaneously to a web site for easy viewing.
There will also be evaluation drop-off locations
You are able to print a certificate of attendance
around the meeting area. Evaluations are very
at your own convenience and without any hassle!
important to all of us. The planning and execu-
Access this system conveniently by visiting
tion of useful and sound continuing education
www.expobadge.com/certification/nkf2008
programs are largely guided by input provided
The online service is available through
July 4, 2008.
NKF Registration, Ticket Sales
and Information
Tuesday
3:00pm–8:00pm
in kidney health care education. NKF expects
Wednesday
7:00am–6:00pm
that all presenters affiliated with the NKF 2008
Thursday
5:30am–6:00pm
Spring Clinical Meetings will provide informa-
Friday
7:00am–5:00pm
tive and fully accurate content that reflects the
Saturday
7:00am–5:00pm
highest level of scientific rigor and integrity.
Sunday
7:00am–1:00pm
Tickets for activities requiring separate
Clinical Meetings are designed for kidney doc-
registration and/or a separate fee are available
tors in the private sector and academia, fellows
at the Ticket Sales Booth in the Registration
and residents with a special interest in kidney
Area. Staff are available at the Meeting Infor-
disease, general internists, pharmacists, physi-
mation Booth to answer any questions that
cian assistants, nephrology nurses and techni-
you may have.
ment of individuals with kidney disease.
p.32
take a few minutes to let us know what you
think, because your feedback really matters!
(information only)
The National Kidney Foundation 2008 Spring
other clinician involved in the care and treat-
help ensure that future programs are informa-
Located in the Foyer, Ballroom Level.
cation programs, NKF promotes excellence
workers, renal and clinical dietitians, and any
by program participants. Your responses will
tive and meet your educational needs. Please
Registration Hours are:
cians, nurse practitioners, nephrology social
CM08 Evaluations – Your Feedback
Really Matters
recorded—no more forms to complete! CME
Spring Clinical Meetings and continuing edu-
Target Audience
noted on page 31.
and CEU credit information will be uploaded
n
in CKD.
ing in the Exhibit Hall during exhibit hours
Badges
Please wear your registration badge for
admission to all meeting activities. There
is a $25.00 replacement fee for lost badges.
National Young Investigator’s Forum
Have you ever wondered what you are going
Wednesday, April 2
to do when you finish your Nephrology train-
Participation by invitation only.
The National Kidney Foundation is pleased to
host the Third National Young Investigators
Forum chaired by Paul Sanders, MD and
Robert Toto, MD. Participants include the winners of the five regional Young Investigators
Forums held in the first quarter of 2008 as well
as those from the 2007 Forums. Presenters
will compete in the Clinical Research or Basic
Research categories. A panel of faculty judges
will select the award winners in each category.
ing? “Career Choices in Nephrology” is your
opportunity to hear from individuals who work
Meet colleagues for cocktails and hors
what career path to choose in nephrology, and
attend one of the dinner symposia.
how to go about getting there. The session
will begin with a panel discussion by individuals currently active in academic medicine as
educators and researchers, private practice,
interventional nephrology, and industry. Learn
why these Nephrologists decided on their
career paths, their backgrounds, what they
did to secure their jobs, and if (and how) they
After the panel discussion, there will be time
for questions and answers followed by a beer/
wine reception and hors d’oeuvres. This is a
great time to network.
program encourages highly-qualified and
interested individuals to enter the field of
Center Foyer, Ballroom Level
Medicine and Pediatric trainees concentrated
exposure to cutting-edge clinical and experimental Nephrology in the stimulating learning
environment. The goals of the program are
to shed light on the broader aspects of the
subspecialty than what house staff experience
on the wards in their daily routine.
Fellows Event: Career Choices in
Nephrology/Fellows Reception
Held in association with Women in Nephrology
Participation by invitation only.
Saturday, April 5, 5:30pm–7:00pm
Coordinators: Sharon Moe, MD, and
Panelists: Sharon Adler, MD, Sumit Kumar, MD,
Chris Lu, MD, Lauren McDonald, MD,
Jose Menoya, MD, Robert Toto, MD, and
Miguel Vazquez, MD
Membership Questions?
NKF professional membership provides
numerous benefits for physicians, pharmacists, advanced practitioners, nurses, technicians, dietitians and social workers. Stop by
the Membership Booth located in the NKF
Registration Area to learn more about how to
become an NKF member.
The Learning Continues
Recordings
Most sessions will be audio taped.* Tapes
and MP3 audio CD-ROMs will be sold in the
National Kidney Foundation Kidney
Learning System (KLS) Store
kidney disease. The program provides Internal
held in the Exhibit Hall from 5:30pm–7:00pm.
d’oeuvres in a relaxed atmosphere before you
Amgen who has made this program possible.
and Pediatric Trainees to CM08. This special
Friday, April 4, for a Networking Reception
fellows and residents who are trying to decide
would do it again if they were starting over.
We are pleased to welcome Internal Medicine
presenters announced.
n
in all aspects of Nephrology. The session is for
NKF gratefully acknowledges the support of
Internal Medicine and Pediatric
Trainees Program
display with authors present. Top poster
The NKF KLS store has many items for professional and patient education and public
awareness. Please stop by to pick up single,
complimentary copies of KLS brochures, to
Registration Area at the “Conference Copy, Inc.”
table will be available following the meeting.
Please refer to the topic list included in your
tote bag for more information or you can
check the NKF web site for this information.
* Speaker permission must be granted in order
to tape a session or a particular speaker.
see newly available materials and to browse
Faculty Slide Presentations
and purchase resources related to CKD care.
Final slide presentations* will be posted on
the NKF web site at the conclusion of the
The (KLS) store hours are:
Thursday
8:00am–6:30pm
Friday
7:00am–6:00pm
Saturday
7:00am–6:00pm
meeting and will be made available to
registrants of CM08.
* Presentations available with faculty
permission only.
Exhibit Hall Information
Exhibits and posters are located in the Exhibit
Hall. Exhibitors are a vital part of the NKF
Spring Clinical Meetings. The NKF thanks our
exhibitors for their continued support of our
educational programs, and cordially invites
attendees to the following receptions:
Thursday, April 3, for the Exhibit Hall Open-
n
ing Reception which will be held at 6:00pm
in the Exhibit Hall. Posters will also be on
p.33
CM08
Corporate Partners
The National Kidney Foundation gratefully acknowledges our corporate partners who have supported the Foundation and enabled us to work
towards its mission of preventing kidney and urinary tract diseases, improving the health and well-being of individuals and families affected
by these diseases, and increasing the availability of all organs for transplantation. A percentage of funds raised are also directed toward the
Foundation’s research program. Interested corporations may call Geraldine C. Connors at 800.662.9010 x215 for information.
The NKF wishes to recognize and thank the following corporate partners:
Platinum
Abbott
Amgen
Genzyme
Roche
Wyeth
Pharmaceuticals
Diamond
Merck & Co., Inc.
GlaxoSmithKline
Abbott Nutrition
Ortho Biotech
Products, L.P.
Schwarz Pharma, Inc
Novartis Pharmaceuticals Corporation
Bronze
C O R E (Center
for Organ Recovery
& Education)
Fresenius Medical
Care
The Coca-Cola
Company
Watson Laboratories,
Inc.
Friend
Affymax Inc.
Bard Peripheral
Vascular
DaVita
Golf Digest
GSW Worldwide
Contributor
Bristol-Myers Squibb
Company
Strides for
Nephropathy
Keryx BiopharmaceuGold
Takeda Pharmaceutiticals
Embassy of the
cals North
United Arab Emirates
Musculoskeletal
America, Inc
Transplant
Foundation (MTF)
Silver
Supporter
NCCC-Charity
Astellas Pharma
PING
US, Inc.
Pfizer, Inc.
Boehringer Ingelheim
Quest Diagnostics
Pharmaceuticals, Inc
Lockheed Martin
Satellite Laboratory
Services
Sigma-Tau Pharmaceuticals
The Binding Site, Inc.
Tourneau
United Healthcare
CB Richard Ellis
p.34
WHERE THERE’S A
THERE’S A
WAY
TO SAVE A LIFE!
You can give the gift of life... even when yours is over... through the National
Kidney Foundation’s Planned Giving Program. Your financial contribution to fight
kidney disease can come by way of your will... life insurance... real estate
or gifts of securities, and your estate can even enjoy a tax break! For more
information contact the National Kidney Foundation.
1.800.622.9010 www.kidney.org
Breakfast, Lunch and
Dinner Symposia
Wednesday, April 2
7:30pm–9:30pm
12:00pm–2:00pm
7:00pm–9:00pm
Dietary Phosphorus and Outcomes Cardiovascular Disease in CKD Patients Association of Mineral Metabolism, in Patients with CKD Pre-Dialysis and on Dialysis
Vitamin D Therapy, and Calcimimetrics on
Chronic Kidney Disease Patient Survival Shire Pharmaceuticals
Supported by an educational grant from Abbott
7:30pm–9:30pm
An Evidence-Based Review of the 7:00pm–9:00pm
Optimal Patient Outcomes: Identification
and Treatment of Iron Deficiency Anemia Thursday, April 3
Management of Hyperphosphatemia and in Early CKD
6:00am–8:00am
its Pharmacoeconomic Impact on Patients Supported by an educational grant from
Effects of Glycemic Control on Outcomes with Stage 5 CKD: New Perspectives for AMAG Pharmaceuticals, Inc.
Optimal Outcomes in 2008
in Diabetics with Chronic Kidney Disease
Novo Nordisk
Fresenius Medical Care – North America
6:00am–8:00am
6:00am–8:00am
Trends and Challenges in CKD Progression
and Management in Older Adults
Ortho Biotech Products, L.P.
Saturday, April 5
Friday, April 4
6:00am–8:00am
Assessing the Role of Proteinuria in the Progression of Chronic Kidney Disease
6:00am–8:00am
Chronic Kidney Disease Interventions: Improving CKD and CVD Outcomes
6:00am–8:00am
Exploring the Link Between Chronic Kidney Disease and Cardiovascular Disease: Reducing Mortality
New DOPPS Findings on Optimizing Practices
for the Hemodialysis Team
Supported by an educational grant from Amgen
p.36
DISCLOSURE OF planners and FACULTY
COMMERCIAL RELATIONSHIPS
The National Kidney Foundation is required by the Accreditation Council
The faculty member is also required to disclose to the activity audience
for Continuing Medical Education to disclose significant support or sub-
when an unlabeled use of a commercial product, or an investigational
stantial financial relationships between planners, presenters and com-
use not yet approved for any purpose, is discussed during an educa-
mercial entities for all Continuing Medical Education (CME) activities.
tional activity. The intent of this disclosure is to provide attendees with
NKF sent a “Faculty Disclosure Form” to the faculty participating in
information prior to their participation in the educational activity.
the 2008 Spring Clinical Meetings (April 2–6, 2008, in Dallas, Texas).
All invited speakers for the National Kidney Foundation 2008 Spring
All faculty members participating in a NKF-sponsored activity are
Clinical Meetings are expected to complete a “Faculty Disclosure
expected to disclose to the participants prior to the educational activity
Form.” Speakers who did respond, but have nothing to disclose, are
the existence of any significant financial or other relationships held
listed with no information next to their name. Speakers who did not
by themselves, and/or family members, with the manufacturer(s) of
complete a disclosure form prior to presentation are not allowed to
any commercial product(s) or provider(s) of any commercial service(s)
present as per the Foundation’s Disclosure Policy. Meeting participants
discussed in an educational presentation.
may also refer to the Session Chair introductory remarks for each
session for final listings of disclosures and off-label or unapproved
usages of a product.
Faculty Disclosure listing
Kara Abbas
Stephen Ash
Joanne Bargman
Martin Abrahamson
Officer/director or holder of more:
Lois Bates
Grant/research support: Pfizer; Speaker’s
Ash Access Technologies
Daniel Batlle
bureau: Eli Lilly, GlaxoSmithKline, Merck,
Arif Asif
Novo Nordisk, Novartis, Pfizer, Sanofi-
Gerald Beck
Cassandra Aspinall
Aventis, Takeda
Srinivasan Beddhu
John Asplin
Kenneth Abreo
Full/Part time employment: Litholink Cor-
Ann Beemer Cotton
Beth Adams
poration; Consultant/scientific advisor: Altus
Sharon Adler
Pharmaceuticals
Grant/research support: Aspreva, Genzyme,
Carolyn Atkins
Genentech
Mary Ann Baily
Anil Agarwal
George Bakris
Zalman Agus
Grant/research support: NIH (NIDDK/NHLBI)
Michael Allon
Glaxo-Smith Kline, Forest; Consultant/
Consultant/scientific advisor: VascAlert
Gerald Appel
scientific advisor: Abbott, Boerhinger-
Judith Beto
Ingelheim, BMS/Sanofi-Aventis, Forest,
Consultant/scientific advisor: Amgen;
Glaxo-Smith Kline, Merck, Novartis,
Speaker’s bureau: Amgen, Shire
Walgreens, Gileada, Sankyo; Speaker’s
Peter Blake
bureau: Abbott, Boerhinger-Ingelheim, BMS/
Mary Ellen Brabec
Sanofi-Aventis, Forest, Glaxo-Smith Kline,
Speaker’s bureau: Shire Pharmaceuticals
Merck, Novartis, Walgreens, Gileada, Sankyo
Kathleen Brady
Lynda Ball
Speaker’s bureau: Abbott
Julie Barboza
Emmauel Bravo
Grant/research support: Merck, Pfizer, Aspreva;
Consultant/scientific advisor: Merck, Pfizer,
Astra Zeneca, Aspreva, Genentech;
Speaker’s bureau: Merck, Pfizer, Astra;
Zeneca, Aspreva, Genentech
George Aronoff
Filitsa Bender
Laurie Benton
Suzanne Bergman
Tomas Berl
Jeffrey Berns
Anatole Besarab
p.37
Barry Brenner
Abbott, Roche, INEOS, Watson; Speaker’s
Genzyme, Ineos, Mitsubishi; Speaker’s
Consultant/scientific advisor: Genzyme,
bureau: Abbott, Amgen, Watson
bureau: Amgen, Genzyme, Mitsubishi
Novartis
Ronald Crossno
Robert Duncan
K. Bridget Brosnihan
Full/Part time employment: VistaCare
Paul Eggers
Teri Browne
John Crouch
Karen Egloso
John Burkart
Jim Curtis
Richard Eisenstaedt
Grant/research support: Baxter, Genzyme,
Other financial or material support: Home
Speaker’s bureau: Ortho Biotech
Abbott, Watson, NxStage; Consultant/
Dialysis Plus
scientific advisor: Baxter, Genzyme,
Garabed Eknoyan
Kirsten de Groot
NxStage; Speaker’s bureau: Baxter
Consultant/scientific advisor: Aspreva;
Kimberly English
David Bushinsky
Speaker’s bureau: Roche
Consultant/scientific advisor: Amgen,
Jan Deane
Genzyme, Shire, Ilypso, Relypsz; Speaker’s
Andrea DeKam
bureau: Amgen, Genzyme, Shire, Ilypso,
Relypsz; Officer/director or holder of more:
Amgen
Francis Delmonico
Speaker’s bureau: Astellas, Roche;
Other financial or material support: Wyeth;
Jessica Farrell
Daniel Feig
Speaker’s bureau: TAP Pharmaceticals
Harvey Feldman
Harold Feldman
Fredric Finkelstein
Full/Part time employment: New England
Michael Flessner
Mary Beth Callahan
Organ Bank, The Transplantation Society
Charles Foulks
Donna Calvin
Laura Dember
Speaker’s bureau: Amgen
Ellen Case
Grant/research support: Neurochem, Inc.
Stanley Franklin
Claire Casselman
Vincent Dennis
Consultant/scientific advisor: AtCor Medical,
Lee Cauble
Consultant/scientific advisor: Fresenius
Sheldon Chaffer
Medical Corporation
Christopher Chan
Peter DeOreo
Alfred Cheung
Thomas Depner
Dolph Chianchiano
David DeWalch
Michael Choi
Lesley Dinwiddie
Jessica Cabness
Louise Clement
Carolyn Cochran
Jean Colaneri
Allan Collins
Grant/research support: Amgen, Roche,
NxStage, Baxter; Consultant/scientific
advisor: Amgen, Roche, NxStage
Danilo Concepcion
Bonnie Conrad
Consultant/scientific advisor: Arrow Interna-
Bristol-Myers Squibb, Merck, Pfizer; Speaker’s bureau: Merck, Bristol Myers Squibb,
Allon Friedman
Barbara Fromm
Joel Glickman
Deborah Glidden
tional, Graftcath, Inc., Excelsior; Speaker’s
Speaker’s bureau: Amgen, Abbott
bureau: Hoffmann La Roche of Canada
Elaine Go
Bradley Dixon
David Goldfarb
Consultant/scientific advisor: Proteon
Consultant/scientific advisor: Altus
Therapeutics, Pervasis Therapeutics
Pharmaceuticals, OxThera, TAP
Bart Dolmatch
Pharmaceuticals
Consultant/scientific advisor: Edwards
Thomas Golper
Lifesciences, Bard
Consultant/scientific advisor: Baxter
Mary Ann Dooley
Thomas Gonwa
Consultant/scientific advisor: Aspreva,
Grant/research support: Wyeth, Genzyme
Gabriel Contreras
Teva, Genentech, Amgen, Human Genome
Janelle Gonyea
Sandra Coorough
Sciences, Roche, IDEC, UCB
John Gowan
Daniel Coyne
Tilman Drueke
Michael Grasso
Grant/research support: Abbott, Amgen,
Grant/research support: Amgen, Genzyme,
Consultant/scientific advisor: Karl Storz,
Roche, Watson; Consultant/scientific advisor:
Shire; Consultant/scientific advisor: Amgen,
Boston Scientific, Cook Urological
p.38
Tom Greene
Priscilla Hollander
Norma Knowles
Grant/research support: Keryx Corporation
Consultant/scientific advisor: Pfizer, Novo
Stephen Korbet
Loic Guillevin
Nordisk, Sanofi Aventis; Speaker’s bureau:
Andrea Kostick
Kay Hall
Pfizer
Full/Part time employment: DaVita
Norman Hollenberg
Lisa Hall
Jean Holley
Lee Hamm
Tricia Howard
Haewook Han
Kirk Hughes
Jeff Harder
Lawrence Hunsicker
John Hartman
Grant/research support: Keryx, Sanofi-Aventis;
Jeanette Hasse
Mary Hastings Hagar
Rebecca Hays
Consultant/scientific advisor: Keryx, Pfizer,
Sanofi-Aventis, Isotechnika, Teijin Group,
CorMedix Pharmaceuticals; Speaker’s bureau:
Bristol-Myers Squibb, Sanofi-Aventis
Csaba Kovesdy
Sumit Kumar
Dana Kumjian
Warren Kupin
Kristin Larson
Thu Le
Nathan Levin
Grant/research support: Roche; Consultant/
scientific advisor: Fresenius, Roche
Edmund Lewis
Other financial or material support: Keryx
Mikhaelle Heald
Marianne Hutton
David Hellmann
Consultant/scientific advisor: Shire;
Kirstie Lewis
Brenda Hemmelgarn
Speaker’s bureau: Shire
Julia Lewis
Grant/research support: Amgen, Merck
Ajay Israni
Grant/research support: Keryx Biopharma-
Elizabeth Henery
Grant/research support: Roche, Amgen,
ceuticals, Novartis
Johann Herberth
Bristol Myers Squibb
Anne Liles
Consultant/scientific advisor: Amgen
Bertrand Jaber
Robert Lindsay
Charles Herzog
Consultant/scientific advisor: NxStage
Robert Lockridge
Grant/research support: Amgen, Medtronic,
Medical, Inc., Advanced Magnetic, Inc.
Consultant/scientific advisor:
Astra Zeneca, NIH; Consultant/scientific
Aimee Jaremowicz
Renal Solutions, Inc.
advisor: Amgen, Medtronic, Roche, Ortho
Stephanie Johnstone
Charmaine Lok
BioTech, Guidant, CorMedix; Other financial
Sheila Jowsey
Cynthia Lord
Peter Juergensen
Elena Lucio
Kamyar Kalantar-Zadeh
Cathi Martin
Grant/research support: Abbott, Amgen,
Consultant/scientific advisor: Shire;
Shire, Watson, Genzyme; Speaker’s bureau:
Speaker’s bureau: Amgen, Shire
Abbott, Amgen, Shire, Watson, Genzyme
Arthur Matas
Marcia Kalista Richards
Ivan Maya
Judith Kari
Maureen McCarthy
Pamela Kent
William McClellan
Full/Part time employment: Genzyme
Consultant/scientific advisor: Amgen, Roche
Rita-An Kiely
Peter McCullough
Paul Kimmel
Lauren McDonald
Consultant/Scientific advisor: Pfizer,
Officer/director or holder of more: Fresenius
Fresenius; Stockholder: Johnson & Johnson,
Medical Care
Amgen, Merck, Lilly, Pfizer, Fresenius
Samy McFarlane
Lisa Kindy
Jennifer McGuoirk
or material support: RoFAR
Jonathan Himmelfarb
Deborah Hinnen
Consultant/scientific advisor: Lilly, Aventis,
Intuity; Speaker’s bureau: Lilly, Aventis,
Roche, APhA, AADE
L. Tammy Ho
Consultant/scientific advisor: Abbott;
Speaker’s bureau: Orthobiotec
Kimberly Hodge
Consultant/scientific advisor: NxSTAGE
Medical
R. Michael Hofmann
Ronald Hogg
Grant/research support: Pronova Biocare,
Merck, Roche
Jeffrey Hoggard
Alan Kliger
Full/Part time employment: Abbott
Bobbie Knotek
Laboratories
p.39
Stephanie McIntyre
Allen Nissenson
Roger Rodby
Dianne McKay
Grant/research support: Amgen, Hoffman-
James Rodrigue
Pat McKevitt
La Roche, NIH; Consultant/scientific advisor:
Carol Roe
Beth McQuiston
Rajnish Mehrotra
Speaker’s bureau: Baxter Health Care
Ravindra Mehta
Mark Meier
David Mendelssohn
Advanced Magnetics, Affymax, DaVita OCMO,
Amgen, Hoffman-La Roche; Speaker’s
bureau: Watson Pharma
Ann O’Hare
Edmond O’Riordan
Emil Paganini
Grant/research support: Quark Pharmaceuti-
Arturo Rolla
Speaker’s bureau: Lilly, Novo Nordisk,
GlaxoSmithKline, Roche
Jamie Ross
Prabir Roy-Chaudhury
Bharat Sachdeva
Antoine Samaha
Joe Merighi
cals, Biosite, Inc., Amgen; Consultant/scien-
Jeffery Metzger
tific advisor: NxStage Medical, Quark Phar-
Miriam Michael
maceuticals, Biosite, Inc., Amgen; Speaker’s
Speaker’s bureau: Genzyme
Cindy Miller
bureau: Watson Pharmaceuticals
Eduardo Sanchez
Meredith Miller
Robert Page
Speaker’s bureau: Sanofi Aventis
Ronald Miller
Speaker’s bureau: Pfizer, Astra-Zeneca
Paul Sanders
Richard Mishler
Joni Pagenkemper
Gail Sansivero
Orson Moe
Paul Palevsky
Grant/research support: Elcam Medical;
Sharon Moe
Jessie Pavlinac
Grant/research support: Genzyme;
Marc Penn
Consultant/scientific advisor: Genzyme,
Grant/research support: Athersys; Other
Amgen, Ineos; Speaker’s bureau: Genzyme
financial or material support: AcelleRX
Michele Mokrzycki
Therapeutics
Anne Moore
Mark Perazella
Speaker’s bureau: Gundersen Lutheran
Beth Piraino
Medical Foundation
Marc Pohl
Bruce Morgenstern
Megan Prescott
Other financial or material support:
Pat Preston
Astra-Zeneca
Consultant/scientific advisor: Johnson &
Donna Morton de Souza
Johnson, Ortho-McNeil
Wajeh Qunibi
Alvin Moss
Grant/research support: NABI Biopharma-
Salim Mujais
ceutical, Fresenius
Mary Murphy
Jai Radhakrishnan
Patrick Murray
Consultant/scientific advisor: Genentech
Grant/research support: NxStage Medical,
Panduranga Rao
Inc.; Consultant/scientific advisor: Scios, Inc.,
Robert Reilly
NxStage Medical, Inc.; Speaker’s bureau:
Cleo Richard
Scios, Inc., NxStage Medical, Inc.
Mark Roberts
Mohanram Narayanan
Dialysis
Grant/research support: Archimedes, Inc.;
Andrew Narva
Consultant/scientific advisor: Archimedes, Inc.
Beverly Sneed
Ira Nemeth
Bruce Robinson
Laboratories Renal Care Division
Marianne Neumann
Michael Rocco
Mi-Kyung Song
p.40
Milagros Samaniego
Consultant/scientific advisor: AngioDynamics, Boston Scientific, Genentech, Elcam
Medical
Mark Sarnak
Grant/research support: Amgen
Mary Schira
Kathy Schiro Harvey
Donald Schon
Consultant/scientific advisor: Bard; Speaker’s bureau: Bard; Other financial or material
support: MedComp, AngioDynamics
Anton Schoolwerth
Grant/research support: Amgen; Consultant/scientific advisor: OrthoBiotech, Inc.;
Donna Secker
Mary Ann Sevick
Edward Siew
Edward Silverhardt
Full/Part time employment: Center for
Applied Behavioral Sciences, DaVita Sparks
Full/Part time employment: Abbott
Lawrence Spergel
Robert Toto
Barbara Weis Malone
Stuart Sprague
Grant/research support: Novartis;
Consultant/scientific advisor: Wyeth;
Consultant/scientific advisor: Abbott;
Consultant/scientific advisor: Merck, Amgen;
Speaker’s bureau: Abbott
Speaker’s bureau: Merck, Amgen, Novartis
Steven Weisbord
Glen Stanbaugh
Mandy Trolinger
Grant/research support: Roche; Speaker’s
Alison Steiber
Lara Tushla
bureau: Amgen
Grant/research support: Sigma Tau
Tracey Tyus-Bailey
John Jason White
Pharmaceuticals, Inc.; Speaker’s bureau:
Mark Unruh
Robert Whitlock
Sigma Tau Pharmaceuticals, Inc.,
Grant/research support: Baxter
Karen Wiesen
Genzyme, Abbott
Aris Urbanes
Alan Wilkinson
Lesley Stevens
Tushar Vachharajani
Wolfgang Winkelmayer
Ramiro Valdez
Grant/research support: GlaxoSmithKline,
Joseph Vande Griend
Amgen, Astellas; Consultant/scientific
Speaker's bureau: Quest Diagnostics
Stephanie Stewart
Kristin Stockard
Dana Sturtevant
Wadi Suki
Grant/research support: Genzyme;
Consultant/scientific advisor: Genzyme;
Speaker’s bureau: Genzyme
Mary Sundell
Duane Sunwold
Lynda Szczech
Grant/research support: Ortho Biotech
Paul Szczybor
Harold Szerlip
Michael Talamantes
Joseph Vassalotti
Miguel Vazquez
Joyce Vergili
Speaker’s bureau: Shire Pharmaceutical
Thomas Vesely
Consultant/scientific advisor: W.L. Gore,
Pervasis Therapeutics, Elcam, Inc.
Ronald Victor
Theodôr Vogels
Bradley Warady
Speaker’s bureau: Genentech
Consultant/scientific advisor: Watson,
Amgen, Ortho Biotech, Roche; Speaker’s
bureau: Watson, Amgen, Ortho Biotech
Myles Wolf
Grant/research support: Shire; Consultant/
scientific advisor: Ineos; Speaker’s bureau:
Abbott, Genzyme
Jack Work
Consultant/scientific advisor: Vascular
Access; Speaker’s bureau: Vascular Access
Linda Wright
Stephen Textor
Kurt Wargo, David Warnock
Ravi Thadhani
Grant/research support: Genzyme, Amgen;
Grant/research support: Abbott; Speaker’s
Consultant/scientific advisor: Genzyme, Amgen
bureau: Abbott, Genzyme
Sarah Washburn
Charlie Thomas
Tiffany Washington
Cheryl Thomas
Amy Waterman
Grant/research support: Waterpik, Sonicare,
Pat Weber
Speaker’s bureau: Astellas
Steven Wu
Qingyu Wu
Alexander Yevzlin
Speaker’s bureau: Pfizer
Kim Zuber
Grant/research support: Amgen, Genzyme
Corporation
Kathryn Thurber-Smith
Matthew Weir
Trent Tipple
Consultant/scientific advisor: Bristol-Myers
Ashita Tolwani
Squibb, Sanofi Aventis, MSD Pharmaceuticals,
Speaker’s bureau: Gambro Renal Products
Novartis, Boehringer Ingelheim; Speaker’s
Faith Tootell
bureau: Bristol-Myers Squibb, Sanofi Aventis,
Joseph Torrealba
MSD Pharmaceuticals, Novartis, Boehringer
Jay Wish
Grant/research support: Gambro Renal
Products
Proctor and Gamble
Alexander Wiseman
Richard Ward
Maria Taylor
Biotene; Other financial or material support:
advisor: Genzyme, Fresenius, Roche
Ingelheim
p.41
Physician Program
Pre-Conference Courses and Workshops
Transplant Course: Transplantation Trends in the 21st Century
Know the current strategies to minimize cardiovascular morbid-
n
ity and mortality from the early stages of chronic kidney disease
through transplantation.
Wednesday April 2, 2008
8:00am–3:45pm
Preregistration and course fee of $150 are required for meeting
Course Directors: Milagros D. Samaniego, MD and Dianne McKay, MD
registrants. Participation is limited. Light breakfast, box lunch,
Session 220
and course syllabus included.
Course Description: The 2008 Transplant Course has been designed to
review both the most recent advances in transplant immunosuppression
and diagnostics, and current interventions to increase the donor pool
and minimize long-term morbidity in the kidney transplant recipient.
The course presents an update on immunosuppressants and new im-
time/faculty
topic
8:00am–8:30am
Breakfast
8:30am–8:45am
Introduction
munosuppression trends — including steroid withdrawal and avoidance protocols. The new diagnostic techniques — including the recent
8:45am–9:15am
changes in the Banff classification of allograft pathology, and the
New Immunosuppression Trends
state-of-the-art of genomic and proteonomic diagnostics — will be
reviewed using a case discussion format and computer interaction
9:30am–10:15am Delayed Graft Function, Dialysis
with the audience.
R. Michael Hofmann, MD
and CRRT in Organ Transplant
Recipients
The course will also address three challenging areas of kidney transplantation in the 21st century: the management of chronic kidney
disease and dialysis in recipients of other solid organ transplants, the
treatment of the kidney transplant candidate and recipient with chronic
10:15am–10:30am
Break
10:30am–11:00am TA, IF: The ABC of Transplant
Jose Torrealba, MD
Pathology – Case Presentations
Target Audience: This course is designed for community nephrologists,
11:15am–12:00pm
Genomics and Proteonomics in
transplant nephrologists, nephrology fellows, transplant coordinators,
Edmund O’Riordan, MD
Kidney Transplantation: Unravel-
infections, and the current interventions to diagnose and manage
cardiovascular disease in the transplant candidate and recipient.
ing the Molecular Imprinting of
transplant pharmacists and other professionals involved in the care of
Transplant Dysfunction
the kidney transplant patient.
Course Objectives: Upon completion of this course the attendee
12:00pm–1:00pm
should be able to:
Discuss current and upcoming immunosuppressants, their mecha-
n
nisms of action, and the new immunosuppression trends.
Lunch with Faculty
1:00pm–1:30pm
Paired-Kidney Exchange
Ajay Israni, MD, MS
Programs: The Next Trend
1:40pm–2:30pm
Management of the Transplant
Alexander Wiseman, MD
Patient with Chronic Infection:
Discuss the impact of delayed graft function in kidney transplant
n
outcomes, and the practical aspects of dialysis in kidney and other
solid organ transplant recipients with acute kidney injury or CKD.
Be familiar with the updated Banff 2005 classification of allograft
n
pathology with emphasis on the current terminology of acute and
How I Treat My Patients
chronic allograft rejection and new diagnostic categories.
Understand the concept and formats of paired kidney exchange
n
programs, and the role of these programs to improve access of
dialysis patients to kidney transplantation.
Manage kidney transplant patients and candidates with chronic
n
viral and fungal infections.
p.42
time/faculty
topic
2:40pm–3:10pm
Cardiovascular Disease: From
Alan Wilkinson, MD
CKD to Transplantation and Back
3:20pm–3:40pm
Roundtable: Questions
All Faculty
and Answers
3:45pm Closing Remarks
Integrated Hemodialysis/Peritoneal Dialysis Course
7:30am–5:30pm
Course Director: Joanne M. Bargman, MD, FRCPCC
Session 221
Course Description: This course is designed with multiple goals for the
kidney health care professional involved in identifying the physiology
and techniques of peritoneal dialysis and hemodialysis. The relationship
between clinical outcomes and different renal replacement modalities
registrants. Limited to 125 participants. Light breakfast, box
lunch, and course syllabus included.
time/faculty
topic
7:30am–8:00am
Breakfast
8:00am–8:10am
Introduction
8:10am–8:50am
Comparative Outcomes of
Peter Blake, MD, FRCPC, FRCPI
HD and PD
8:50am–9:20am
Modality Selection and Initiation
John M. Burkart, MD
of Dialysis
9:20am–10:00am The Hemodialysis Prescription
Robert D. Toto, MD
and Monitoring Solute Clearance
10:00am–10:40am
Prescribing PD: Why PD is Not HD
10:40am–10:55am
Break
10:55am–11:30am
Blood Pressure and Euvolemia in
Robert D. Toto, MD
Hemodialysis
11:30am–12:05pm
Blood Pressure and Euvolemia
John M. Burkart, MD
in PD
Target Audience: Practicing nephrologists, nephrology fellows
12:05pm–1:00pm
LUNCH – Intradialytic Complica-
in training, advanced practitioners and nephrology nurses.
Bertrand L. Jaber, MD, FASN
tions: Selected Case Studies
1:00pm–1:30pm
Vascular Access for Hemodialysis
Jack Work, MD
– Case Studies (Noninfectious)
1:30pm–2:00pm
Insertion and Management of the
Beth Piraino, MD
PD Catheter
2:00pm–2:40pm
Hemodialysis-Related Infections
to treat chronic kidney disease will be addressed. The attendee will also
gain an understanding of infectious and noninfectious complications,
the importance of proper access in both PD and HD, potential complications of access problems, and learn how to identify treatment related
complications and discuss treatment strategies.
Course Objectives: Upon completion of this course, the attendees
should be able to:
Identify the physiology and techniques of peritoneal dialysis and
n
hemodialysis
Understand the relationship between clinical outcomes and different
n
renal replacement modalities to treat chronic kidney disease.
Understand the basis and practical application of dialysis dose pre-
n
scription in peritoneal and hemodialysis.
Understand the infectious and noninfectious complications of perito-
Laura Dember, MD
n
neal and hemodialysis.
Understand the importance of proper access in both peritoneal dialy-
n
sis and hemodialysis and potential complications of access problems.
2:40pm–3:20pm
PD-Related Infections
Beth Piraino, MD
Identify treatment-related complications in peritoneal and hemodi-
n
alysis and discuss potential treatment strategies.
p.43
Physician Program
time/faculty
topic
time/faculty
topic
3:20pm–3:35pm
Break
7:15am–7:45am
Breakfast
3:35pm–4:15pm
Noninfectious Complications
7:45am–8:00am
Welcome and Introduction
of PD
Kenneth Abreo, MD and
Arif Asif, MD
4:15pm–5:00pm
Home Hemodialysis Therapies
Christopher Chan, MD
5:00pm–5:30pm Vascular Anatomy of Importance
Kenneth Abreo, MD
to the Interventional Nephrologist
It’s About the Money: Reimburse8:15am–8:30am Road Map for the Interventionilist:
Dialysis Patients
Richard Mishler, MD
Types of AVFs and AVGs
Closing Remarks
8:30am–8:45am
How to Increase the Number
Thomas Golper, MD, FASN, FACP ment Guidelines in the Care of
5:30pm
8:00am–8:15am
Alexander Yevzlin, MD
and Quality of Incident ArterioVenous Fistulas
8:45am–9:00am
Interventional Nephrology Course
7:45am–4:30pm
Course Co-Directors: Kenneth Abreo, MD and Arif Asif, MD
Session 222
The Art of Access Examination
Tushar Vachharajani, MD,
FASN, FACP
9:00am–9:15am
Examining Arteriovenous Grafts
Ivan Maya, MD
for Problems
9:15am–9:30am
The ABCs of Surveillance:
Anatole Besarab, MD
Is it Necessary?
9:30am–9:45am
Fistula Maturation:
Bart Dolmatch, MD
The Interventionalist’s Role
9:45am–10:15am
Break
10:15am–10:30am
Excellent Vascular Access but Ter-
Arif Asif, MD
rible Hand Pain: What Do You Do?
10:30am–10:45am
The Dos and Don’ts of Balloon
Steven Wu, MD
Angioplasty
Target Audience: This course is designed for nephrologists, fellows and
10:45am–11:00am
The Swollen Arm: Diagnosis and
other kidney health care professionals.
Anil Agarwal, MD
Treatment of Central Vein Stenosis
11:00am–11:15am
The Thrombosed Vascular Access:
Jeffrey Hoggard, MD
Thrombolysis and Angioplasty
11:15am–11:30am
The When, Where, and How of
Bharat Sachdeva, MD
Stents and Stent Grafts
Course Description: Diagnostic and interventional procedures are critical to the care of nephrology patients. This course introduces a variety of
interventional and diagnostic procedures that are critical to the care of
kidney patients. The procedures include: renal biopsy, placenebt ad renivak of temporary and permanent central venous catheters and peritoneal dialysis catheters, and monitoring as well as salvage procedures for
failing or thrombosed fistulas and grafts and insertion of intravascular
coils and stents. Recent updates on hand ischemia and its management
as well as intravascular stent insertion and its benefits will also be provided. In addition to didactic sessions, workshops to provide hands-on
training, focusing on insertion of tunneled dialysis catherers, percutaneous balloon angioplasty and declotting procedures.
p.44
time/faculty
topic
11:30am–11:45am
Complications of Endovascular
Jack Work, MD
Procedures: Prevention
and Treatment
11:45am–12:00pm
Contrast Nephropathy, Contrast
Aris Q. Urbanis, MD
Allergy, and Conscious Sedation:
Minimizing the Dangers
12:00pm–1:30pm
Lunch
1:30pm–1:45pm
Tunneled Hemodialysis
Stephen R. Ash, MD, FACP
Catheters: Hate Them but Can’t
Do Without Them
1:45pm–2:00pm The Bad and The Ugly of Tunneled
Jamie Ross, MD
Hemodialysis Catheters
2:00pm–2:15pm
Peritoneal Dialysis: The Endan-
Gabriel Contreras, MD, MPH
gered Dialysis Modality
2:15pm–2:30pm
Where Do I Begin: Interventional
Donald Schon, MD
Training and Interventional Centers
Dialysis Unit Management Course
8:00am–5:00pm
Course Director: Peter B. DeOreo, MD, FACP
Session 223
Course Description: The emphasis of this course will be on the role of
the key members of the facility management in leading the physician
and patient care staff toward quality outcomes. In the coming era of
diminished reimbursement, reimbursement contingent on achieving
quality outcomes, the facility leadership will increasingly be faced
with choices and trade-offs. Efficient management leads to the operating
margin that sustains the quality mission. Topics will include the
understanding of national quality goals, trade-offs in cost, quality and
value as well as understanding the ethical dilemmas created by quality
contingent reimbursement.
Target Audience: Designed for physician directors and nurse managers.
The course will also be of interest to patient care supervisors, administrators and quality managers.
Course Objectives: Upon completion of this course, the attendees
should be able to:
Workshop Sessions
Understand the national quality goals
n
Understand the trade-offs in cost, quality, value
n
2:30pm–4:30pm
Workshop A
Location: San Antonio 1
(Leader: Stephen R. Ash,
Tunneled Hemodialysis Catheter
MD, FACP)
Insertion
Understand the ethical dilemmas created by quality contingent
n
reimbursement
Understand the impact of bundling on facility revenue
n
Understand the role of the key professionals in measuring and
n
Jamie Ross, MD
managing quality
Anil K. Agarwal, MD
Understand the new AAMI water standards and water system
n
Ivan D. Maya, MD
disaster recovery
Sumit Kumar, MD
Steven Wu, MD
Workshop B
Location: San Antonio 4
(Leader: Donald Schon, MD)
Balloon Angioplasty Workshop
Aris Q. Urbanis, MD
Alexander S. Yevzlin, MD
Bharat Sachdeva, MD
Tushar Vachharajani, MD
Jeffrey Hoggard
p.45
Physician Program
time/faculty
topic
8:00am–8:30am
Welcome and Breakfast
8:30am–9:30am
The National Quality Agenda Pay
Jay B. Wish, MD
for Performance
9:30am–10:30am
The Ethics of Adverse Selection in
Mary Ann Baily, PhD
the Era of Pay for Performance
10:30am–10:45am
Break
10:45am–11:45am
Using Data to Drive Improvement
John W. Hartman, MD
“Good Enough is Good Enough”
11:45am–12:45pm
Intelligent Design in Medication
George Aronoff, MD
Protocols
12:45pm–1:15pm
Lunch Break
1:15pm–2:15pm
The Role of the Medical Director
Alan S. Kliger, MD
in Quality and Safety
2:15pm–2:45pm
The Role of the Registered Nurse
Carol Roe, RN, JD
in Quality and Safety
2:45pm–3:00pm
Break
3:00pm–3:45pm
What’s Happening in Financing
of ESRD
3:45pm–4:45pm
Update on AAMI Water Standards
Richard A. Ward, PhD
and Water System Disaster Recovery
Nephrology Recertification: An Audience Participation
Forum for Fun, Education and ABIM Credit
9:00am–5:00pm
Session 224
Course Director: Harold M. Szerlip, MD
Course Description: One of the requirements for nephrology recertification is to successfully obtain a total of 100 points with a minimum of 20
points in medical knowledge. This hurdle must be cleared before taking
the secure exam. Participation in the NKF’s “Nephrology Recertification Audience Participations Test for Credit” is a painless, fun and an
educational way to complete one of those booklets. Each multiple
choice question will be answered by the audience using a computerized
response system. The results will be displayed and then an expert will
discuss the question, present appropriate background information and
make a conclusion as to what he/she thinks is the correct answer. Audience discussion will be encouraged. At this time, each member of the
audience will have the opportunity to record their “official” answer for
credit. At the end of the day you will have completed one of the requirements for recertification, learned a great deal and have fun doing it!
Course Requirements: The Nephrology Recertification Course will
review SEP Nephrology Module 27-R as well as the 2007 update (A7-E).
For those attendees already enrolled in the ABIM Maintenance of
Certification Program (MOC), please confirm that you bring these
booklets and the answer sheets on-site.
Course Objectives: Upon completion of this course, participants will be
able to:
Identify aspects of general nephrology
n
Identify new developments in the field
n
4:45pm–5:00pm
Questions and Closing Comments
Obtain credit towards recertification in nephrology.
n
p.46
Course Faculty:
Pre-registration and course fee of $50 ($25 for fellows) are required
John Jason White, MD
for meeting registrants. Participation is limited. Light breakfast,
Harold M. Szerlip, MD, FACP, FCCP
box lunch, and course syllabus included.
time
topic
time
topic
7:30am–8:00am
Breakfast
7:30am–8:00am
Registration and ContinentalBreakfast
8:00am–11:30am
Review of SEP Nephrology
Module 27-R
11:30am–12:00pm
Question and Answer Session
12:00pm–1:00pm
Lunch
1:00pm–4:30pm
Review of the 2007 Update (A7-E)
4:30pm–5:00pm
Question and Answer Session
5:00pm
Concluding Remarks
8:00am–8:15am
Welcome, Introduction, and Some
Marc A. Pohl, MD
Reflections on Ray W. Gifford, Jr., MD
8:15am–8:45pm
Concurrent Use of Pulse Pressure
Stanley S. Franklin, MD, FACP,
and Mean Arterial Pressure Best
FACC
Defines Hypertensive Cardiovascular
Risk: New Data from the Framingham
Heart Study
Ray W. Gifford Jr., MD Hypertension Symposium
8:45pm–9:15pm
Is There a Blood Pressure That Is
Larry G. Hunsicker, MD
Too Low?
9:15pm–9:30pm
Discussion
9:30pm–10:00pm
What is Someone from the North-
Norman K. Hollenberg, MD, PhD
Do with Well Being?
Session 225
7:30am–5:30pm
Course Director: Marc A. Pohl, MD
10:00pm–10:30pm
Genetic Determinants of Hyper-
Thu H. Le, MD
tension and Kidney Injury in a
Mouse Model of Chronic Kidney
Disease
Target Audience: This activity is designed for advanced nephrologists,
physicians in training, as well as other physicians who are interested
and involved with the management of hypertension and cardiovascular
disease.
east USA Doing in a Tropical Rain
Forest, and What Has That Got to
10:30pm–10:45pm
Discussion
10:45pm–11:00pm
Break
11:00pm–11:30pm
ACE2 and Ang-(1-7) in Normoten-
K. Bridget Brosnihan, PhD
sive and Hypertensive Pregnancy
11:30pm–12:00pm
BOLD MR to Evaluate Tissue Oxy-
Stephen C. Textor, MD
genation in Renovascular Disease
12:00pm–12:15pm
Discussion
12:15pm–1:15pm
LUNCHEON
Course Objectives: Upon completion of this course, attendees will be
able to:
Review the latest advances in basic physiology, biochemistry, and mo-
n
lecular biology relative to hypertension, vascular damage, myocardial
infarction, and heart failure
Acquire the latest information and new direction in the management
n
of atherosclerosis and cardiovascular disease
Review the pathophysiology of hypertension and the implications
n
for therapy
Examine recent clinical trials in hypertension
n
p.47
Physician Program
time
topic
1:15pm–1:45pm
Heart Felt Lesson on Stem Cell
Marc Penn, MD, PhD
Based Ischemic Tissue Repair
1:45pm–2:15pm
The Cardiac Protease Corin and
Qingyu Wu, MD, PhD
Hypertension
2:15pm–2:30pm
Discussion
2:30pm–3:00pm
Dietary Salt and Endothelial
Paul W. Sanders, MD
Function
3:00pm–3:30pm
Uric Acid: A Mediator of Early
Daniel I. Feig, MD, PhD, MS
Onset Essential Hypertension
3:30pm–3:45pm
Discussion
3:45pm–4:00pm
BREAK
4:00pm–4:30pm
The Sympathetic Nervous System
Ronald G. Victor, MD
in Hypertensive Disorders
4:30pm–5:00pm
Aldosterone and the Kidney:
Emmanuel L. Bravo, MD
From Bench to Bedside
5:00pm–5:15pm
Discussion
5:15pm–5:30pm
Concluding Remarks
5:30pm
Adjourn
Nephrology 201 For Advanced Practitioners
Session 620
7:30am–5:30pm
Please see page 64 for course details.
Separate Registration and Fee Required.
p.48
Leading the Way...
yesterday, today & tomorroW.
Since the 1970s, Novartis researchers have been actively working to improve quality of life and
survival for every person undergoing transplant surgery. Today, Novartis remains committed to
research and development, targeting new ways to ensure even greater transplant success.
By researching new pathways, Novartis strives to improve the function and sustainability of
every transplanted organ with reduced side effects from treatment.
Together we can make a bigger difference.
©2007 Novartis
2/07
NTP-OT-0059-A
WORKSHOPS
Separate Registration and Fee Required
An additional fee of $30 per workshop is required (includes a box
Management of Hyperphosphatemia Using Calcium vs. Non-Calcium Based Binders
lunch). Tickets for these workshops may be purchased at the NKF
Session 232
Ticket Sales Booth in the Registration Area. Space is limited, so
Friday, April 4, 12:00pm–1:15pm
participation is available on a first-come, first-served basis.
Chair: Stuart M. Sprague, DO
Controversies in Living Donor Transplantation
Volume Overload in the
Dialysis Patient
Session 230
Session 233
Thursday, April 3, 12:00pm–1:30pm
Chair: Milagros D. Samaniego, MD
Chair: Joel Glickman, MD, FACP
Access to kidney transplantation has been curtailed by the lack of
Chronic fluid overload is a major cause of left ventricular hypertrophy
sufficient deceased donor organs. In order to overcome the imbalance
(LVH) in dialysis patients. Moreover, since LVH may be a modifiable risk
between organ demand and offer, living donors have become the pre-
factor, volume control may improve life expectancy by decreasing car-
ferred source of organs for kidney transplantation. To increase living
diovascular risk. Given that prevention is always the best strategy, the
donation, the monetary compensation of the donor or the provision of
first talk will address novel methods to increase dietary sodium adher-
medical care following donation has been proposed. These proposi-
ence. In the second talk, we will review the benefits of diuretic use to
tions pose both financial and ethical difficulties.
provide consistent and improved volume status. We will conclude with
To discuss the alternatives and current proposals in front of Congress,
two world leaders in kidney transplantation: Dr. Francis Delmonico –
a lively question and answer period — please feel free to bring a
challenging case!
former President of the Board of Directors of UNOS, and
Dr. Arthur Matas – current President of the American Society of
Transplant Surgeons, will discuss the different alternatives to increase
living donation, the current initiatives to eliminate the sale of organs
abroad, and the Pros and Cons of donor compensation.
Hemoglobin Targets for Anemia Management in CKD
Session 234
Chair: Jeffrey Berns, MD
Impact of Surveillance on AV Graft Outcomes
Session 231
Friday, April 4, 12:00pm–1:15pm
Co-Chairs: Charmaine Lok, MD and Michael Allon, MD
Recent randomized controlled trials in patients with CKD, showing
either lack of benefit or harm with targeting hemoglobin levels above
12 or 13 g/dl with ESA therapy have led to reexamination of the appropriate hemoglobin target in these patients. Additional information
regarding risks of ESA therapy in patients with cancer appears to have
influenced considerations about the appropriate hemoglobin target in
This workshop promises a high energy debate on the impact of access
CKD patients. The FDA has also focused attention in this matter. There
surveillance on arteriovenous grafts outcomes. The various methods
has also been much discussion of the difference between hemoglobin
of access surveillance, their advantages, challenges, and costs will be
“target” and achieved hemoglobin levels. This discussion will consider
reviewed and examined in this dynamic lunchtime session. Extra time
the pros and cons of targeting and maintaining hemoglobin levels
is provided to allow the participant to interact with expert speakers to
above and below 12 g/dl.
explore the future directions in this important area of access care.
p.50
Physician
Program
Accreditation
Note: Acquiring 40.5 hours requires continu-
Credit Hours: Pre-Conference Courses
ous participation from Wednesday morning
5.25
Transplant Trends in the
by the Accreditation Council for Continuing
through Saturday morning. Many participants
21st Century
Medical Education to provide continuing medi-
opt for periodic breaks, which make their re-
9.0Integrated Hemodialysis/Peritoneal
cal education for physicians. The National
ported credit hours somewhat less. Additional
Kidney Foundation takes responsibility for the
credits are provided for courses requiring
6.75Interventional Nephrology
content, quality and scientific integrity of this
separate registration, as noted ahead.
CME activity.
CME Credit
The National Kidney Foundation designates
Dialysis
7.5
Dialysis Unit Management
8.0
Nephrology Recertification
7.5
Nephrology 201 for Advanced
Practitioners
8.0Gifford Hypertension Symposium
this educational activity for a maximum of 40.5
AMA PRA Category 1 CreditsTM. Physicians
should only claim credit commensurate with
the extent of their participation in the activity.
Vist the KDIGO booth #719.
The First Global Nephrology
Guidelines Are Now Available
Prevention, Diagnosis,
Evaluation and Treatment
of Hepatitis C in
Chronic Kidney Disease,
published in Kidney International,
April 2008
www.kdigo.org
©2008 National Kidney Foundation, Inc. All rights reserved.
02-77-435A
p.51
Physician
Program
Wednesday, April 2
time/location
8:00am–3:45pm
|Texas D
session # session
220
notes
|Transplantation Trends in the 21st Century
Course Director(s)
credits
5.25
Dianne McKay, MD
7:30am–5:30pm
|Texas C
221
|Integrated Hemodialysis/Peritoneal Joanne M. Bargman, MD, FRCPC 9.0
Dialysis Course
|Grapevine 1
225
|Ray W. Gifford Jr., MD Hypertension Symposium
Marc A. Pohl, MD
8.0
Kenneth Abreo, MD
6.75
Merck & Co., Inc.
8:30am–5:30pm
|Texas 6
222
|Interventional Nephrology Course
Arif Asif, MD
8:00am–5:00pm
|Texas 1/2
Joint with Councils
¯
Joint with Physicians
|Dialysis Unit Management Course
7.5
224
|Nephrology Recertification Course
Herald M. Szerlip, MD
8.0
801
|Association of Mineral Metabolism, Vitamin D Chair: Myles Wolf, MD, MMSc
1.5
9:00am–5:00pm
|Texas 3/4
223 7:30pm–9:30pm
|Grapevine D
Therapy, and Calcimimetrics on Chronic Kidney
Disease Patients Survival
|Welcome and Introductions
|Associations of Mineral Metabolism with Myles Wolf, MD, MMSc
Patient Survival
|Impact of Vitamin D Therapy on Patient Survival
Daniel Coyne, MD
|Does Direct Modulations of the CaR Affect Stuart Sprague, DO
Patient Survival?
|Questions and AnswersAll Faculty
˘
Separate Registration and/or Fee Required
·
p.52
Thursday, April 3
time/location
6:00am–8:00am
|Grapevine C
session # session
notes
faculty
802
Chair: Martin J. Abrahamson, MD 1.75
|The Impact of Glycemis Control in Patients credits
Novo Nordisk
|Glycemic Control in Patients with CKD Mark S. Roberts, MD, MPP
|How Low Should You Go?
|When and How to Use Insulin in Patients with
Chronic Renal FailureArturo R. Rolla, MD
|Panel Discussion/Question and Answer SessionAll Faculty
|Grapevine D
|Trends and Challenges in CKD Progression 803
Chair: Ann O’Hare, MD
1.5
Ortho Biotech, L.P.
|Epidemiology of Chronic Kidney Disease in Lesley Stevens, MD, MS, FRCPC
˘
|Natural History of Chronic Kidney Disease Separate Registration and/or Fee Required
Older Adults
Brenda Hemmelgarn, MD
in the Elderly
|Reasons Why Evidence for the Management Ann O’Hare, MD
of CKD in Younger Individuals May Not Be
Generalizable to Older Adults with CKD
8:00am–9:45am
|Texas C
260
|Secondary Hypertension
Chair: Marc A. Pohl, MD
|When to Suspect Secondary HypertensionRonald Victor, MD
|Endocrine Causes of HypertensionEmmanuel Bravo, MD
|Secondary Hypertension Due to Drugs
Matthew R. Weir, MD
|Texas 1/2
|Controversies in Transplantation
Co-Chairs: Alan Wilkinson, MD
272
|Re-Transplantation: Patient Selection and 1.75
and R. Michael Hofmann, MD
1.75
·
Panduranga S. Rao, MD, DNB, MS
Management of Candidates on Dialysis
|Kidney Transplantation for Other Solid-Organ Thomas A. Gonwa, MD, FASN, FACP
Recipients: A Nephrologist’s Point of View
|Transplantation of the Elderly Alan Wilkinson, MD
|From CKD to Transplantation: ¯
Dianne McKay, MD
Joint with Councils
Management of the Pregnant Patient
p.53
Physician
Program
Thursday, April 3
time/location
8:00am–9:45am
|Texas D
Continued
session # session
notes
faculty
261
Chair: Kamyar Kalantar-Zadeh, MD 1.75
|Nephrogenic Systemic Fibrosis
|Lessons Learned from the NSF Registry
|Pathophysiology and Treatment Options Robert Reilly, MD
credits
Mark A. Perazella, MD
for NSF: What are the Data?
|Risk-Benefit of Gadolinium vs. Iodinated Roger Rodby, MD
Contrast in CKD
|9:45am–10:00am
|Break
10:00am–12:00pm
|Texas C
262
|Acute Kidney Injury
Joint with Councils
¯
·
and Ravindra Mehta, MD
|Impact of AKI on Long-Term Kidney Outcomes
|Impact of AKI on Patient OutcomesRavindra Mehta, MD
|Urinary Markers for AKI
|Strategies for Prevention of Contrast NephropathyEmil Paganini, MD
|Texas D
|Improving Vascular Access Outcomes
263
Paul W. Eggers, PhD
Paul M. Palevsky, MD
Co-Chairs: Ivan D. Maya, MD
2.0
and Charmaine Lok, MD
|Salvage of Early Fistula FailureAntoine Samaha, MD
|Pharmacologic Strategies to Delay Access Stenosis
|Debate: Fistula First – Is It Right for Everyone?
Prabir Roy-Chaudhury, MD
YesArif Asif, MD
No
Thomas Vesely, MD
12:00pm–1:30pm
|Ft. Worth 6/7
230
|Workshop: Controversies in Living Donor Transplantation
˘
Chair: Milagros D. Samaniego, MD 1.5
|Debate: Increasing the Donor Pool:
Is It Time to Compensate Donors?
ProArthur Matas, MD
Con
Francis Delmonico, MD
12:00pm–2:00pm
|Grapevine C
804
|Dietary Phosphorus and Outcomes in Patients with CKD
Chair: Stuart Sprague, DO
1.5
|DEBATE: Should Phosphorus be Controlled
by Dietary Restrictions in CKD?
Dietary Phosphorus Control Increases Death Risk!
Dietary Phosphorus Control Improves Survival!
Daniel Coyne, MD
˘
Co-Chairs: Michele Mokryzcki, MD 2.0
p.54
Thursday, April 3
time/location
2:00pm–3:00pm
|Texas A/B
Continued
session # session
264
notes
faculty
|NKF Presidential Address – The National Allan J. Collins, MD, FACP
credits
1.0
Kidney Foundation: Advancing Public Health in the U.S. and Around the World
|Shaul Massry Distinguished Lecture – Randomized Tom Greene, PhD
Co-Chairs: Michael Allon, MD and Observational Studies in Nephrology:
How Strong is the Evidence?
|3:00pm–3:30pm
|Break
3:30pm–5:15pm
|Texas A/B
265
|Late Breaking News
and Beth Piraino, MD
|Aggrenox Prevention of Graft Stenosis: Bradley Dixon, MD
|Primary Results for the Dialysis Access Harold Feldman, MD
|Consortium (DAC) Study GroupGerald Beck, PhD
|Daily Dialysis Studies: An Update
|International Quotidian RegistryRobert Lindsay, MD
|FREEDOM Study
Bertrand L. Jaber, MD
6:00pm–7:30pm
|Exhibit Hall
Nathan Levin, MD
|Frequent HD Network Trial
˘
1.75
|Opening Ceremonies in the Exhibit Hall – Visit Posters/Exhibits
7:30pm–9:30pm
|Grapevine C
815
|An Evidence-Based Review of the Management of Hyperphosphatemia and Its Pharmacoeconomic Impact on Patients with Stage 5 CKD: New Perspectives for Optimal Outcomes in 2008
Chair: Vincent Dennis, MD
1.5
|A Review of Recent Clinical Studies of Patients Lynda Szczech, MD
·
|A Pharmacoeconomic Analysis of Phosphate Wolfgang Winkelmayer, MD
Binders in the Treatment of Patients with Stage 5
¯
CKD: Impact on the Health Care System
Joint with Councils
p.55
Physician
Program
FRIday, April 4
time/location
6:00am–8:00am
session # session
notes
faculty
credits
|Grapevine D
809
|Assessing the Role of Proteinuria in the 1.5
Progression of Chronic Kidney Disease
|Proteinuria and Progression: Primary and Barry Brenner, MD
Secondary Prevention
|Fabry Disease; Proteinuria Without Hypertension: David Warnock, MD
Targets for Therapy
|Proteinuria: The Primary Outcomes Determinate Daniel C. Batlle, MD
Joint with Councils
in Progression of CKD
¯
·
810
|New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen |Improving Delivery of Pre-ESRD Care, Case DiscussionRonald Pisoni, PhD, MS
|Has Catheter Use Increased Due to Fistula First? Lawrence Spergel, MD, FACS
No! Case Discussion
|Managing Multiple Targets for Best Patient Outcomes, David Mendelssohn, MD, FRCPC
Case Discussion
|7:00am–8:00am
|Continental Breakfast in Exhibit Hall – Visit Posters/Exhibits
266
|Update on Nephrolithiasis
8:00am–10:00am
|Texas C
Co-Chairs: Michael J. Choi, MD and David Goldfarb, MD
|Obesity, Dieting and Kidney Disease
Orson Moe, MD
|Bariatric Surgery and Kidney Stones
John Asplin, MD
|Urologic Treatment of Stone Disease
Michael Grasso, MD
|Case Discussions
Michael J. Choi, MD
|Texas D
|Management of AKI
Chair: Ivan D. Maya, MD
267
2.0
|Management of Cardio-Renal Syndrome
Patrick Murray, MD
|Management of Hepato-Renal Syndrome
Warren Kupin, MD
|Debate: CRRT vs. IHD for ARF
2.0
CRRT is BettterAshita Tolwani, MD, MSc
IHD is BetterEmil Paganini, MD
|Texas B
284
|What’s New in PD
Chair: Michael Flessner, MD, PhD 2.0
Optimizing Peritoneal Membrane
Transport and Function
Michael Flessner, MD, PhD
|Prevention and Treatment of Peritonitis
Beth Piraino, MD
|PD for Management of CHF
John M. Burkart, MD
|10:00am–10:15am |Break
˘
|Grapevine C
p.56
Friday, April 4
time/location
10:15am–12:00pm
|Texas D
Continued
session # session
notes
faculty
credits
268
|End-of-Life Issues in CKD
Chair: Beth Piraino, MD
1.75
|Incorporating Palliative Care into the Dialysis UnitAlvin Moss, MD
|CPR vs DNR in the Dialysis Unit
Jean L. Holley, MD
|Withholding and Withdrawing Dialysis
Mi-Kyung Song, PhD, RN
12:00pm–1:15pm
|Exhibit Hall
|Lunch in the Exhibit Hall – Visit Posters/Exhibits
|Austin 1/2/3
|Workshop: Impact of Surveillance on 231
˘ AV Graft Outcomes
|Debate: Access Surveillance Improves Graft Outcomes
Co-Chairs: Charmine Lok, MD 1.25
and Michael Allon, MD
Yes!Anatole Besarab, MD
No!
Jack Work, MD
12:00pm–1:15pm
232
|Workshop: Management of Hyperphosphatemia Using Calcium vs. Non-Calcium Based Binders
˘ Chair: Stuart M. Sprague, DO
|Non-Calcium Binders
Wadi N. Suki, MD
|Calcium Binders
Wajeh Qunibi, MD
|Home Dialysis for the 21st Century
1.25
˘
|Austin 4/5/6
1:15pm–3:15pm
|Texas C
269
|Innovative Approaches to Dialysis ModalitiesRobert S. Lockridge, Jr., MD
|Assessing Adequacy Across Dialysis Modalities/ 2.0
Joanne M. Bargman, MD, FRCP
Timing of Home Dialysis Modalities
|Debate: Is Conventional Dialysis Outdated? HD 3x weekly vs. Daily HD
Michael Rocco, MD, MSCE
Con
Thomas Depner, MD
|Texas D
Chair: Srinivasan Beddhu, MD
270
2.0
|Late-Breaking Controlled Trials: Sulodexide vs. Placebo
|Obesity and CKD
·
Pro
for Treatment of Diabetic NephropathyEdmund J. Lewis, MD
|Interactions Between Obesity and Inflammation in CKD |Debate: Is Obesity Good or Bad in CKD Patients?
Obesity is “Good”
Csaba Kovesdy, MD, FASN
Obesity is “Bad”Allon Friedman, MD
|Break
¯
|3:15pm–3:30pm
Joint with Councils
p.57
Physician
Program
Friday, April 4
time/location
3:30pm–5:30pm
|Texas D
Continued
session # session
notes
faculty
credits
271
Chair: Miguel Vazquez, MD
2.0
|Fluid and Electrolytes
|Update on Management of Hyperkalemia
Daniel Batlle, MD
|Update of Hypophosphatemia
Zalman S. Agus, MD
|Update on Hyponatremia Therapy
Tomas Berl, MD
|Update on Metabolic AlkalosisL. Lee Hamm, MD
|Texas B
|International and National Guideline Activities: 2008 285
Co-Chairs: Garabed Eknoyan, MD 2.0
and Michael Rocco, MD, MSCE
|KDIGO: Opening Remarks and Guideline Update: Garabed Eknoyan, MD
Hepatitis C in CKD; Care of the Transplant Patient
|An Overview of the KDIGO CKD-MBD Guidelines
Joint with Councils
¯
Tilman Drüeke, MD
|KDOQI 2008 and Beyond
|KDOQI Clinical Practice Guidelines for Nutrition in Bradley Warady, MD, and
|Children with CKD: 2008 Update
Donna Secker, PhD
·
5:30pm–7:00pm
|Exhibit Hall
|Networking Reception in the Exhibit Hall – Visit Posters/Exhibits
7:00pm–9:00pm
|Grapevine D
811
|Cardiovascular Disease in CKD Patients Pre-Dialysis and On Dialysis
Chair: Mark J. Sarnak, MD
1.5
|Sudden Cardiac Death in Pre-Dialysis CKD Charles Herzog, MD
Patients and in Patients Undergoing Dialysis
|Calcium and Phosphorus as Cardiovascular David Bushinsky, MD
Risk Factors
|Coronary Artery Disease: Screening and Therapy
Mark J. Sarnak, MD
|Grapevine C
|Optimal Patient Outcomes: Identification and Treatment Chair: Anatole Besarab, MD
812
1.5
of Iron Deficiency Anemia in Early CKD
AMAG Pharmaceuticals, Inc.
|Prevalence and Diagnosis of Anemia in Patients with CKD Allen R. Nissenson, MD
|State of the Art in Treatment of Iron Deficiency Anemia: Ajay K. Singh, MB, MRCP
|Case Review and Panel DiscussionAnatole Besarab, MD
˘
Sharon Moe, MD, and
p.58
Saturday, April 5
time/location
6:00am–8:00am
|Grapevine D
session # session
notes
faculty
credits
814
Chair: Tammy Ho, MD
1.5
|Exploring the Link Between Chronic Kidney Disease and Cardiovascular Disease: Reducing Mortality
Tammy Ho, MD
|Exploring the Association Between Cardiovascular Tammy Ho, MD
Disease and Chronic Kidney Disease
|Mechanisms that Contribute to Altered Ravi Thadhani, MD
Cardiovascular Regulation in Chronic
Kidney Disease
|Management Strategies for Reducing Kamyar Kalantar-Zadeh, MD
Cardiovascular Risk Factors in Chronic
Kidney Disease
813
|Chronic Kidney Disease Interventions: Improving CKD and CVD Outcomes Chair: Peter McCullough, MD
1.5
|Grapevine C
˘
A Breakfast Symposium
|KEEP Overview and Social Conceptions of Allan J. Collins, MD
Kidney Disease: Myths vs. Realities
|Glycemic Control in Kidney Disease
Samy McFarlane, MD
|Interventions and CVD Interactions in Diabetics Peter McCullough, MD
with Proteinuria
8:00am–10:00am
|Texas A
273
|Hemodialysis Catheters: Minimizing Risk and Maximizing Outcomes
Co-Chairs: Michele Mokrzycki, MD 2.0
|Prevention of HD Catheter Infections Charmaine Lok, MD
|Individualized Management of HD Catheter- Michael Allon, MD
·
|Impact of Blood Pressure Control in CKDGeorge Bakris, MD
Related Bacteremia
|Treatment and Prevention of HD
Michele Mokrzycki, MD
Catheter Thrombosis
274
|Nutrition and Inflammation in CKD
Co-Chairs: Srinivasan Beddhu, MD 2.0
and Kamyar Kalantar-Zadeh, MD
|Inflammation and Wasting SyndromesRavi Thadhani, MD
|Is Malnutrition a Misnomer in Dialysis Patients?
|Insulin Resistance and Muscle Wasting in CKDEdward Siew, MD
Joint with Councils
¯
|Texas B
p.59
Physician
Program
Saturday, ApriL 5
time/location
Continued
session # session
notes
|10:00am–12:00pm |Brunch Served in Exhibit Hall – Visit Posters/Exhibits
|10:00am–10:15am |Break
faculty
credits
Co-Chairs: Michael J. Choi, MD 1.75
10:15am–12:00pm
|Texas D
275
|Update on Primary Glomerular Disease
and Gerald Appel, MD
|Focal Segmental Glomerulosclerosis
Stephen M. Korbet, MD
|Membranous Nephropathy
Jai Radhakrishnan, MD
|IgA NephropathyGerald Appel, MD
|Texas C
|Pharmacy and CKD
276
Co-Chairs: Maria Taylor, PharmD 1.75
and Kurt Wargo, PharmD
|Drug Dosing in CKD: Which GFR Equations to Use
Kurt Wargo, PharmD
|Prescribing Cardiovascular Medications in Alfred Cheung, MD
Dialysis Patients
12:00pm–1:15pm
Joint with Councils
|Austin 1/2/3
¯
·
˘ Chair: Joel Glickman, MD
|Enhancing Dietary Adherence to Sodium Restriction
Mary Ann Sevick, RN, ScD
|Use of Diuretics in Patients on Dialysis
Filitsa H. Bender, MD
|Austin 4/5/6
234
|Workshop: Hemoglobin Targets for Anemia Chair: Jeffrey S. Berns, MD
Management in CKD
233
|Workshop: Volume Overload in the Dialysis Patient
|Debate: Should We Target Hemoglobin Levels > 12 in CKD
˘ Hemoglobin > 12 g/dl is Good!
1.25
1.25
Hemoglobin > 12 g/dl is Bad!Lynda Szczech, MD, MCSE, FASN
1:15pm–3:15pm
|Texas D
277
|Why is Home Dialysis Under-Utilized in the U.S.?
Chair: Fredric Finkelstein, MD
|National Disparities in PD
|Factors Affecting Dialysis Modality Choice in the U.S.Rajnish Mehrotra, MD, FACP, FASN
|Approaches to Increasing Utilization of PD in the U.S.
Fredric Finkelstein, MD
|Texas A
|Lupus Nephritis: Controversies and Consensus
Co-Chairs: Julia B. Lewis, MD
278
2.0
Salim Mujais, MD
2.0
and Michael J. Choi, MD
|Debate: Induction Therapy of Lupus Nephritis
Use CyclophosphamideEdmund J. Lewis, MD
Use MycophenolateGerald Appel, MD
|Debate: Maintenance Therapy of Lupus Nephritis
Use CyclophosphamideEdmund J. Lewis, MD
Use MycophernolateGerald Appel, MD
|New Therapies for Lupus Nephritis
|3:15pm–3:30pm
|Break
Mary Anne Dooley, MD, MPH
˘
|Pharmacist Role in the Management of CKDAnne Liles, PharmD
p.60
Saturday, ApriL 5
time/location
3:30pm–5:30pm
|Texas C
Continued
session # session
notes
faculty
credits
279
Chair: Maria Taylor, PharmD
2.0
|Symptoms in CKD Patients
|Complaints of Dialysis Patients
Steven Weisbord, MD
|Sleep Disorders in Dialysis Patients
Mark Unruh, MD, MSc
|Pain Management in Dialysis Patients Maria Taylor, PharmD
|Depression in Dialysis Patients
Fredric Finkelstein, MD
|Texas A
|ESRD Quality Improvement
Chair: William McClellan, MD
280
|The ESRD Program: History of Quality
2.0
William McClellan, MD
Improvement Data
|Pay for Performance: What Lies Ahead?Alan S. Kliger, MD
|Debate: Pay for Performance: Will it Improve Patient Outcomes?
Pro
Jonathan Himmelfarb, MD
Con
John C. Stivelman, MD
|Texas D
490
|“Decrease the Increase”: A Model of Preventative ¯Glen H. Stanbaugh, MD
2.0
˘
Medicine in the 21st Century; Delaying the Anton C. Schoolwerth, MD, FAHA
Progression of CKD to ESRDEduardo Sanchez, MD, MPH
Robert Duncan, MPH
5:30pm–7:00pm
|Grapevine B
101
|Fellows Event: Career Choices in Nephrology/
Co-Chairs: Milagros D. Samaniego, MD
Faculty Reception (By Invitation Only)
and Sharon Moe, MD
·
¯
Joint with Councils
p.61
Physician
Program
Sunday, April 6
time/location
8:00am–10:00am
|Grapevine D
session # session
notes
faculty
credits
281
Co-Chairs: Michael J. Choi, MD 2.0
|Secondary Nephrotic Syndrome
and Gerald Appel, MD
|Light Chain-Related Glomerular DiseaseLaura Dember, MD
|Debate: HIV Associated Nephropathy: Is Biopsy Needed for Diagnosis
Biopsy is Not RequiredLynda Szczech, MD
Biopsy is Required
|Thrombotic Microangiopathy
Michael J. Choi, MD
|Grapevine A
|Caring for the Dialysis Patient
Joint with Councils
282
|Treatment of Blood Pressure in Dialysis Patients
|Management of Intradialytic Hypotension
Thomas Depner, MD
|Primary Care of the Dialysis Patient
Suzanne Bergman, MD
|Screening for Malignancy in the Dialysis Patient
Jean L. Holley, MD
|10:00am–10:15am |Break
¯
Paul Kimmel, MD
2.0
John Burkart, MD
10:15am–12:15pm
|Grapevine D
283
|ANCA Vasculitis: Treatments and Outcomes
Co-Chairs: Julia B. Lewis, MD 2.0
and Kirsten de Groot, MD
|Induction Therapy in ANCA Vasculitis
Kirsten de Groot, MD
|Maintenance Therapy in ANCA VasculitisLoic Guillevin, MD
|Controversial Issues in Small Vessel David Hellmann, MD
Vaculitis: A Rheumatologist View
|Panel DiscussionAll Faculty
|12:15pm
|Meeting Adjourns
˘
·
p.62
aDvaNCeD PraCTiTiONer
PrOgraM
Program Committee
Host Committee
Continuing Education Information
LaurieE.Benton,RN,PA-C,BS,MPAS
CheriGoldstein,PA-C
aaPa accepts Category i credit from aOaC-
Program Co-Chair
Dallas Nephrology associates, Dallas, Tx
CMe, prescribed credit from aaFP, and aMa
Scott and White Hospital, Temple, Tx
BarbaraWeisMalone,BSN,RN,CFNP
Program Co-Chair
TamiHyziewiczCase,PA-C
Scott and White Hospital, Temple, Tx
Program Goal
university of Colorado Health
To improve patient outcomes by enhancing
ScienceCenter, aurora, CO
Category i CMe credit for the Pra from organizations accredited by aCCMe.
This program is pending approval with the
american academy of Nurse Practitioners.
the advanced practitioners’ knowledge
DeborahGlidden,ARNP,BC,CNN
base and skills that affect the kidney and
by the accreditation Council for Continuing
Nephrology associates of Central Florida,
clinical practice.
Medical education to provide continuing medi-
Orlando, Fl
cal education for physicians. The National
Kidney Foundation designates this educational
TriciaHoward,MHS,PA-C
activity for a maximum of 32.0AMA PRA
South university, Savannah, ga
category 1 creditsTM. Physicians should claim
credit commensurate with the extent of their
Join us for a special session...
• KDIGO Preview of KDIGO CKD-MBD Guidelines
• KDOQI 2008 and Beyond
• KDOQI Clinical Practice Guidelines for
Nutrition in Children with CKD 2008 Update
Join
Friday, april 4, 2008
3:30 pM – 5:30 pM
rooM texas c
us on
©2008 National Kidney Foundation, Inc. All rights reserved.
• KDIGO Update Hepatitis C and Transplant Guidelines
02-77-435A
2008 international and
national Guideline activities:
p.63
ADVANCED PRACTITIONER
PRE-CONFERENCE COURSES
Session 620
Wednesday, April 12, 7:30am–5:30pm
Course Director: Laurie E. Benton, RN, PA-C, BS, MPAS
Course Description: This course is designed to take you from the
anatomy and physiology of the kidney through the clinical challenges
specific to the treatment of the different stages of kidney disease and
co-morbidities. Lectures and topics are presented by physicians and
advanced practitioners specializing in the field of nephrology. The content is selected to help you understand, diagnose and treat the basic,
to the most complex, nephrology patients. Whether you are a beginning or seasoned practitioner, it provides an outstanding opportunity to
learn through case studies relevant to your everyday clinical practice.
Target Audience: This course is designed for physician assistants and
time/faculty
topic
7:30am–8:00am
Continental Breakfast
8:00am–8:15am
Laurie E. Benton, RN, PA-C,
BS, MPAS
8:15 am–9:45am
Nephrotic vs. Nephritic Syndrome
Michael J. Choi, MD
9:45am–10:00am
Break
10:00am–11:00am
Transplant Medications (all types)
Mohanram Narayanan,
MD, FASN
11:00am–12:00pm
CKD Start to Finish
Kathleen Brady, MS, BC-ANP
nurse practitioners.
12:00pm–1:00pm
Lunch
1:00pm–2:00pm
Diagnostic Dilemmas in Dialysis,
Tricia Howard, MHS, PA-C
Part 1
2:00pm–3:00pm
Diagnostic Dilemmas in Dialysis,
Deborah Gidden ARNP,
Part 2
BC, CNN
3:00pm–3:15pm
Break
3:15pm–4:15pm
Nephrology Case Presentations
Charles J. Foulks, MD
4:15pm–5:15pm
Acute Renal Failure
Paul Szcybor, PA-C
5:15pm–5:30pm
p.64
Closing Remarks/Adjourn
Transplantation Trends in
the 21st Century
Session 220
Session 223
See page 42 for course details.
Session 221
˘
Wednesday, april 2
time/location
7:30am–5:30pm
|Texas 5
session # session
notes Course Director(s)
credits
620
˘Laurie E. Benton, PA-C, 7.5
|Nephrology 201 for Advanced Practitioners
|Integrated Hemodialysis/Peritoneal Joint with Physicians
221
·
RN, BS, MPAS
|Texas C
˘· Joanne M. Bargman, MD, FRCPC 9.0
Dialysis Course
8:00am–3:45pm
|Texas D
220
|Transplantation Trends in the 21st Century
˘· Milagros D. Samaniego, MD
5.25
Dianne McKay, MD
8:00am–5:00pm
223 Spring Clinical Meetings ’08
˘· Peter B. DeOreo, MD, FACP
7.5
Joint with Councils
|Texas 1/2
¯
Program
p.65
Program
Wednesday, april 2
time/location
7:30pm–9:30pm
|Grapevine D
Continued
session # session
notes faculty
801
·
|Association of Mineral Metabolism, Vitamin D credits
Chair: Myles Wolf, MD, MMSc 1.5
Patient Survival
Daniel Coyne, MD
Patient Survival?
Joint with Councils
¯
·
Thursday, April 3
time/location
6:00am–8:00am
|Grapevine C
session # session
802
|The Impact of Glycemis Control in Patients notes faculty
·
credits
Chair: Martin J. Abrahamson, MD 1.5
Novo Nordisk
|Grapevine D
|Trends and Challenges in CKD Progression 803
·
1.5
Ortho Biotech, L.P.
Older Adults
|Natural History of Chronic Kidney Disease Brenda Hemmelgarn, MD
in the Elderly
˘
p.66
Thursday, April 3
time/location
8:30am–10:00am
|Austin 4/5
notes faculty
credits
630
|WORKSHOP: Microscopy of Urinalysis Slides ˘
Peter Juergensen, PA-C
1.5
660
|The Renal Transplant EvaluationAlexander Wiseman, MD
1.0
675
|NKF and Students: A New Model for KEEP
Cynthia Lord, MHS, PA-C
1.0
661
|Derm Dilemmas in NephrologyElizabeth Adams, PA, MS
1.0
10:00am–11:00am
|Grapevine 5/6
session # session
10:00am–11:00am
|Austin 4/5
Continued
11:00am–12:00pm
|Austin 4/5
|12:00pm–2:00pm Appaloosa 4
12:00pm–2:00pm
|CAP Networking Luncheon (All are welcome!)
|Grapevine C
804
·
Chair: Stuart Sprague, DO
1.5
˘
Daniel Coyne, MD
2:00pm–3:00pm
|Texas A/B
264
|NKF Presidential Address –Allan J. Collins, MD, FACP
1.0
The National Kidney Foundation: Advancing Public
Health in the U.S. and Around the World
|Shaul Massry Distinguished Lecture – Randomized and Observational Studies in
Nephrology: How Strong is the Evidence? 662
|Hypertension and the Geriatric Patient
¯
1.0
363
|Sleep Disorders and Restless Legs
¯
Kimberly English, RN, FNP
1.0
4:00pm–5:00pm
|Texas 4
·
3:00pm–4:00pm
|Texas 5/6
Tom Greene, PhD
·
6:00pm–7:30pm
|Opening Ceremonies in the Exhibit Hall – Visit Posters/Exhibits
¯
|Exhibit Hall
Joint with Councils
p.67
Program
Thursday, April 3
time/location
7:30pm–9:30pm
|Grapevine C
Continued
session # session
notes faculty
credits
815
·
1.5
Joint with Councils
¯
·
FRiday, April 4
time/location
6:00am–8:00am
session # session
|Grapevine D
809
|Assessing the Role of Proteinuria in the Progression of Chronic Kidney Disease
notes faculty
credits
·
1.5
Targets for Therapy
|Grapevine C
810
No! Case Discussion
|Managing Multiple Targets for Best Patient Outcomes,
Case Discussion
|7:00am–8:00am
|Continental Breakfast in Exhibit Hall – Visit Posters/Exhibits
8:00am–9:00am
|Texas 5/6
664
|Understanding and Reading the Renal Ultrasound
David DeWalch, MSPA, PA-C, MS, MA 1.0
˘
p.68
FriDay, April 4
time/location
Continued
session # session
notes
|Texas 5/6
665
|Cholesterol Challenges in CKDRobert Page, PharmD, FCCP, |10:00am–10:15am faculty
|Break
268
·
|CPR vs. DNR in the Dialysis Unit
Jean L. Holley, MD
|12:00pm–1:15pm
|Workshop: Chair-Side Hemodialysis Evaluation
˘Arif Asif, MD
666
|Pediatric Renal DiseasesRonald Hogg, MB, ChB
667
|Surviving Malpractice: A Practical Approach
|3:15pm–3:30pm
Kristen Larson, RN, ANP, GNP, CNN 1.0
and Lisa Zokas Kindy, JD
˘
|Break
3:30pm–4:30pm
|Texas 5/6
1.0
2:15pm–3:15pm
|Texas 5/6
1.25
1:15pm–2:15pm
|Texas 5/6
1.75
12:00pm–1:15pm
|San Antonio 1/2/3 631
1.0
FAHA, BCPS
10:15am–12:00pm
|Texas D
credits
9:00am–10:00am
668
|Over-the-Counter Medication Complications
Johann Herberth, MD, FACP, FASN 1.0
285
|International and National Guideline Activities: 2008 Co-Chairs: Garabed Eknoyan, MD 2.0
3:30pm–5:30pm
|Texas B
·
Sharon Moe, MD, and
Tilman Drüeke, MD
Donna Secker, PhD
5:30pm–7:30pm
|Exhibit Hall
·
7:00pm–9:00pm
|Grapevine D
811
·
1.5
Joint with Councils
¯
Risk Factors
Mark J. Sarnak, MD
p.69
Program
FriDay, April 4
time/location
7:00pm–9:00pm
|Grapevine C
Continued
session # session
notes faculty
credits
812
·
1.5
Joint with Councils
¯
·
Saturday, April 5
time/location
6:00am–8:00am
session # session
|Grapevine C
813
|Chronic Kidney Disease Interventions: Improving CKD and CVD Outcomes notes faculty
credits
1.5
Chair: Peter McCullough, MD
Samy McFarlane, MD
with Proteinuria
|Grapevine D
814
|Exploring the Link Between Chronic Kidney Disease
and Cardiovascular Disease: Reducing Mortality
Chair: Tammy Ho, MD
1.5
Tammy Ho, MD
Kidney Disease
|Management Strategies for Reducing Cardiovascular
Risk Factors in Chronic Kidney Disease
˘
p.70
Saturday, April 5
time/location
8:00am–9:00am
|Texas 5/6
session # session
notes faculty
669
|Lupus Nephritis Updates: From Bench to Bedside
670
|Making CKD Part of Primary CareAndrew S. Narva, MD, FACP
|10:00am–10:15am |Break
|10:00am–12:00pm
|Brunch Served in Exhibit Hall – Visit Posters/Exhibits
|Clinical Trials: The Money Angle
Kim Zuber, PAC, MSPS
1.0
672
|Appropriate Treatments for the Diabetic Patient: Part I
Miriam Michael, MD
1.0
673
|Appropriate Treatments for the Diabetic Patient: Part II
Joseph Vande Griend, PharmD
1.0
100
|Allied Health Networking Reception
2:15pm–3:15pm
|Texas 5/6
671
1:15pm–2:15pm
|Texas 5/6
6:00pm–7:00pm
|Grapevine A
time/location
8:00am–10:00am
|
Grapevine A
session # session
282
notes faculty
credits
·
2.0
John Burkart, MD
Thomas Depner, MD
Suzanne Bergman, MD
Jean L. Holley, MD
10:15am–12:15pm
|
Grapevine D
283
|ANCA Vasculitis: Treatments and Outcomes
·
Co-Chairs: Julia B. Lewis, MD 2.0
and Kirsten de Groot, MD
|Induction Therapy in ANCA Vasculitis
|Maintenance Therapy in ANCA VasculitisLoic Guillevin, MD
|Controversial Issues in Small Vessel Joint with Physicians
David Hellmann, MD
Vaculitis: A Rheumatologist View
|Panel DiscussionAll Faculty
¯
Sunday, April 6
¯
˘
1.0
10:15am–11:15am
|Texas 5/6
1.0
9:00am–10:00am
|Texas 5/6
Harvey A. Feldman, MD, FACP
credits
·
Continued
Joint with Councils
p.71
NEPHROLOGY NURSE AND
TECHNICIAN PROGRAM
Program Committee
Host Committee
Gay Grauke, BA
The National Kidney Foundation is an approved
Program Chair
ESRD Network of Texas, Inc., Dallas, TX
provider of continuing nursing education by the
Children’s Medical Center Dallas, Dallas, TX
Bobbie Knotek, RN, BSN, CNN
Program Co-Chair
Elaine Go, RN, NP
St. Joseph Hospital, Laguna Niguel, CA
Elizabeth Henry, RN, CNN
Scott and White Hospital, Temple, TX
Glenda Harbert, RN, CNN, CPHQ
Sandra Hinton, RN, BSN
Medical City Dallas Hospital, Dallas, TX
Nancy Nardelli, RN, CCRC
Medical City Dallas Hospital, Duncanville, TX
accredited as an approver of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accredition.
It has been assigned code 6EXQ7J-PRV-06.
This educational activity has been approved
for 38.5 contact hours.
Program Goal
The goal of this program is to improve patient
Marianne Neumann, RN, CNN
outcomes by enhancing the kidney health
Albany Dialysis Center, Albany, NY
care professional’s knowledge base and skills
Beverly Sneed, RN, BSN
New York State Nurses Association, which is
which affect the kidney and clinical practice.
Continuing Education Chair
Abbott Renal Care, Grand Prairie, TX
p.72
Nephrology Nurse and Technician Program
Pre-Conference Courses and Exams
Chronic Kidney Disease
(CKD) 101
7:30am–4:30pm
Course Director: Marianne Neumann, RN, CNN
Session 320
Course Description: The one-day intensive course discusses the five
stages of CKD: presentation, evaluation, complications and treatments. Upon completion of this course, participants will be able to describe normal renal anatomy and physiology, list the major causes of
kidney disease in the adult population, and outline treatment choices
time/faculty
topic
7:30am–8:00am
Registration and
8:00am–8:30am
Review of Normal Renal Anatomy
Sheldon C. Chaffer, MD
and Physiology
8:30am–9:15am
CKD Stage 1
9:15am–10:00am
for patients with CKD who require renal replacement therapies.
10:00am–10:15am
Target Audience: Nurses and technicians who are new to the field of
10:15am–11:00am
nephrology or who wish to refresh their knowledge.
Pre-conference courses require a separate registration fee of $100.
Light breakfast, box lunch, and course syllabus included.
Participation is limited.
CKD Stage 2
Break
CKD Stage 3
11:00am–12:00pm
CKD Stage 4 and
Introduction to Stage 5
12:00pm–1:00pm
Lunch Break
1:00pm–1:45pm
Hemodialysis
1:45pm–2:30pm
Peritoneal Dialysis
Bonnie Conrad, RN, CDN
2:30pm–2:45pm
Break
2:45pm–3:30pm
Vascular Access
Gail Sansivero, RN, MS, ANP
3:30pm–4:15pm
Introduction to Transplant
Jean Colaneri, MS, ACNP
4:15pm–4:30pm Spring Clinical Meetings ’08
Questions and Adjourn
p.73
Nephrology Nurse and Technician Program
Pre-Conference Courses and Exams
Continued
Session 620
Session 223
Wednesday, 7:30am–5:30pm
Transplant Course: Transplantation Trends in the 21st Century
NNCO Certification Exams
Session 220
Session 300
Sunday, April 6, 8:30am–12:30pm
The National Nephrology Certification Organization (NNCO) endorses
the concept of voluntary, periodic certification by examination for all
individuals in the field of nephrology technology. Certification is one
part of a process called credentialing. It focuses specifically on the
individual and is an indication of current competence in a specialized
Session 221
area of practice. Certification in nephrology technology is highly valued
and provides formal recognition in the profession of nephrology technology. The NNCO Examinations in Clinical Nephrology Technology and
Biomedical Nephrology Technology are written examinations composed of a maximum of 200 multiple-choice objective questions with
a total testing time of four (4) hours each. Certification in Nephrology
Technology is recognized for a period of four years at which time the
candidate must retake and pass the current Certification Examination
in Clinical Nephrology Technology or Biomedical Nephrology Technology or meet such alternative requirements as are in effect at that
time in order to retain certification. Eligible candidates who pass this
examination are eligible to use the registered designation CBNT after
their names and will receive certificates from the NNCO.
p.74
Nephrology Nurse and
Technician Program
Wednesday, April 2
time/location
7:30am–4:30pm
session # session
notes course director(s)
credits
320
|CKD 101
˘
6.75
620
|Nephrology 201 for Advanced Practitioners
¯˘Laurie E. Benton, RN, PA-C, BS, MPAS 7.5
|Texas D
220
|Transplantation ·˘
Trends in the 21st Century
Dianne McKay, MD
7:30am–5:30pm
·˘
Joanne M. Bargman, MD, FRCPC 9.0
|Ft. Worth 4/5/6
7:30am–5:30pm
|Texas 5
8:00am–3:45pm
5.25
|Texas C
221
|Integrated Hemodialysis/Peritoneal Dialysis Course
8:00am–5:00pm
223
·˘
7.5
801
|Association of Mineral Metabolism, Vitamin D ·
Chair: Myles Wolf, MD, MMSc
1.5
|Texas 1/2
7:30pm–9:30pm
|Grapevine D
˘
Patient Survival
Daniel Coyne, MD
Patient Survival?
·
¯
Joint with Councils
p.75
Technician Program
Thursday, April 3
time/location
6:00am–8:00am
|Grapevine D
session # session
803
|Trends and Challenges in CKD Progression notes faculty
credits
·
1.5
Ortho Biotech, L.P.
Older Adults
in the Elderly
8:00am–9:45am
|Grapevine 1/2
560
|Multicultural Approaches to Health Care
|Texas 1/2
272
|Controversies in Transplantation
¯
·
Joint with Councils
¯
·
|Re-Transplantation: Patient Selection and 1.75
Co-Chairs: Alan Wilkinson, MD 1.75
and R. Michael Hofmann, MD
Management of Candidates on Dialysis
|Kidney Transplantation for Other Solid-Organ Thomas A. Gonwa, MD, FACP, FASN
Recipients: A Nephrologist’s Point of View
|Transplantation of the ElderlyAlan Wilkinson, MD
From CKD to Transplantation:
|Management of the Pregnant Patient Dianne McKay, MD
|Improving Vascular Access Outcomes
Co-Chairs: Ivan D. Maya, MD 10:00am–12:00pm
|Texas D
263
·
|Salvage of Early Fistula FailureAntoine Samaha, MD
|Pharmacologic Strategies to Delay Access Stenosis
|Debate: Fistula First – Is It Right for Everyone?
YesArif Asif, MD
No
2.0
Thomas Vesely, MD, FSIR
˘
Kirk Hughes, MD
p.76
Thursday, April 3
time/location
10:00am–11:00am
|Texas 1/2
Continued
session # session
360
notes faculty
|New Regulations: Working Together to Lessen the Carolyn Atkins, RN, BS, CCTC credits
1.0
Impact on the Young Adult
11:00am–12:15pm
|Texas 1/2
376
|What the Dialysis Nurse Needs to Know About the New Transplant Conditions of Participation Barbara Weis Malone, BSN, RN, CFNP 1.25
Kay Hall, BSN, RN, CNN
12:30pm–2:00pm
|Grapevine B
362
|CNNT Networking Luncheon and Research Presentation: Donna Calvin, APRN, BC-FNP, CNN 0.5
African Americans Perception of Risk for 2:00pm–3:00pm
|Texas A/B
Diabetes Complications
264
|NKF Presidential Address – Allan J. Collins, MD, FACP
1.0
|Shaul Massry Distinguished Lecture – Randomized and Observational Studies in
·
3:00pm–4:00pm
|Texas 5/6
Tom Greene, PhD
Nephrology: How Strong is the Evidence? ˘
662
|Hypertension and the Geriatric Patient
¯
1.0
366
|The What, Where, and Why of Data: Jan Deane, RN, CNN
2.0
·
Kimberly English, RN, FNP
1.0
3:00pm–5:00pm
|Texas 1/2
How It Impacts What We Do
4:00pm–5:00pm
|Texas 4
363
|Restless Leg Syndrome and Obstructive Sleep Apnea in Nephrology Patients
6:00pm–7:30pm
|Exhibit Hall Opening Ceremonies – Visit Posters/Exhibits
·
|
¯
Joint with Councils
p.77
Technician Program
fridAY, April 4
time/location
6:00am–8:00am
session # session
|Grapevine D
809
notes faculty
credits
·
1.5
Targets for Therapy
Joint with Councils
|Grapevine C
¯
·
No! Case Discussion
Case Discussion
|7:00am–8:00am
|Grapevine 6
|Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits
8:00am–11:15am
364
|On Course with Cannulation Lynda Ball, BSN, CNN, RN
369
|The Fate of Dialysis CathetersLesley Dinwiddie, MSN, 3.25
8:00am–9:00am
|Texas 3
1.0
RN, FNP, CNN
|Texas 1/2
365
|How to Satisfy Medicare: Helpful Hints on How to Have Fewer Deficiencies in the Water Treatment Area
9:00am–10:00am
|Texas 1/2
361
|Improving Immunizations: The Safe and Timely Immunization Coalition
10:15am–12:00pm
268
|End-of-Life Issues in CKD |Texas D
·
Jackie Crouch
1.0
Jan Deane, RN, CNN
1.0
1.75
|Incorporating Palliative Care Into the Dialysis UnitAlvin Moss, MD
Jean L. Holley, MD
|Pediatrics and Transplant
Bruce Morgenstern, MD
10:15am–12:15pm
|Texas 4
489
¯
Sandra Coorough, ACSW, LCSW
Janelle E. Gonyea, RD, LD
Mary Murphy, RN, CTTC
2.0
˘
810
p.78
fridAY, April 4
time/location
session # session
|12:15pm–1:15pm
Continued
notes faculty
credits
·
2.0
1:15pm–3:15pm
|Texas C
269
|Home Dialysis for the 21st Century
|Innovative Approaches to Dialysis ModalitiesRobert S. Lockridge, Jr., MD
Assessing Adequacy Across Dialysis Modalities
|Timing of Home Dialysis Modalities
|Debate: Is Conventional Dialysis Outdated? HD 3x weekly vs Daily HD
Joanne M. Bargman, MD, FRCP
Pro
Con
Thomas Depner, MD
1:15pm–2:15pm
|Texas 3
368
|Using Research to Facilitate Self-Care
Cleo J. Richard, RN, PhD
1.0
367
|Emerging Infectious Diseases: Pat Preston, MS
1.0
Jeffrey C. Metzger, MD
2.0
·
2:15pm–3:15pm
|Texas 1/2
Impact on the Health Care Worker
3:30pm–5:30pm
375
|Bio-Terrorism: What Healthcare Separate Registration and/or Fee Required
|Texas 1/2
˘
Professionals Need to Know
|Texas B
285
|International and National Guideline Activities: 2008 and Michael Rocco, MD, MSCE
Sharon Moe, MD, and
Tilman Drüeke, MD
Children with CKD: 2008 Update
5:30pm–7:00pm
|
·
Donna Secker, PhD
7:00pm–9:00pm
|Grapevine D
811
·
1.5
Joint with Councils
¯
Risk Factors
Mark J. Sarnak, MD
p.79
Technician Program
Saturday, April 5
time/location
6:00am–8:00am
session # session
|Grapevine C
813
credits
·
1.5
Samy McFarlane, MD
with Proteinuria
8:00am–9:00am
|Texas 1/2
370
|Triaging Disaster: Lessons LearnedIra Nemeth, MD
1.0
|Texas 1/2
371
|Earthquakes, Tornados, Floods, Oh My! Jim Curtis, CHT, CNCT
1.0
Developing Policies for Any Possible Disaster
Lisa Hall, MSSW, LCSW
372
|On Course with Cannulation
Lynda K. Ball, BSN, CNN
Joint with Councils
¯
·
9:00am–10:00am
9:00am–12:15pm
|Grapevine 6
|10:00am–12:00pm |Brunch Served in Exhibit Hall – Visit Posters/Exhibits
10:15am–11:15am
| Texas 4
3.25
485
|Transplant Tourism
¯
Michael Talamantes, LCSW, MSSW 1.25
374
|Why Advance Directives Require Physician Orders Ronald Miller, MD
10:15am–12:15pm
|Texas 1/2
2.0
for Implementation
12:15pm –1:15pm
|
1:15pm–3:15pm
|Texas B
|Lunch Break
488
|The CMS Transition to New ESRD Regulations
¯
Judith Kari
2.0
280
|ESRD Quality Improvement
·
Chair: William McClellan, MD
2.0
3:30pm–5:30pm
|Texas A
|The ESRD Program: History of Quality William McClellan, MD
Improvement Data
|Pay for Performance: What Lies Ahead?Alan S. Kliger, MD
|Debate: Pay for Performance: Will it Improve Patient Outcomes?
Pro
Con
˘
p.80
Saturday, April 5
time/location
3:30pm–4:30pm
|Texas 1/2
Continued
session # session
notes faculty
credits
373
|Truths, Myths and Mistakes in the Dialysis Procedure
Danilo B. Concepcion, CCHT, CHT 1.0
377
|Learning From and Listening to Their Bodies: Cleo J. Richard, RN, PhD
4:30pm–5:30pm
|Texas B
1.0
Clients Experiences During Hemodialysis
6:00pm–7:00pm
|
100
sunday, april 6
time/location
8:00am–10:00am
|Grapevine A
¯
session # session
notes faculty
credits
282
·
2.0
John Burkart, MD
Thomas Depner, MD
Suzanne Bergman,MD
Jean L. Holley, MD
8:30am–12:30pm
|Appaloosa 2
˘
300
|NNCO Certification Exam
˘
590
|CKD and Diabetes Management: ¯
11:15am–12:15pm
|Grapevine B
Clinical Pearls and Patient Teaching Strategies
1.0
BC-ADM, CDE
|Adjourn
·
|12:15pm
Debbie Hinnen, ARNP, ¯
Joint with Councils
p.81
RENAL AND CLINCAL
DIETITIAN PROGRAM
Program Committee
Host Committee
Valerie Brinkman-Kaplan, MS, RD, LD Program Chair
U.S. Renal Care/Tarrant Dialysis Centers
Genzyme Renal, Vermilion, OH
Central Fort Worth
Marianne Hutton, RD, CDE
Fort Worth, TX
Program Co-Chair
Donna Cavil, RD, LD Fresenius Medical Care – North America,
Haltom, TX
Santa Rose, CA
Mary Ann Fuller, RD, LD Carolyn Cochran, RD, LD, MS, CDE
DaVita Arlington Dialysis
Dallas Nephrology Associates, Dallas, TX
Lake Dallas, TX
Aimee Jaremowicz, RD
Mindy Gentile, MS, RD, LD DSI – Diversified Specialty Institute, Chicago, IL
NutrePletionTM Resources
Joni Pagenkemper, MS, MA, RD, LMNT
Arfrances Johnson, LD, RD, MS Omaha, NE
Liberty Dialysis
DaVita Littleton Dialysis, Littleton, CO
A total of 48.0 CPE credits have been applied
for through the Commission on Dietetic Registration of the American Dietetic Association.
McKinney, TX
Creighton University Medical Center,
Mandy Trolinger, MS, RD
Fort Worth, TX
Nadiya Lakhani, RD, LD Fresenius
Dallas, TX
Debbie Lindsay, RD, LD Mansfield, TX
Michelle Trahan MS, RD, LD
Genzyme Renal
Richardson, TX
Judy Yang , RD, LD
USRC/TDC-PD Clinic
Fort Worth, TX
p.82
Renal and Clinical DIETITIAN Program
Pre-Conference Courses
Strategies I: Building a Foundation
time/faculty
topic
10:00am–10:10am
Break
10:10am–10:30am
Subjective Global Assessment
Maureen McCarthy, MPH, RD,
7:30am–5:00pm
Course Co-Directors: Maureen McCarthy, MPH, RD, CSR, LD, and Louise Clement, MS, RD, CSR, LD
CSR, LD
Nutrition Guidelines
Session 520
Course Description: Technologies of dialysis, nutrition guidelines,
and introductions to dialysis adequacy, anemia management and
bone disease management will be presented. Case studies will be
utilized to illustrate principles. These case studies will also
include nutrition diagnostic statements using standardized language,
as encouraged by the Standardized Language Task Force of the
American Dietetic Association. Participants will gain a solid foundation
to practice as an entry-level nutrition specialist in the dialysis setting or
10:30am–11:40am
Hemodialysis
11:40am–12:15pm
Peritoneal Dialysis
Karen Wiesen, MS, RD, CSR
12:15pm–1:00pm
Lunch
1:00pm–2:00pm
Understanding Biochemical
stage kidney disease, are practiced.
Cathi Martin, RD, LDN
Markers
Target Audience: This course is designed for dietitians who are new to
Special Issues
in other settings where treatment of chronic kidney disease, and end-
renal nutrition, as well as for dietitians who work in non-renal settings
but wish to strengthen their basic knowledge in this dynamic area.
This course requires a separate registration fee of $100. Light breakfast, box lunch and course syllabus included. Participation is limited.
2:00pm–2:35pm
Diabetes and the Kidneys
Patricia Weber, MS, RD, CDE
2:35pm–2:50pm
Break
2:50pm–4:20pm
Basic Principles of Bone Disease
Jennifer McGuoirk, MS, RD, LDN in ESRD
time/faculty
topic
7:30am
Breakfast
4:20pm–4:50pm
Basic Principles of Anemia
Kara Abbas, MS, RD, CSR
7:50am–8:00am
4:50pm–5:00pm
Closing Remarks/Evaluations
5:00pm
Adjourn
CSR, LD
8:00am–8:30am
Physiology of the Kidneys
CSR, LD
8:30am–9:30am Technology of Hemodialysis and
Lee Cauble, CHT, LPN
Peritoneal Dialysis
9:30am–10:00am
Introductions to the ESRD Popu-
Louise Clement, MS, RD, CSR, LD lation and Programs: Overview
of Government and Professional
Programs, and Other Resources
p.83
Renal and Clinical DIETITIAN Program
Pre-Conference Courses
Continued
Strategies II: Applying the Principles
7:15am–5:00pm
Course Director: Jessie Pavlinac, MS, RD, CSR, LD
Session 521
time/faculty
topic
7:15am–7:55am
Registration and
8:00am–8:10am
8:10am–9:45am
Nutrition Care Process and
Standardized Language for
Nutrition Diagnosis
Course Description: Participants will benefit from an in-depth review
of cutting-edge topics in renal disease presented in this full-day course.
Experts will examine advanced concepts in patient care, physical assessment, and research for the renal dietitian. Nationally recognized
leaders in the field of renal nutrition will present topics.
9:45am–10:00am
Break
10:00am–11:30am
Nutrition Diagnosis Terminology
and Interactive Case Studies
Target Audience: This course is designed for experienced renal dietitians.
11:30am–12:30pm
Lunch
12:30pm–2:00pm
Nutrition Intervention Terminology
and Interactive Case Studies
Course Faculty:
Judith Beto, PhD, RD
Maureen McCarthy, MPH, RD, CSR, LD
2:00pm–2:15pm
Break
2:15pm–4:15pm
Nutrition Monitoring, Evaluation
and Assessment Terminology and
Interactive Case Studies
4:15pm–4:55pm
Implementing Standardized
Language in Your Organization
p.84
4:55pm–5:00pm
Closing Remarks/Evaluation
5:00pm
Adjourn
RENAL AND CLINCAL
DIETITIAN PROGRAM
Wednesday, April 2
time/location
7:30am–5:00pm
|Austin 1/2/3
session # session
notes
course director(s)
credits
520
˘
Maureen McCarthy, 7.5
|Strategies I: Building a Foundation
MPH, RD, CSR, LD
Louise Clement, MS, RD, CSR, LD
7:15am–5:00pm
|Austin 4/5/6
521
|Strategies II: Applying the Principles
˘
Jessie Pavlinac, MS, RD, CSR, LD 7.5
801
|Association of Mineral Metabolism, Vitamin D ·
Chair: Myles Wolf, MD, MMSc
7:30pm–9:30pm
|Grapevine D
1.5
Patient Survival
Daniel Coyne, MD
˘
Thursday, April 3
time/location
6:00am–8:00am
|Grapevine C
session # session
notes
faculty
802
· Chair: Martin J. Abrahamson, MD 1.75
|The Impact of Glycemis Control in Patients credits
·
Novo Nordisk
¯
Patient Survival?
Joint with Councils
p.85
RENAL AND CLINCAL
DIETITIAN PROGRAM
Thursday, April 3
time/location
|Grapevine D
Continued
session # session
notes
faculty
credits
803
·
1.5
|Trends and Challenges in CKD Progression and Management in Older Adults
Ortho Biotech, L.P.
Older Adults
in the Elderly
8:00am–9:45am
|Grapevine 1/2
560
|Multicultural Approaches to Health Care
|Grapevine 1/2
561
|Creative Strategies for Patient Compliance
Donna Morton de Souza, MPH, RD 2.0
|Grapevine 3/4
562
|Tainting of the Golden Years: CKD in the Julie Barboza, APRN-BC, MSN, RD 2.0
Joint with Councils
¯
·
Kirk Hughes, PhD
1.5
Geriatric Population
12:00pm–2:00pm
|Grapevine C
804
· Chair: Stuart Sprague, DO
1.5
Daniel Coyne, MD
12:30pm–2:00pm
|Grapevine D
563
|CRN Networking Luncheon
264
|NKF Presidential Address – Allan J. Collins, MD, FACP
2:00 am–3:00pm
|Texas A/B
1.0
|Shaul G. Massry Distinguished Lecture – Randomized and Observational Studies in
Nephrology: How Strong is the Evidence? Tom Greene, PhD
·
3:00pm–3:30pm
|Grapevine 1/2
564
|Joel D. Kopple Award Presentation – Dietitian: Powerhouse Behind the Patients
Recipient: Alison Steiber, 0.5
RD, PhD, LD
˘
¯
10:00am–12:00pm
p.86
Thursday, April 3
time/location
3:30pm–4:30pm
Continued
session # session
notes
faculty
credits
|Grapevine 3/4
565
|Promoting Patient Participation in the Dialysis Setting
1.0
|Grapevine 1/2
566
|What’s Up at Night? Nutritional Management of the Mary Ellen Brabec, RD, CSR.
1.0
Nocturnal Hemodialysis Patient
LDN, MHS
4:30pm–5:30pm
|Grapevine 3/4
588
|Breaking News Bits: Latest Research
|Sevelamer HCL Use and Circulating Endotoxin 1.0
Phyllis Sun, MS, RD, LDN
and Inflammatory Biomarkers in HD Patients:
A Preliminary Report
|Plasma B6 Vitamins in HD Subjects Taking Louise Clement, MS, RD, CSR, LD
Prescription or Over the Counter Renal
MVI Supplements
4:30pm–5:30pm
|Grapevine 5/6
567
|Defining, Recognizing, and Achieving Adequate Faith Tootell, MS, RD, CSR, FADA
1.0
1.5
HD and PD Dialysis Dosages
6:00pm–7:30pm
˘
|
7:30pm–9:30pm
|Grapevine C
815
·
·
6:00am–8:00am
|Grapevine D
809
· 1.5
¯
|Fabry Disease; Proteinuria Without Hypertension: Joint with Councils
David Warnock, MD
Targets for Therapy
p.87
RENAL AND CLINCAL
DIETITIAN PROGRAM
Friday, April 4
time/location
6:00am–8:00am
session # session
|Grapevine C
810
|New DOPPS Findings on Optimizing Practices for the Hemodialysis Team – A Multi-Discipline Panel Discussion Supported by an educational grant from Amgen notes
faculty
credits
|Improving Delivery of Pre-ESRD Care, Case DiscussionRonald Pisoni, PhD, MS
No! Case Discussion
Case Discussion
|7:00am–8:00am
568
|MNT and CKD: Making a Difference
8:00am–10:00am
|Grapevine 1/2
|Grapevine 3/4
569
|CRRT: Dosing the Nutrition and Beyond
Joint with Councils
¯
·
2.0
Kim Hodge, RN
10:15am–12:00pm
|Grapevine 1/2
570
|Monitoring Growth in Children with CKD: Meredith Miller, RD, LD
1.5
1.5
Putting Dietary Recommendations to Practice
|Texas D
268
·
Jean L. Holley, MD
|12:00pm–1:15pm
1:15pm–3:15pm
|Grapevine 1/2
572
|An Introduction to the Spirit and Skills Dana Sturtevant, MS, RD
2.0
Joni Pagekemper, MS, MA, RD, LMNT2.0
of Motivational Interviewing
|Grapevine 5/6
580
|Extreme Makeover: Plant-Based Diets and CKD
Duane Sunwold
3:30pm–4:30pm
|Grapevine 3/4
573
|IgA Nephropathy and Fish Oils
Ronald Hogg, MD
1.0
|Grapevine 1/2
574
|Resistance Training – Good for the Body and
Stephanie McIntyre, RD
1.0
·
2.0
Good for People With Kidney Disease
3:30pm–5:30pm
|Texas D
271
|Fluid and Electrolytes
|Update on Management of Hyperkalemia
Daniel Batlle, MD
|Update of Hypophosphatemia
Zalman S. Agus, MD
|Update on Hyponatremia Therapy
Tomas Berl, MD
|Update on Metabolic AlkalosisL. Lee Hamm, MD
˘
Carolyn Cochran, RD, LD, MS, CDE
Ann Beemer Cotton, MS, RD
Kathy Schiro Harvey, MS, RD, CSR 2.0
p.88
Friday, April 4
time/location
3:30pm–5:30pm
|Texas B
Continued
session # session
notes faculty
285
·
|International and National Guideline Activities: 2008 credits
Sharon Moe, MD, and
Tilman Drüeke, MD
Donna Secker, PhD
|Enteral Nutrition Challenges in the CKD Patient
Marcia Kalista Richards, 1.0
1.0
4:30pm–5:30pm
|Grapevine 1/2
575
MPH, RD, CNSD, LDN
|Grapevine 3/4
589
|Breaking News: Latest Research
|Nutrition Practices of Renal Dietitians in Joyce Vergili, MS, RD, LDN, CDE
|Complementary Intradialytic Nutrition Mary B. Sundell, RD, LDN, CCRP
˘
Hemodialysis Centers Supplementation in Dialysis Patients
|Does Nutrition Specific Quality of Life Questionnaire
Haewook Han, PhD, RD, CSR, LDN
Measure the Impact of Nutrition on the Health
Related Quality of Life in HD Patients? 5:30pm–7:00pm
|
7:00pm–9:00pm
|Grapevine D
811
·
1.5
David Bushinsky, MD
|Calcium and Phosphorus as Cardiovascular ·
Risk Factors
Mark J. Sarnak, MD
¯
Joint with Councils
p.89
RENAL AND CLINCAL
DIETITIAN PROGRAM
friday, April 4
time/location
7:00pm–9:00pm
|Grapevine C
Continued
session # session
notes faculty
credits
812
·
1.5
Joint with Councils
Saturday, April 5
¯
·
time/location
6:00am–8:00am
session # session
|Grapevine D
814
|Exploring the Link Between Chronic Kidney Disease and Cardiovascular Disease: Reducing Mortality
notes faculty
credits
1.5
Chair: Tammy Ho, MD
Tammy Ho, MD
Kidney Disease
|Management Strategies for Reducing Kamyar Kalantar-Zadeh, MD
Cardiovascular Risk Factors in Chronic
Kidney Disease
|Grapevine C
813
|Chronic Kidney Disease Interventions: Improving CKD and CVD Outcomes Chair: Peter McCullough, MD
1.5
Samy McFarlane, MD
with Proteinuria
˘
p.90
Saturday, April 5
time/location
8:00am–10:00am
|Texas B
Continued
session # session
notes faculty
274
·
|Nutrition and Inflammation in CKD
Co-Chairs: Srinivasan Beddhu, MD 2.0
and Kamyar Kalantar-Zadeh, MD
|Inflammation and Wasting SyndromesRavi Thadhani, MD
|Is Malnutrition a Misnomer in Dialysis Patients
|Insulin Resistance and Muscle Wasting in CKDEdward Siew, MD
576
|Oral Health and CKD
Cheryl Thomas, RDH
1.0
577
|Gut Health: Prebiotics and Probiotics
Jeanette Hasse, PhD, RD, 1.0
9:00am–10:00am
|Grapevine 3/4
|10:00am–12:00pm
|Brunch Served in the Exhibit Hall – Visit Posters/Exhibits
578
|Sensations of Tasting and Smelling
Sarah Washburn, MS, RD, CD
1.5
Barbara Fromm, MS, RD
|Clinical Conversations Luncheon
˘¯
See page 100 for topics and faculty information
1:15pm–3:15pm
|Texas B
488
¯
Judith Kari
|Grapevine 3/4
582
|Staying Ahead to Keep Ahead: What You Need
Mary Hastings Hagar, PhD, RD, FADA1.0
to Know About Public Policy
Dolph Chianchiano, JD, MPA
583
|Using the New Standardized Language
Maureen McCarthy, 2.0
3:30pm–4:30pm
|Grapevine 1/2
in Your Chart Notes
487
˘
12:15pm–1:15pm
|Grapevine A
FADA, CNSD
10:15am–12:00pm
|Grapevine 1/2
8:00am–9:00am
|Grapevine 1/2
credits
1.0
MPH, RD, CSR, LD
4:30pm–5:30pm
|Grapevine 1/2
584
|It’s Not All in Your Head: Beth McQuiston, MD, MS, RD, LDN 1.0
581
|Transplantation
Jeanette Hasse, 1.0
|Texas 5/6
·
Neurological Issues in Renal Patients
PhD, RD, FADA, CNSD
6:00pm–7:00pm
100
¯
¯
|Grapevine B
Joint with Councils
p.91
RENAL AND CLINCAL
DIETITIAN PROGRAM
Sunday, April 6
time/location
8:00am–8:50am
session # session
notes faculty
credits
|Grapevine B
585
|Stage Management of CKD and Diabetes: Janelle E. Gonyea, RD, LD
1.0
A Nutritional Model
586
|Cutting-Edge Therapies for Diabetes Management
Priscilla Hollander, MD
1.0
587
|An Odyssey for 2008: Renal Pharmacology
Mary Schira, PhD, APRN, BC, ACNP 1.0
|Grapevine B
590
|CKD and Diabetes Management: Debbie Hinnen, APRN, CDE,
Clinical Pearls and Patient Teaching Strategies
BC-ADM, FAAN
11:45am–12:15pm
591
|Diabetes Panel Question and AnswerAll Sunday Morning Faculty
8:55am–9:45am
|Grapevine B
10:00am–10:50am
|Grapevine B
10:55am–11:45am
|Grapevine B
12:15pm
|Meeting Adjourns
Joint with Councils
1.0
¯
˘
·
p.92
NEPHROLOGY SOCIAL
WORKER PROGRAM
Florida Board of Clinical Social Work, Mar-
Program Committee
Kati Malarcher, LMSW
Fresenius Medical Center – North America
riage and Family Therapy and Mental Health
Program Chair
Plano, TX
Counseling, Provider Number BAP 614,
Mayo Clinic, Rochester, MN
Christina Denman, LMSW
Andrea DeKam, LMSW
Fresenius Medical Center – North America
Program Co-Chair
Plano, TX
University of Michigan Dialysis, Livonia, MI
McKinney Dialysis Center
Continuing Education Coordinator
McKinney, TX
Center, Phoenix, AZ
Jessica Farrell, MSW, LCSW-P
Duke University Medical Center, Durham, NC
expires March 31, 2009.
The National Kidney Foundation Council of
n
Nephrology Social Workers, approval number PCE 2410, is approved as a Continuing
Education Provider by the California Board
Jodi Patterson, LMSW
Phoenix Children’s Hospital Kids Kidney
n
of Behavioral Sciences. This course meets
the qualifications for continuing education
credit for LCSWs as required by the California
Maggie Marek, LMSW
Baylor All Saints Fort Worth
Board of Behavioral Sciences.
Massachusetts social workers may receive
n
Fort Worth, TX
Category II continuing education credit
hours upon their own submission.
Lisa Pratka, LMSW
John Q. Gowan, LMSW
Medical City Transplant
It is the conference registrants responsibility
ESRD Network #14, Dallas, TX
Dallas, TX
to make sure their home state (if not noted
Rebecca Hays, MSW
Debra Jordan, LMSW
University of Wisconsin Hospital and Clinics,
DaVita North Dallas Dialysis Center
Madison, WI
Dallas, TX
above) accepts the ASWB ACE provider as sufficient for CEUs, or if they need to do anything
additional to independently receive state CEUs.
Cindy Miller, MSW, LCSW
Advanced Renal Care, Tampa, FL
Kristin Stockard, LICSW
A minimum of 38.0 continuing education
Children’s Hospital and Region Medical
credit hours for social workers (for the entire
Center, Seattle, WA
program) have been applied for through the
Lara Tushla, LCSW, MSW
Rush Presbyterian Hospital, Chicago, IL
following agencies:
2008 Program Goals
Participants will gain the knowledge and
n
skills for outcome-oriented clinical nephrology social work practice.
Participants will gain knowledge of biopsy-
n
chosocial variables affecting chronic kidney
The National Kidney Foundation Council
n
of Nephrology Social Workers, provider
#1014, is approved as a provider for social
disease patients and their families.
Participants will learn skills to ameliorate
n
and address biopsychosocial variables
work continuing education by the Associa-
Host Committee
tion of Social Work Boards (ASWB)
Marybeth Callahan, ACSW, LCSW, ACP
www.aswb.org, phone: 1.800.225.6880,
Dallas Transplant Institute
through the Approved Continuing Educa-
Dallas, TX
tion (ACE) program. The National Kidney
Josefina Houchins, LMSW
DaVita Oak Cliff Dialysis Center
Dallas, TX
Foundation Council of Nephrology Social
Workers maintains responsibility for
affecting kidney disease patients and
their families.
Participants will gain knowledge and
n
skills to address issues of diversity among
chronic kidney disease patients and health
care professionals.
the program.
Marianne Moncrief, LMSW
Dallas, TX
p.93
Nephrology Social Worker Program
Pre-Conference Course
Nephrology Social Work: An Outcomes-Driven Practice Model
time
topic
8:45am–9:00am
9:00am–9:30am
Introduction to Outcomes-Driven
Nephrology Social Work
8:00am–5:00pm
Course Directors: Mary Beth Callahan, ACP, ACSW, LCSW, Stephanie Johnstone, LCSW, MSW, and Megan Prescott, MSW
9:30am–10:30am
Designing Interventions to
Session 420
Course Description: This full-day training will focus on a contemporary
model of Nephrology Social Work practice that targets specific variables
such as adherence behavior, depression, social support, satisfaction
with care, conflict resolution, team training, quality-of-life measurement
Enhance Outcomes
10:30am–10:45am
Break
10:45am–11:30am
Phases of Adjustment to CKD
(continued)
and modality selection to enhance overall outcome goals. The training
will also focus on restructuring social work services within your
organization and applying case management and time-saving strategies
to make the delivery of those services possible.
Phases of Adjustment to CKD:
11:30am–12:00pm
Improving Adherence Behavior
12:00pm–12:30pm
Lunch
12:30pm–1:30pm
Improving Transplant Outcomes
1:30pm–1:40pm
Stretch Break
1:40pm–2:25pm
Prevention and Management
Target Audience: Nephrology Social Workers
of Depression
2:25pm–2:45pm
Improving Rehabilitation Outcomes
2:45pm–3:00pm
Break
3:00pm–3:15pm
Patient, Staff and Team Satisfaction
3:15pm–4:15pm
Understanding and Managing
the Challenging Patient
4:15pm–4:45pm
Evolving into an Outcomes-Driven
Model of Practice
p.94
4:45pm–5:00pm
Questions and Evaluations
5:00pm
Adjourn
NEPHROLOGY SOCIAL
WORKER PROGRAM
Wednesday, April 2
time/location
8:00am–5:00pm
|Grapevine 3/4
session # session
notes Course Director(s)
420
˘
|Nephrology Social Work:
credits
Stephanie Johnstone, LCSW, BCD 8.0
An Outcomes-Driven Practice Model
Mary Beth Callahan, ACP, ACSW, LCSW
Megan Prescott, MSW, LCSW
Thursday, April 3
time/location
6:00am–8:00am
|Grapevine D
session # session
803
|Trends and Challenges in CKD Progression notes faculty
credits
·
1.5
Ortho Biotech, L.P.
˘
|Natural History of Chronic Kidney Disease Separate Registration and/or Fee Required
Older Adults
Brenda Hemmelgarn, MD
in the Elderly
8:00am–9:00am
|Texas 3
460
|Trans 101: “Miss”understood and “Miss”representedLois Bates 1.0
|Texas 3
483
|Ethical Controversies in Public Solicitations for Organs
1.0
|Texas 4
462
|Nephrology 101
1.0
463
|Diagnosing Personality Disorders
Sheila Jowsey, MD
2.0
464
|The Dangers of Chronic Stress, Edward G. Silverhardt, 9:00am–10:00am
10:15am–12:15pm
|Texas 3
Linda Wright, MHSC, MSW, RSW
·
10:15am–12:15pm
|Texas 4
MSW, LCSW, LSCSW, BCD
¯
Compassion Fatigue and Burnout
2.0
Joint with Councils
p.95
NEPHROLOGY SOCIAL
WORKER PROGRAM
Thursday, April 3
time/location
12:30pm–2:00pm
|Grapevine A
Continued
session # session
466
notes faculty
|CNSW Networking Luncheon
credits
Patricia M. McKevitt, 0.5
MSW, ACSW, LCSW
2:00pm–3:00pm
|Texas A/B
264
|NKF Presidential Address – ·Allan J. Collins, MD, FACP
1.0
The National Kidney Foundation: Advancing
Public Health in the U.S. and Around the World
|Shaul G. Massry Distinguished Lecture – Randomized and Observational Studies in
Tom Greene, PhD
Nephrology: How Strong is the Evidence? 3:30pm–5:30pm
|Texas 3
467
|Depression in the CKD Setting: The Time to Mark Meier, LICSW, MSW
2.0
Claire J. Casselman, MSW, 2.0
Act is Now
|Spirituality and Chronic Illness: On Being Some Body and Soul
Joint with Councils
¯
·
˘
LICSW, LMSW
6:00pm–7:30pm
|
Friday, April 4
time/location
6:00am–8:00am
|Grapevine C
session # session
810
notes faculty
credits
No! Case Discussion
Case Discussion
7:00am–8:00am
|
8:00am–10:00am
|Texas 4
469
|Brief Introduction to the Clinical Assessment of Competence
Ramiro Valdez, PhD
Rita-An Kiely, ACSW, LCSW
2.0
8:00am–9:00am
|Research: Doing What You Love – Showing What Works p.96
Jessica Cabness, PhD, MSW
1.0
Friday, April 4
time/location
9:00am–10:00am
Continued
session # session
notes faculty
|Research: Literature Review and Measurement Teri Browne, MSW, LSW
Selection in Renal Social Work Research
Tiffany Washington, MSW
credits
2.0
10:15am–12:15pm
|Research Design and Data Analysis for Renal Joseph Merighi, MSW, PhD
2.0
¯
2.0
Social Workers: A User-Friendly Approach
10:15am–12:15pm
|Texas 4
489
|Pediatrics and Transplant
Mary Murphy, RN, CCTC
|12:15pm–1:15pm |Lunch in the Exhibit Hall – Visit Posters/Exhibits
1:15pm–2:15pm
|Texas 4
473
|Negotiating Goals of CareRonald J. Crossno, MD
1.0
|Research: Effective Strategies for Publishing
1.0
Joseph Merighi, MSW, PhD
2:15pm–3:15pm
|Texas 4
474
|Respecting Choices in End-of-Life CareAnne Moore, LMSW
1.0
|Research: JNSW/CNSW Grant Process
1.0
Norma J. Knowles, MSW, LCSW
Jeff Harder, MSW, LICSW
˘
Renal Social Work Research
3:30pm–5:30pm
|Texas 4
478
|Immigration Panel DiscussionRamiro Valdez, PhD
2.0
Charlie Thomas, CISW, ACSW,
LCSW, MSW
Elena Lucio, MSW
Theodor Vogels, MSW
3:30pm–4:30pm
|Research: CNSW Research Grant Winner
Robert Whitlock, MSSW, LCSW, MHA1.0
4:30pm–5:30pm
|Research Panel Discussion
Teri Browne, MSW, LSW
|5:30pm–7:00pm
1.0
Joint with Councils
¯
·
p.97
NEPHROLOGY SOCIAL
WORKER PROGRAM
Saturday, April 5
time/location
6:00am–8:00am
session # session
|Grapevine C
813
credits
·
1.5
Samy McFarlane, MD
with Proteinuria
8:00am–10:00am
|Texas 4
481
|Ethical Dilemmas in Pediatric Practice
Cassandra Aspinall, LICSW, MSW 2.0
Kathryn Thurber-Smith, LICSW
8:00am–9:00am
|Dare to Self-Care
Kristie Lewis, LLMSW
1.0
Tracey A. Tyus-Bailey, MSW,
Joint with Councils
LMSW, ACSW
¯
·
9:00am–10:00am
|Dial a Donor: The Living Donor |Telephone Screening Process
|10:00am–12:00pm |Brunch Served in the Exhibit Hall – Visit Posters/Exhibits
Andrea Kostick, MSW, LICSW
1.0
Mikhaelle Heald, LMSW
2.0
10:15am–12:15pm
|Pediatric Practice: Clinical Studies and Skills Building
Karen Egolso, MSW, BSW,
LSW, LNSW
10:15am–11:15am
|Texas 4
485
|Transplant Tourism
Michael Talamantes, LCSW, MSSW 1.0
491
|Update on the Proposed Kidney
Trent Tipple, MD, FAAP
11:15am–12:15pm
|Texas 3 1.0
Organ Allocation System
˘
p.98
Saturday, April 5
time/location
12:15pm–1:15pm
|Grapevine A Continued
session # session
notes faculty
487
˘¯
|Clinical Conversations Luncheon
See page 100 for topics
and faculty
1:15pm–3:15pm
|Texas B
credits
488
¯
Judith Kari
490
|“Decrease the Increase” Regarding CKD
¯Glen H. Stanbaugh, MD
2.0
3:30pm–5:30pm
|Texas D
2.0
Anton C. Schoolwerth, MD, FAHA
Eduardo Sanchez, MD, MPH
Robert Duncan
3:30pm–4:30pm
|Getting Patients Through Transplant Fast Amy Waterman, PhD
and Without Dropping Out:
1.0
What Really Makes the Difference
4:30pm–5:30pm
|Life with a Kidney Transplant
1.0
100
¯
Sunday, April 6
time/location
8:00am–10:00am
|Grapevine1/2
session # session
493
notes faculty
|Ethics and the Many Shades of GrayEllen Case, BSW, MSW, LICSW
credits
2.0
10:15am–12:15pm
|Grapevine1/2
494
|CNSW Town Hall Meeting
CNSW Executive Committee
This session is a must for all nephrology social work
attendees! Join us to learn all about the new nephrology
social work certification, in-depth information about
CNSW projects and opportunities, and to ask questions
and make suggestions to the CNSW Executive Committee.
12:15pm
Meeting Adjourns
¯
|Grapevine A
James R. Rodrigue, PhD
6:00pm–7:00pm
˘
·
Joint with Councils
p.99
CLINICAL CONVERSATIONS LUNCHES
Indulge in stimulating moderated discussions with your colleagues:
These roundtable discussions present various topics that are clinically relevant to the care and treatment
of your patients.
Topics and presenters:
Renal and Clinical Dietitian Program:
1
CKD and MNT: Making a Difference // Carolyn Cochran, RD, LD, MS, CDE and Kathy Shiro Harvey, MS, RD, CSR
2
Resistance Training: Good for the Body and Good for People with Kidney Disease // Stephanie McIntyre, RD
3
Oral Health and CKD // Cheryl Thomas, RDH
4
Enteral Nutrition Challenges in the CKD Patient // Marcia Kalista Richards, MPH, RD, CNSD, LDN
5
a.Nutrition Practices of Renal Dietitians in Hemodialysis Centers // Joyce Vergili, MS, RD, LDN, CDE
b.Does Nutrition Specific Quality of Life Questionnaire Measure the Impact of Nutrition on the Health Related Quality of Life in HD Patients? // Haewook Han, PhD, RD, CSR
6
a.Complementary Intradialytic Nutrition Supplementation in Dialysis Patients // Mary Sundell, RD, LD
b.Sevelamer HCL Use and Circulating Endotoxin and Inflammatory Biomarkers in HD Patients: A Preliminary Report // Phyllis Sun, RD
Nephrology Social Worker Program:
7
Trans 101 // Lois Bates
8
The Living Donor Telephone Screening Process // Andrea Kostick, MSW, LICSW
9
Immigration // Ramiro Valdez, PhD, Charlie Thomas, CISW, ACSW, LCSW and Theodor Vogels, MSW
10 Pediatrics and Transplant // Bruce Morgenstern, MD, Sandra Coorough, ACSW, LCSW, Janelle E. Gonyea, RD, LD,
and Mary Murphy, RN, CTRN
One topic per table. Tickets, which include lunch, are $25.00 and are available at the ticket sales booth in the NKF Registration area. Tickets are
available on a first come, first served basis. Register early—tables fill up quickly!
Save 20%
on job postings on the
National Kidney Foundation’s Kidney Career Center
NOW THROUGH APRIL 9, 2008
Looking for that perfect fit?
Visit NKF’s online Kidney Career Center, a leading
resource for making employment connections in the
fast-growing field of kidney health care.
The one-size-fits-all approach of the mega job boards
may not be the best way to find the physicians,
pharmacists, nurses, technicians, dietitians and
social workers you’re looking for.
The Kidney Career Center, is the only job site
that offers employers targeted access to
quality kidney health care professionals, as well as quick and
easy job posting and online job activity reports.
Job-seeking professionals enjoy free and confidential resume
posting, automated e-mail notification of new job listings and
the ability to save jobs for later review.
Kidney Career Center
www.careers.kidney.org
©2008 National Kidney Foundation, Inc. All Rights Reserved. 02-75-483A
p.100
p.101
EXIT
EXIT
IDF
IDF
OFFICE
ROLL-UP DOOR
300
302
304
306
310
312
OFFICE
REGISTRATION
ELEC
305
20'
404
20' 20'
311
20'
418
319
318
314
420
321
20'
428
320
329
20' 20'
30'
323
20'
30'
EXIT
322
STORAGE
229
20'
334
OPERABLE WALL
401
411
419
423
20'
30'
30'
40'
30'
636
20'
Main
Entrance
601
611
20'
40'
30'
30'
629
635
IDF
20'
734
736
738
639
637
740
744
641
645
20'
619
646
IDF
640
644
20'
523
537
539
541
ROLL-UP DOOR
STAFF OFFICE
40'
30'
30'
30'
536
538
439
437
540
544
441
EXIT
OFFICE
40'
711
713
715
STOR
30'
OFFICE
845
ELEC
30'
811
813
30'
821
EXIT
40'
910
912
914
916
20'
938
940
944
20'
40'
839
841
801
40'
REGISTRATION
810
812
30'
846
OPERABLE WALL
840
844
729
739
741
EXIT
719
EXIT
1032
1034
1036
1040
901
20'
905
907
911
20'
915
EXIT
1001
20'
1005
1007
1011
1013
1015
1019
1021
1023
1029
1031
1033
1035
1037
1039
1041
EXIT
STAFF OFFICE
1000
1004
20'
1010
1012
30'
1028
20'
919
929
20' 20'
933
20'
937
939
941
ROLL-UP DOOR
IDF
ROLL-UP DOOR
IDF
NATIONAL KIDNEY FOUNDATION SPRING CLINICAL MEETING
APRIL 2-6, 2008
GAYLORD TEXAN LONGHORN EXHIBIT HALL C-F
GRAPEVINE, TEXAS
OFFICE
EXIT
REGISTRATION
STOR
GUEST
PARCEL
ELEC
OPERABLE WALL
EXIT
SHOW LEGEND & NOTES
REGISTRATION & LOBBY AREAS - 12'
LONGHORN EXHIBIT HALL - 24'
CEILING HEIGHTS:
= FLOOR DRAIN
ELECTRICAL & TELEPHONE / DATA WITH 120/280V,
100 AMP, 3 0, 5 WIRE HEAVY DUTY RECEPTACLE
MOUNTED ON ALL COLUMNS EXCEPT ROW NEAREST
SOUTH WALL, & FLOORS WHERE DESIGNATED.
= PASSENGER ELEVATOR
= FREIGHT ELEVATOR
= WOMEN'S REST ROOM
= MEN'S REST ROOM
= 2'8" x 2'8" COLUMN
= 2'8" x 5'6" COLUMN
FA = FIRE ALARM
FX = FIRE EXTINGUISHER
FHV = FIRE HOSE VALVE
LEGEND:
EXIT
CM08
Exhibitors
company // booth
Abbott // 601
Foundation Medical Staffing // 1029
Nephrology News and Issues // 812
Abbott Nutrition // 711
Fresenius Medical Care // 423
Alaven Pharmaceutical, LLC. // 1000
Fresenius Medical Care // 523
Nephrology Nursing Certification
Commission // 320
Alcavis HDC // 939
Genzyme Corporation // 729
AMAG Pharmaceuticals, Inc. // 919
The Gideons International // 1032
American Academy of Nurse
Practitioners // 537
Hawthorn Pharaceuticals // 536
American Academy of Physician
Assistants // 538
American Association of Kidney
Patients // 302
American Regent, Inc. // 404
American Society of Nephrology // 1005
Amgen // 229
Amgen // 401
AngioDynamics // 319
Arrow International // 1015
Astellas Pharma US, Inc. // 619
Baxter Healthcare // 611
The Binding Site, Inc. // 1004
Boehringer Ingelheim // 419
Breckenridge Pharmaceutical, Inc. // 418
Courier Med // 738
Covidien // 1012
DaVita // 314
DCA—Dialysis Corporation of America // 916
Dialysis and Transplantation // 910
Dialysis at Sea // 639
Dialysis Recruiting Specialists/
The Fortus Group // 912
Diazyme Laboratories // 637
DVA Laboratory Services, Inc. // 937
Elsevier, Inc. // 1011
Evercare // 1036
FMQAI // 439
Health Informatics, Inc. // 306
HemoCue, Inc., A Quest Diagnostics
Company // 1007
Nephro-Path // 420
Nephro-Tech // 1023
Nipro Medical Corporation // 715
Nova Biomedical // 318
Novartis // 321
Novo Nordisk Inc. // 929
Innovation 4 Dialysis // 839
Nutrepletion Resources // 811
Keryx Biopharmaceuticals, Inc. // 901
Omron Healthcare // 322
Kidney Community Early Response
Coalition // 437
Ortho Biotech Products, LP // 801
Llorens Pharmaceutical Int'l Division // 914
Meals for LIFE // 312
MedComp // 903
Medical Nutrition USA, Inc. // 907
Merck & Co., Inc. // 1001
National Association of Nephrology
Technicians/Technologists (NANT) // 1033
National Kidney and Urologic
Disease Information Clearinghouse
(NKUDIC) // 736
National Kidney Foundation // 719
AJKD
KDIGO
KDOQI
KEEP
KLS
NKF cyberNephrology Experience // 334
NKF “People Like Us” Constituent Council
"Hope Street” // 821
NKF Professional Councils // 813
National Kidney Foundation of
North Texas // 1013
Pentec Health // 933
Pfizer // 629
Physician’s Capital Investment // 713
PKD Foundation // 539
Quality Dialysis // 636
Renal and Urology News // 1021
Renal Business Today/
Virgo Publishing Medical Group // 304
Renal Physicians Association // 734
Satellite Healthcare, Inc. // 1028
Satellite Laboratory Services // 311
Scantibodies Clinical Laboratory // 310
Shire // 411
Sigma-Tau Pharmaceuticals, Inc. // 305
Solinmed Billing & Transcription // 739
Specta Laboratories // 428
TEVA Pharmaceuticals // 1019
University of Minnesota Medical
Center, Fairview // 441
U.S. Renal Care, Inc. // 635
National Renal Alliance // 329
U.S. Renal Data System (USRDS) // 300
Natural Balance Bodywork // 938
Watson Nephrology // 911
Nature Publishing Group // 1010
Wyeth Pharmaceuticals // 915
Nephrocor // 810
p.102
2008 Exhibitors
EXHIBITOR PRODUCT/SERVICE DESCRIPTIONS
ABBOTT
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS
Booths 601
Booth 538
Abbott is a global, broad-based health care company devoted to discov-
The American Academy of Physician Assistants is the only national
ering new medicines, new technologies and new ways to manage health.
organization to represent all physician assistants (PAs) in all medi-
ABBOTT Nutrition
Booth 711
cal specialties. For more information about the Academy and the PA
profession, visit our Web site at www.aapa.org.
is THE world leader in adult nutrition. Nepro with Carb Steady is thera-
AMERICAN ASSOCIATION OF KIDNEY PATIENTS
peutic nutrition for people on dialysis clinically shown to help manage
Booth 302
blood glucose response and Suplena with Carb Steady is therapeutic
The American Association of Kidney Patients (AAKP) is the national,
nutrition for people with CKD.
patient organization which, for over 35 years, has been dedicated to
ALAVEN PHARMACEUTICAL, LLC
Booth 1000
UniFiber® (powdered cellulose) is an insoluble fiber supplement
improving the lives of kidney patients and their families by helping them
cope with the emotional, physical and social impact of kidney disease,
thereby enabling them to resume productive and satisfying lives.
clinically proven to restore and maintain bowel regularity. UniFiber is
AMERICAN REGENT, INC.
sodium, potassium, phosphorus and gluten free and contains less than
Booth 404
one net carb per serving. UniFiber has no minimum liquid requirement.
American Regent, “Your IV Iron Company,” is the manufacturer and
www.unifiber.com
distributor of Venofer®, (iron sucrose injection, USP), the #1 prescribed
ALCAVIS HDC
Booth 939
Alcavis HDC is dedicated to supporting the renal community through
education and aid with innovative and progressive antiseptics, disinfectants and medical devices. Our core products are electolytically
produced sodium hypochlorite based solutions available in several
IV Iron in the U.S.1 Venofer® is available in 100mg/5mL single dose vials (preservative free). Venofer® is covered nationally by CMS/Medicare
and has been assigned a permanent national HCPCS Code “J1756” for
services provided on or after January 1, 2003.1 Based on IMS Health,
National Sales Perspectives™ - 3rd Quarter 2007 Results (October
2007) - Total Sales Volume ($) and units (100 mg equivalents).
concentrations for applications that include skin and wound care and
AMERICAN SOCIETY OF NEPHROLOGY
connectivity. Alcavis HDC also distributes peracidic acid for dialyzer
Booth 1005
reprocessing and the MAKY and ARM II reuse machines.
The American Society of Nephrology (ASN) was founded in 1967 as a
AMAG PHARMACEUTICALS, INC.
Booth 919
AMAG Pharmaceuticals is a biopharmaceutical company that utilizes
nonprofit corporation to enhance and assist the study and practice of
nephrology, to provide a forum for the promulgation of research, and to
meet the professional and continuing education needs of its members.
its proprietary nanoparticle superparamagnetic iron oxide technol-
AMGEN
ogy for the development and commercialization of therapeutic iron
Booths 229 & 401
compounds to treat anemia and novel imaging agents to aid in the
Amgen (NASDAQ:AMGN), a biotechnology pioneer, discovers, devel-
diagnosis of cancer and cardiovascular disease. Visit us at http://www.
ops and delivers innovative human therapeutics. Our medicines have
amagpharma.com
helped millions of patients in the fight against cancer, kidney disease,
AMERICAN ACADEMY OF NURSE PRACTITIONERS
Booth 537
The American Academy of Nurse Practitioners (AANP), formed in
rheumatoid arthritis and other serious illnesses. With a deep and
broad pipeline of potential new medicines, we continue to advance
science to serve patients.
1985 to provide NPs with a unified way to network and to advocate for
NP issues at the local, state and federal levels, was the first national
organization created for nurse practitioners of all specialties. With approximately 23,000 individual members and more than 140 group members, AANP represents the interests of approximately 100,000 NPs as
providers of high-quality, cost-effective and personalized healthcare.
p.103
2008 Exhibitors
ANGIODYNAMICS
Booth 319
Booth 419
(www.angiodynamics.com) is a leading provider of innovative medical de-
Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiary of
vices used by interventional radiologists, surgeons, and other physicians
Boehringer Ingelheim, headquartered in Germany, operates globally in
for the minimally invasive treatment of cancer and peripheral vascular
47 countries with approximately 38,400 employees. The company is com-
disease. AngioDynamics’ diverse product line includes radiofrequency
mitted to researching, developing, manufacturing and marketing novel
ablation systems, vascular access products, angiographic products and
products of high therapeutic value for human and veterinary medicine.
accessories, dialysis products, angioplasty products, drainage products,
thrombolytic products, embolization products and venous products.
BRECKENRIDGE PHARMACEUTICAL, INC.
Booth 418
ARROW INTERNATIONAL
Breckenridge Pharmaceutical, Inc. is a privately held pharmaceutical
Booth 1015
marketing, research and development company which has a broad
Arrow International, a leader in central venous devices, presents a
range of branded and generic prescription products in many
broad range of products for the dialysis access community. These
therapeutic categories.
products include acute and chronic hemodialysis catheters and clot
management devices for dialysis grafts and fistula. Our featured products will include the Arrow Cannon Plus chronic hemodialysis catheter
along with the Arrow-Trerotola PTD.
COURIER MED
Booth 738
A Durable Medical Equipment and Supply Company that specializes
in reimbursement and delivery of Dialysis related medical supplies to
ASTELLAS PHARMA US, INC.
patients at their home anywhere in the USA. Among many products,
Booth 619
Courier Med carries: CD-1000 Catheter Access Protector Dressing
Astellas Pharma, Inc. manufactures and markets proprietary phar-
that allows patients living with Catheters to safely resume high risk
maceutical products in specialty therapeutic areas where there is an
activities such as showering (covered by Medicare and most Private
unmet medical need. Astellas Pharma's global mission to explore the
Insurances), Diabetic Supplies, Free Monitors, Less-N-Pain, an afford-
frontiers of human health underscores the company's commitment to
able Topical Anesthetic, and SureSeal Pressure Bandages that reduce
the field of immunology, where aggressive research and development
clotting time, allowing the patient to leave dialysis sooner.
initiatives have helped to put Astellas at the forefront of transplantation.
COVIDIEN
BAXTER HEALTHCARE
Booth 1012
Booth 611
Covidien, formerly Tyco Healthcare, is a global $10 billion manufac-
Baxter Healthcare is a leading provider of a complete and comple-
turer of leading medical devices and supplies, imaging products and
mentary portfolio of dialysis products to support people with kidney
pharmaceuticals. The Company employs more than 43,000 people
disease around the world, including Peritoneal Dialysis, Hemo Dialysis,
worldwide and is dedicated to working with medical professionals to
education tools, and Continuous Renal Replacement Therapy (CRRT)
improve patient outcomes.
for acute renal failure.
DAVITA
THE BINDING SITE, INC.
Booth 314
Booth 1004
DaVita is one of the largest providers of kidney services in the United
Freelite serum free light chain assays are more sensitive than current
States. We care for nearly 100,000 patients through our nationwide
methodologies for detecting multiple myeloma and AL Amyloidosis
network with over 1,200 outpatient centers located in 42 states and the
patients, many of whom first present with renal failure. They replace
District of Columbia.
the need for urine assays.
DCA - DIALYSIS CORPORATION OF AMERICA
Booth 916
Dialysis Corporation of America is a physician-focused organization. At
the core of our company is a philosophy of developing a true alliance
with our physicians. We seek to partner with Nephrologists who want to
expand their dialysis presence, be afforded the opportunity to share in
ownership of dialysis units, seek out management expertise, and gain
control over the clinical quality their patients are currently receiving.
p.104
DIALYSIS AND TRANSPLANTATION
ELSEVIER, INC.
Booth 910
Booth 1011
Available from John Wiley & Sons, Dialysis & Transplantation (D&T) pub-
ELSEVIER is proud to publish the American Journal of Kidney Diseases,
lishes original research pertaining to all aspects of renal replacement
the official journal of the National Kidney Foundation. Please stop by
therapy and renal transplant, with a focus on clinical application. D&T
our booth to view the latest issue of the journal and browse our other
has the largest multidisciplinary audience among nephrology journals
books and journals in the field of Nephrology.
in the United States and is read in more than 120 foreign countries. Visit
www.Eneph.com for submission guidelines/free access to online issues.
EVERCARE
Booth 1036
DIALYSIS AT SEA
Evercare End Stage Renal Disease Program – Uses well-established
Booth 639
Evercare Clinical Model to promote member’s disease self-management
Dialysis at Sea Cruises is the largest provider of dialysis treatment
and care. The program bridges dialysis and the community by providing
aboard cruise ships. We provide nephrologists, nurses and suppliers
management assistance in the unit, home, and during hospitalization.
onboard select sailings ensuring a stress-free environment for dialysis
patients to enjoy the enchantment of cruising.
FMQAI
Booth 439
DIALYSIS RECRUITING SPECIALISTS/
THE FORTUS GROUP
The Centers for Medicare and Medicaid Service (CMS) welcome you to
Booth 912
Web. CROWNWeb provides a secure web interface that enables dialysis
The First full service executive search firm specializing in Dialysis and
facilities to submit and monitor patients’ clinical data in real time, thus
Transplantation, providing recruitment and permanent placement of
helping facilities improve patient care and consequently their overall
dialysis professionals worldwide, including permanent physicians,
quality of life.
Travel nursing and Locum Tenens. Place your future in the hands of
the “Dialysis Recruiting Specialist.” We set the standard in advancing
careers and responding to employers professional needs.
preview the next generation of renal information collection – CROWN-
FOUNDATION MEDICAL STAFFING
Booth 1029
Foundation Medical Staffing is the nation's leading provider of staffing
DIAZYME LABORATORIES
services for nephrologists and dialysis nurses. Our expert agents focus
Booth 637
on your specialty exclusively to find premier travel opportunities and
Diazyme Laboratories is developing a capillary whole blood point of
permanent positions.
care device for the rapid determination of Cystatin C based GFR for use
in the physician office or clinic. Diazyme's products include diagnostic
blood markers for diabetes, renal, cancer, liver and cardiac. Diazyme is
a life science division of General Atomics.
FRESENIUS MEDICAL CARE
Booths 423 & 523
Fresenius Medical Care, the dialysis equipment and products market
leader, offers a comprehensive portfolio of clinically valid, cost-effective
DVA LABORATORY SERVICES, INC.
treatment enhancement tools that positively impact dialysis therapy.
Booth 937
Success@home, our comprehensive home therapies program, provides
DVA Laboratory Services offers state-of-the-art ESRD laboratory testing.
nephrologists and clinicians with the therapy choices, treatment flex-
We recognize the need for precise patient data, and address it with a
ibility, support, and education programs that achieve better outcomes.
comprehensive range of laboratory services including: dialysis specific
testing, client support staff, rapid turn-around times, peritoneal dialysis
testing, water analysis and a leading-edge order entry and reporting system – LabScope Online®. Now you can access LabScope from anywhere,
anytime using LSO On The Go from any computer with Internet access.
GENZYME CORPORATION
Booth 729
Genzyme, a global health care company, delivers innovative biotechnology products and services in therapeutics, surgery and diagnostic areas. Genzyme is the manufacturer of Renvela® (sevelamer carbonate),
Renagel® (sevelamer hydrochloride), and Hectorol® (doxercalciferol).
Genzyme is a leader in health care awareness and education for renal
care specialists and patients worldwide. For more information visit
www.genzyme.com or call 1.800.847.0069
p.105
2008 Exhibitors
THE GIDEONS INTERNATIONAL
KERYX BIOPHARMACEUTICALS, INC
Booth 1032
Booth 901
White New Testaments bound in gold with Psalms and Proverbs.
Keryx is developing ferric citrate, an oral, iron-based compound
Available to all in the medical field free of charge.
that has the capacity to bind to phosphate and form non-absorbable
HAWTHORN PHARMACEUTICALS
Booth 536
Hawthorn Pharmaceuticals, Inc., is a specialty pharmaceutical com-
complexes. Ferric citrate is currently in Phase 2 clinical development
for the treatment of hyperphosphatemia (elevated phosphate levels) in
patients with end-stage renal disease, or ESRD.
pany focused on the sales, marketing and development of niche prod-
KIDNEY COMMUNITY EARLY RESPONSE COALITION
ucts in areas such as Nephrology. Hawthorn's professional sales force
Booth 437
is committed to meeting the needs of patients and physicians in these
The Kidney Community Emergency Response (KCER) Coalition col-
target markets. Hawthorn endeavors to be a distinguished leader and
laboratively develops, disseminates, implements and maintains a
partner in the Nephrology marketplace while bringing innovative prod-
coordinated preparedness and response framework for the kidney
ucts and technologies to market.
community in the event of any type of emergency or disaster.
HEALTH INFORMATICS, INC.
LLORENS PHARMACEUTICAL INT’L DIVISION, INC.
Booth 306
Booth 914
Health Informatics, Inc. (HII) is the renal industry leader in electronic
During the past 22 years, Llorens Pharmaceutical has experienced
medical records and billing software. The TIMETM System has been
significant growth, introducing a diversity of new products in the United
employed in dialysis units for over 20 years and over 42 states.
States and Puerto Rico. Llorens Pharmaceutical is continually working
HII's TIMETM System is the backbone of its outsourced billing solutions
to improve the health and well-being of patients, with products such as
for both dialysis facilities and multi-specialty practices. To learn
Proteinex, Proteinex-18 and Nephronex.
more about our company and services, please visit us on the web
at www.hiiweb.com.
MEALS FOR LIFE
Booth 312
HEMOCUE, INC., A QUEST DIAGNOSTICS COMPANY
Introducing Meals for LIFE, a brand new company specializing in
Booth 1007
delicious microwaveable frozen entrees that are low in Potassium,
HemoCue is a World Leader in Point-Of-Care Testing. The name
Phosphorous, and Sodium. Specifically formulated for diabetics and
HemoCue has long been synonymous with precision, accuracy and
dialysis patients, Meals for LIFE is a convenient and healthy alternative
reliability. HemoCue’s leading point-of-care analyzers allow any
and is readily available in the frozen foods section of your local
healthcare professional the ability to obtain lab quality results anytime,
grocery stores.
anywhere. www.hemocue.com
MEDCOMP
INNOVATIONS 4 DIALYSIS
Booth 903
Booth 839
Medcomp is the market leader for dialysis access catheters. The
Clear Band: ClearBand provides reliable hemostasis and eliminates
Tesio Catheter and Split Cath long-term products have set the stan-
manual pressure following needle or sheath removal. ClearBand
dard for patient care. Medcomp offers a full line of CVCs and acces-
is a soft plastic that comfortably fits the arm without cutting into it.
sories, designed to save peripheral veins and future access sites.
Locking ridges face away from the skin to prevent binding or pinching.
Hemo: Hemo is a topical hemostasis pad with calcium ions to speed
up the clotting process for reliable hemostasis.
MEDICAL NUTRITION USA, INC.
Booth 907
Medical Nutrition USA, Inc. develops and distributes products for
nutritionally at-risk individuals under medical supervision. Our lowvolume Pro-Stat® products are ideal for ESRD patients, as they provide
15 grams of protein and up to 101 calories per ounce. Fiber-Stat, our
liquid fiber supplement, delivers 11 grams of soluble fiber per ounce.
p.106
MERCK & CO., INC.
KDOQI – Kidney Disease Outcomes Quality Initiative
Booth 1001
Stop by the NKF booth to learn about the newest KDOQI activity;
Merck & Co., Inc. is a global research-driven pharmaceutical company
Pediatric Nutrition Guideline Update: 2008 and learn why KDOQI is
dedicated to putting patients first. Established in 1891, Merck discovers,
recognized throughout the world for significantly improving patient
develops, manufactures and markets vaccines and medicines to address
outcomes. There are 12 current sets of KDOQI Guidelines. Visit the
unmet medical needs. For more information, visit: www.merck.com.
booth or the website for more information on KDOQI's new guideline
National Association of Nephrology
Technicians/Technologists (NANT)
implementation programs: http://www.kidney.org/Professionals/kdoqi/
KEEP – Kidney Early Evaluation Program
Booth 1033
Over 110,000 people across the country have participated in the NKF’s
NANT promotes education and advances the professional role of the
Kidney Early Evaluation Program (KEEP). To learn more about this
multidisciplinary team in delivering the highest quality of care to the
free, community-based health screening for people at increased risk
CKD patient. It provides educational opportunities, encourages the
for chronic kidney disease (CKD) and all the recent KEEP program
development of nephrology professionals in leadership roles and
updates, stop by booth #719. You can also pick up a free copy of
achieves recognition of technology practitioners in the total care of the
the KEEP Annual Data Report which will be published in AJKD's April
CKD patient.
2008 supplement.
NATIONAL KIDNEY AND UROLOGIC DISEASE
INFORMATION CLEARINGHOUSE (NKUDIC)
KLS™ – Kidney Learning System
Booth 736
provides educational programs and practical tools for physicians and
National Kidney and Urologic Disease Information Clearinghouse
health care professionals, CKD patients and their families and those
(NKUDIC) is an information and referral service of the National Insti-
at increased risk for CKD. KLS incorporates new science into all its
tute of Diabetes & Digestive & Kidney Diseases (NIDDK), one of the
educational resources, drawing from the ongoing guideline develop-
The National Kidney Foundation's KIDNEY LEARNING SYSTEM™ (KLS)
National Institutes of Health. The clearinghouse responds to inquiries,
ment process and regularly published KDOQI Guidelines updates
develops and distributes publications, and provides referrals to kidney
which are used by government health agencies, professional societ-
and urologic organizations.
ies, physicians, nurses, dieticians, social workers, pharmacists and
NATIONAL KIDNEY FOUNDATION
Booth 719
AJKD – American Journal of Kidney Diseases
American Journal of Kidney Diseases (AJKD), the official journal of the
National Kidney Foundation, is the world's leading journal in clinical
nephrology. Please visit the NKF booth to browse AJKD and the two
other journals from the National Kidney Foundation and Elsevier:
Advances in Chronic Kidney Diseases and Journal of Renal Nutrition.
KDIGO – Kidney Disease: Improving Global Outcomes
Kidney Disease Improving Global Outcomes (KDIGO)
Visit the booth to learn about KDIGO Guidelines, including the first
global guideline for the Prevention, Diagnosis, Evaluation and Treat-
patient groups. KLS programs are researched, tested, peer-reviewed,
produced and fully supported by the professional KLS staff of the
National Kidney Foundation. KLS offers a full line of CME/CE programs
as well as clinical tools and online clinician support resources, such
as a GFR calculator and interactive clinical action plans. Visit our Web
site at www.kidney.org/KLS for a comprehensive presentation of CKD
educational resources.
NKF CYBERNEPHROLOGY EXPERIENCE
Booth 334
Come relax and enjoy a special area in the expo hall devoted to cyberNephrology to gain hands-on experience with some of the many
resources available. This booth area is sponsored in part by Amgen.
ment of Hepatitis C in CKD, and for a demonstration of KDIGO's online
tool for accessing and comparing the latest nephrology guideline recommendations from around the world. KDIGO was established in 2003
as an independently incorporated non-profit foundation governed by an
international Board with the stated mission "to improve care and outcomes of kidney patients worldwide through coordination of initiatives
to develop and implement clinical practice guidelines." www.kdigo.org
p.107
2008 Exhibitors
NKF “PEOPLE LIKE US” CONSTITUENT COUNCIL /
"HOPE STREET”
THE NATIONAL KIDNEY FOUNDATION OF
NORTH TEXAS
Booth 821
Booth 1013
The NKF’s “People Like Us” initiative empowers, educates and encour-
North Texas affiliate of the National Kidney Foundation which serves
ages people affected by CKD, transplantation and donation to become
Dallas, Fort Worth and 64 surrounding counties.
advocates on public policy and other issues related to their health.
"People Like Us" is comprised of advocates from the NKF's constituent
groups: Patient and Family Council (PFC), transAction Council and the
National Donor Family Council (NDFC), and living donors. This booth
includes a wide variety of patient educational materials and empowerment tools to help them and their loved ones become their own best
advocate. One such tool featured in the booth is "Hope Street," the
NKF's comic strip "reality series" of, by and for the dialysis community.
NKF PROFESSIONAL COUNCILS
Booth 813
The National Kidney Foundation Council of Nephrology Nurses and
Technicians (CNNT), a 500-strong volunteer professional membership
organization, participates in public services directed toward prevention, detection and the care of persons with kidney and/or related
diseases. The Council advocates and contributes to the professional
development of members through education, networking and the dissemination of information related to professional practice and quality of patient care. CNNT invites all meeting attendees to stop by the
Booth to learn more about the council and its activities.
The National Kidney Foundation Council of Nephrology Social Workers
(CNSW) upholds and supports the profession of nephrology social
work through advocacy and the creation of patient and professional
education materials. With over 800 social work members the council
provides assistance, education and support to patients and their families in dealing with the psycho social stresses and lifestyle readjustments encountered by patients in all stages of CKD. Visit Booth 813 to
learn about new publications and professional resources and how to
get involved.
The National Kidney Foundation Council on Renal Nutrition (CRN),
is a 1,700-member volunteer professional organization dedicated to
promoting quality nutritional care and education to kidney patients.
Members impact regulatory and legislative issues and actively promote
the professional education of the renal dietitian. The Council stimulates,
supports and disseminates nutrition-related research, and develops
NATIONAL RENAL ALLIANCE
Booth 329
National Renal is a dialysis provider where physicians are partners. If
you are a physician who would like to receive the benefits of ownership
and be in control of your dialysis unit, please call Kim at (866) 312-9400
ext. 4424.
NATURAL BALANCE BODYWORK
Booth 938
Deep tissue Corrective Massage, Chair Massage, stress reduction
education, food/mood connection education, 30 day cleansing program
for wellness and weight loss, video demonstration.
NATURE PUBLISHING GROUP
Booth 1010
Nature Publishing Group brings leading scientific and medical
research to your desk top. The NPG portfolio combines the continued
excellence of Nature and its associated research and review journals,
over 42 leading academic and society journals, including Kidney
International and Eight Nature Clinical Practice journals. Visit Booth
1010 for free sample copies.
NEPHROCOR
Booth 810
Nephrocor™ offers renal biopsy and chemistry profiles for the diagnosis, treatment and management of kidney diseases. A full service anatomic and clinical pathology laboratory, Nephrocor™ serves nephrologists throughout the U.S.
NEPHROLOGY NEWS AND ISSUES
Booth 812
Nephrology News & Issues® (www.nephronline.com), is a national,
peer-reviewed news journal covering the political, social, and economic issues surrounding the delivery of dialysis and transplantation.
Stop by the booth for the latest issue, along with the 2008 Renal Care
Calendar and Meetings Guide, and Renal Resource and Buyer’s Guide.
patient and professional public education materials encouraging quality
nutrition care for CKD patients. Come see us at Booth 813 and view
our display of professional resources for renal dietitians.
p.108
NEPHROLOGY NURSING CERTIFICATION
COMMISSION
NOVA BIOMEDICAL
Booth 320
Nova’s new StatSensor™ Creatinine Meter is a handheld point-of-care
The Nephrology Nursing Certification Commission (NNCC) was es-
analyzer for accurate, 30-second measurement of creatinine and es-
tablished in 1987 to develop and implement certification examinations
timated Glomerular Filtration Rate (eGFR) on capillary blood. Stat-
for nephrology nursing. The NNCC offers the following examinations:
Sensor's small, 1.2 microliter whole blood samples can be obtained
Certified Nephrology Nurse-Nurse Practitioner (CNN-NP), Certified
virtually painlessly by fingerstick.
Nephrology Nurse (CNN), Certified Dialysis Nurse (CDN), Certified
Clinical Hemodialysis Technician (CCHT). For more information, stop
by our booth or visit our website at www.nncc-exam.org
Booth 318
NOVARTIS
Booth 321
For over 20 years, Novartis Pharmaceuticals Corporation has been
NEPHRO-PATH
a leading contributor to the advancement of transplant science and
Booth 420
medicine. Our focus remains on developing meaningful therapeutic
Under the direction of Patrick D. Walker, MD, NephroPath offers more
advances that improve the quality of life of transplant recipients and
than 30 years of experience interpreting renal biopsies. Because
enhancing the long-term success of transplantation. Please visit our
we understand the critical effect time to diagnosis can have on the
exhibit where Specialists from Novartis will be available to discuss our
outcome of many renal diseases, we offer complete results (Light,
products, answer questions and supply scientific information.
Immunofluorescence, and Electron Microscopy) on the same day we
receive a biopsy.
NOVO NORDISK INC.
Booth 929
NEPHRO-TECH
Novo Nordisk Inc., Princeton, N.J., is the United States headquarters
Booth 1023
of Novo Nordisk A/S, a global healthcare company leader in diabetes
Nephro-Tech, Inc. provides high quality pharmaceuticals at affordable
care. It manufactures and markets a comprehensive line of diabetes
prices. Introducing Vital-D Rx™; treat vitamin D (25-OH D3) deficiency
care products, growth hormone therapy, and treatment for specific
daily. Nephron FA® is an iron, vitamin, stool softener combination.
types of hemophilia. Novo Nordisk is committed to research to address
Great for PD patients! NephPlex Rx is one of the most cost-effective,
unmet medical needs.
®
renal multivitamins on the market that contains zinc. The MagneBind®
products are magnesium/calcium combination phosphate binders–
reduce calcium intake without compromising binding ability. Calphron
is 667 mg calcium acetate and costs $15.00/200 through Nephro-Tech,
Inc. RenaPlex® is a direct sell multivitamin costing $9.00/100 plus
$4.95 shipping. Call 800-879-4755 for more information.
NUTREPLETION RESOURCES
Booth 811
NutrePletion Resources is “Your First Choice for Nutritional Solutions.”
This specialty pharmacy provides nationwide coverage for the parenteral nutrition needs of the end stage renal disease patient. Our
pharmacists, reimbursement specialists, and field based registered
NIPRO MEDICAL CORPORATION
dietitians work closely with dialysis facility staff to provide high quality
Booth 715
IDPN and IPN services.
Nipro Medical Corporation is a worldwide manufacturer of disposable
medical products specializing in the renal and med-surg markets.
Includes bloodlines, safety fistula needles, dull needles, dose-saver
syringes, safety and non-safety syringes and needles. Expert staff
specializes in product inservice and technical support in which CEU
credits are earned. Quality and prices ensures you receive the lowest
cost care for your facility.
OMRON HEALTHCARE
Booth 322
The most important feature of Omron blood pressure monitors is that
they consistently provide accurate results. This is why every Omron
blood pressure model has been tested, evaluated and proven to meet
the rigorous safety and accuracy standards set by independent
organizations.
p.109
2008 Exhibitors
ORTHO BIOTECH PRODUCTS, L.P.
RENAL AND UROLOGY NEWS
Booth 801
Booth 1021
Ortho Biotech Products, L.P. markets PROCRIT (Epoetin alfa) used to
Renal & Urology News is a monthly tabloid with a circulation of 16,000
treat anemia associated with serious medical conditions. The company
Nephrologists, dialysis nurses and urologists. The publication’s pri-
also markets other biotechnology products. It is based in Bridgewater,
mary editorial mission is to report on new scientific developments of
New Jersey.
interest to these three specialist groups. News coverage focuses on
®
PENTEC HEALTH
Booth 933
Pentec Health - a niche specialty pharmacy company that is a provider
of IDPN/IPN therapies to the ESRD population tracking outcomes data.
website at www.pentechealth.com
PFIZER
Booth 629
Please visit the Pfizer Inc, U.S. Pharmaceuticals exhibit featuring:
LIPITOR® (atorvastatin calcium)
PHYSICIANS’ CAPITAL INVESTMENT, LLC
Booth 713
Physicians’ Capital Investment, LLC is the innovator of the seamless approach to patient care facilities. From design, to construction, to finance,
to operations; PCI’s staff has over 85 years of combined healthcare
experience in providing state of the art healthcare facilities, allowing our
physician partners to focus on their number one priority… their patients.
PKD FOUNDATION
Booth 539
Stop by our booth to learn about our new KidneyWise Nutrition
Program, featuring a cookbook and website tailored to each stage of
kidney disease! The PKD Foundation fights polycystic kidney disease
(PKD) through research funding and patient education. Learn
more today!
QUALITY DIALYSIS
Booth 636
Dialysis services are performed at home in an environment, which is
safe, secure, and closely monitored to insure that patient care is not
compromised. With increasing demand for quality medical care and the
reduced funds available to the health care system, medical providers
are seeking alternatives that are cost effective without compromising
quality care.
medical conferences but also includes reporting on recently published
papers in peer-reviewed journals. Various features and departments
complement the news coverage.
RENAL BUSINESS TODAY/VIRGO PUBLISHING
MEDIA GROUP
Booth 304
Renal Business Today delivers top-notch editorial content for practicemanagement professionals. http://www.renalbusiness.com/.
www.renalbusiness.com offers daily news, an editorial library, a blog by
editor Keith Chartier, Pharma Corner, a free E-newsletter and more.
RENAL PHYSICIANS ASSOCIATION
Booth 734
The Renal Physicians Association is a national organization with the
expertise and successful track record of pro-actively defending the
discipline of the nephrology practice. Membership is comprised of
healthcare providers in the subspecialty of internal medicine known as
nephrology. Stop by to check out RPA’s latest programs and publications or visit us at www.renalmd.org.
SATELLITE HEALTHCARE INC. /WELLBOUND
Booth 1028
Satellite Healthcare is an established leader in driving clinical excellence through joint ventures with nephrologists. Through its partners
WellBound and Satellite Dialysis, Satellite Healthcare provides early
patient wellness education, superior clinical support services and a
complete range of dialysis therapy choices. This comprehensive offering allows Satellite Healthcare to advance the standard of chronic
kidney disease care while optimizing patient wellness.
SATELLITE LABORATORY SERVICES
Booth 311
Satellite Laboratory Services, an independent, full service ESRD laboratory provides a complete renal testing menu, simplified management
tools and easy access to laboratory services backed by dedicated service
personnel. We provide a single source for all your laboratory needs.
p.110
SCANTIBODIES CLINICAL LABORATORY
U.S. RENAL CARE, INC.
Booth 310
Booth 635
Scantibodies Clinical Laboratory (SCL) will showcase a new study
Founded in 2000, US Renal Care works in partnership with nephrolo-
demonstrating a dramatic decrease in adynamic bone disease in renal
gists to develop and operate outpatient dialysis centers. We support
patients resulting from use the PTH Accuratio™ Third generation test-
our physician partners and clinical staff with strong financial resources,
ing. SCL invites clinical labs worldwide to join the 10-year initiative to
experienced operations management, state of the art technology, and
compare accuracy/stability of PTH assays.
patient and family education.
SHIRE
U.S. RENAL DATA SYSTEM (USRDS)
Booth 411
Booth 300
Shire is a leading global specialty pharmaceutical company focusing
The USRDS Coordinating Center, funded by NIDDK, is the national reg-
on specialist physicians and their patients in the areas of attention
istry that collects, analyzes, and distributes information on trends and
deficit and hyperactivity disorder (ADHD), human genetic therapies
patient outcomes in the ESRD population. Annual Data Report CDs,
(HGT), gastrointestinal (GI) and renal diseases.
handouts, and website demonstrations will be available.
SIGMA-TAU PHARMACEUTICALS, INC.
Booth 305
University of Minnesota Medical Center,
Fairview
Sigma-Tau Pharmaceuticals is the manufacturer and distributor of
Booth 441
Carnitor® (levocarnitine) Injection. Carnitor Injection is covered nation-
We lead the nation in living donor kidney transplantation. We celebrate
ally by CMS/Medicare. The Carnitor Injection Reimbursement Assistance
45 years of pioneering research in living donor transplantation. We
Program provides in-depth support services regarding reimbursement
have performed over 10,000 adult and pediatric transplants in kidney,
policy, documentation requirements and claims troubleshooting.
kidney/pancreas, pancreas, liver, heart, heart/lung, lung, intestinal and
Contact the Reimbursement Hotline at 800-490-3262 for assistance.
islet cells.
Please visit www.carnitor.com for more information.
WATSON NEPHROLOGY
SOLINMED BILLING & TRANSCRIPTION
Booth 911
Booth 739
Watson Nephrology, marketers of Ferrlecit® (sodium ferric gluco-
1.) Ensuring your Financial Health with Medical Billing & Transcription
nate complex in sucrose injection), offers specialty products includ-
Services. 2.) Medical Billing: 60% cost-reduction to you, patentable
ing injectable iron therapy, oral iron supplements, and renal vitamin
technology for ERROR-free billing, superfast payment cycle, lowest
formulations. Watson Nephrology, a Division of Watson Pharma, Inc.
cost. 3.) Transcription: 99.6-100% accuracy, 12-24 hour turnaround,
demonstrates their commitment to the nephrology community through
6-7 cents/line! 4.) Leading with Low Cost solutions & ERROR-free
anemia education programs and support of national organizations
service. 972-347-9026. www.solinmed.com
such as the National Kidney Foundation.
SPECTRA LABORATORIES
WYETH PHARMACEUTICALS
Booth 428
Booth 915
Spectra is the leading provider of renal-specific laboratory services.
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in
Our advanced equipment, specimen packaging, and reporting applica-
the areas of women’s health care, cardiovascular disease, central
tions help provide rapid and reliable test results. Our on-site training
nervous system, inflammation, transplantation, hemophilia, oncology,
by a team of renal clinicians and coordination of STAT testing services
vaccines and nutritional products.
help customers deliver optimal patient care.
TEVA PHARMACEUTICALS
Booth 1019
Teva Pharmaceuticals, the nation's leading generic manufacturer,
markets over 320 products and 1100 SKU's in all major therapeutic
areas, including immunosuppressive agents to prevent the rejection of
kidney, liver and heart allograft.
p.111
Keep Learning & Growing
Join the National Kidney Foundation Today!
Thousands of renal health care professionals rely on membership in the National Kidney
Foundation to help them keep abreast of the latest developments in kidney prevention and
treatment through industry-leading journals, newsletters, authoritative guidelines, brochures, online
information, clinical meeting and CME courses.
The NKF relies on the support of its
members to carry out its mission to
s Support kidney patients and families
s Encourage organ donation
s Offer early detection programs
s Provide comprehensive public and
professional education
s Sponsor scientific research
s Spearhead advocacy programs to ensure the
rights and welfare of kidney patients, their
families and kidney professionals.
If you are a member, renew now at 2007 prices.*
VaLdg`
I]Z?djgcVad[
CZe]gdad\nHdX^
KdajbZ',L^ciZg'%%,
8djcXâd[CZe]g
HdX^VaLdg` Zgh
KdajbZ',L
If you’re not a member, join now and start receiving NKF
membership benefits.
dad\n
^ciZg'%%,
[CZe]gdad\nHdX^VaLdg`
I]Z?djgcVad
h^hGZ\^bZc/
Ê Ê =ZbdY^Van
ijgZ
6GZk^Zld[i]ZAîZgV
h^h/B^hhZYVcY
=ZbdY^Van
H]dgiZcZYIgZVibZcih
\VcY8@9
KdajciZZg^c
i;daadl^c\GZcVa
:beadnbZc
IgVcheaVciVi^dc
bjcîn:bZg\ZcXn
@^YcZn8db
GZhedchZ8dVaî^dc
Go to the membership desk or www.kidney.org for a
complete list of member benefits and to register online.
* Current members can save $25 off their NKF Membership
Fee when they recruit a new member.
*Offer good through 5/30/08. The renewal and new member forms must be mailed together in order to receive the discount. The new member will pay the
full price for their membership. Both renewing and new members will lose the option to complete their transactions online and must mail in their forms together for
processing. New members can download the PDF of the member application from www.kidney.org.
U www.kidney.org
© 2008 National Kidney Foundation, Inc. All rights reserved. 0280-366A
p.112
NATIONAL KIDNEY FOUNDATION’S PROFESSIONAL COUNCILS
RESEARCH GRANT RECIPIENTS 2007–2008
Council of Nephrology
Social Workers Grants
Jackie Carder, MS, RD, CDE, and Council of Nephrology Nurses and
Technicians Grant
Mary Beth Callahan, ACSW, LCSW
Kay Taylor, RD, CDE
Robert W. MacKinnon, RN, CNN
Dialysis Center of Lincoln
Caritas St. Elizabeth’s Medical Center
Dallas, Texas
Lincoln, Nebraska
Brighton, Massachusetts
Title of Project: Kidney Transplant Patient
Title of Project: Comparison of Predicted Resting
Title of Project: The Impact of Continuous
Employment Potential: Re-valuation of an
Metabolic Rate to Measured Resting Metabolic
Renal Replacement Therapy (CRRT) Staffing
Important Outcome Measure by Use of New
Rate in Maintenance Dialysis Patients
and Technique on Nursing Resource Utilization,
Methodologies
Council on Renal Nutrition Grants
Joyce Vergili, MS, RD
Caroline Jennette, MSW
Columbia University Teachers College
University of North Carolina
New York, New York
Chapel Hill, North Carolina
Title of Project: Nutritional Practices of Renal
Title of Project: Renal Replacement Therapy
Dietitians in Hemodialysis Centers Throughout
and Barriers to Choice: The Patient’s Perspective
the United States
Quality of Care and Patient Safety
Joseph Merighi, PhD
Boston University School of Social Work
Title of Project: A Nationwide Survey of Kidney
Transplant Social Workers’ Job Roles, Responsibilities, and Occupational Well-Being
p.113
GAYLORD TEXAN
FLOOR PLAN
p.114
FACULTY
Kara Abbas, MS, RD, CSR
Arif Asif, MD
Gerald Beck, PhD
Abbott
University of Miami School of Medicine
Cleveland Clinic Foundation
Gilbert, AZ
Miami, FL
Cleveland, OH
Cassy Aspinall, MSW, LICSW
Children’s Hospital and Regional Medical
Center
Salt Lake City, UT
Boston, MA
Seattle, WA
Kenneth Abreo, MD
John R. Asplin, MD
Methodist Hospital
Louisiana State University Health Sciences
Litholink Corporation
Westfield, IN
Center
Chicago, IL
Shreveport, LA
Ann Beemer Cotton, MS, RD, CNSD
Filitsa H. Bender, MD
University of Pittsburgh Medical Center
Beth Adams, PA
Children’s Medical Center Dallas
Pittsburgh, PA
Henry Ford Hospital
Dallas, TX
Detroit, MI
Laurie E. Benton, RN, PA-C, BS, MPAS
Mary Ann Baily, PhD
Scott and White Hospital, Texas A&M
Sharon Adler, MD
The Hastings Center
Health Science Center College of Medicine
UCLA Medical Center
Garrison, NY
Temple, TX
Torrance, CA
George Bakris, MD, FAHA, FASN
Suzanne M. Bergman, MD
Anil K. Agarwal, MD
University of Chicago
University of Alabama at Birmingham
Ohio State University
Chicago, IL
Birmingham, AL
Dublin, OH
Lynda K. Ball, RN, BSN, CNN
Tomas Berl, MD
Zalman S. Agus, MD
Northwest Renal Network
University of Colorado Health Sciences
University of Pennsylvania
Seattle, WA
Center
School of Medicine
Philadelphia, PA
Michael Allon, MD
Birmingham, AL
Gerald Appel, MD
Columbia University College of Physicians
and Surgeons
New York, NY
George Aronoff, MD
University of Louisville
Louisville, KY
Stephen R. Ash, MD, FACP
Clarian Arnett Health
Lafayette, IN
Julie Barboza, MSN, RD, APRN-BC
Denver, CO
Evercare Renal Disease (RD) Program
Jeffrey S. Berns, MD
Berkley, MA
Lois Bates
Howard Brown Health Center
Chicago, IL
Daniel C. Batlle, MD
Chicago, IL
Gerald A. Beathard, PhD
RMS Lifeline
Paige, TX
School of Medicine
Philadelphia, PA
Anatole Besarab, MD
Henry Ford Hospital
Detroit, MI
Judith Beto, PhD, RD
Loyola University Medical Center
Maywood, IL
Peter Blake, MD, FRCPC, FRCPI
Victoria Hospital
London, Ontario, Canada
Mary Ellen Brabec, MHS, RD, CSR, LDN
Diversified Specialty Institutes
Hazel Crest, IL
p.115
FACULTY
Kathleen Brady, MS, BC-ANP
Claire Casselman, MSW, LMSW, LICSW
Danny Concepcion, CCHT, CHT
University of Michigan Health Systems
St. Joseph Hospital Renal Center
Center
Ann Arbor, MI
Orange, CA
Lee Cauble, MPH, RD, CSR, LD
Bonnie Conrad, RN, CDN
Emmanuel Bravo, MD
DCI/ Desert Dialysis Center
Albany Regional Kidney Center
Tucson, AZ
Albany, NY
Donna Calvin, APRN, BC-FNP, CNN
Gabriel Contreras, MD, MPH
Barry Brenner, MD
University of Illinois at Chicago
University of Miami School of Medicine
Chicago, IL
Miami, FL
Denver, CO
Cleveland, OH
Boston, MA
Valerie Brinkman-Kaplan, MS, RD, LD
Scott and White Clinic, Texas A&M
Phoenix Children’s Hospital Kid’s Kidney
US Renal Care/Tarrant Dialysis Centers
University HSC
Center
Central Fort Werth
Temple, TX
Phoenix, AZ
Christopher Chan, MD
Daniel Coyne, MD
Bridget K. Brosnihan, PhD
University of Toronto
Chromalloy American Kidney Center
Wake Forest University School of Medicine
St. Louis, MO
Fort Worth, TX
Winston–Salem, NC
Alfred Cheung, MD
Ronald J. Crossno, MD
Teri Browne, MSW, LSW
University of Utah
Vista Care Hospice
Salt Lake City, UT
Rockdale, TX
Glenview, IL
Dolph Chianchiano, JD Jackie Crouch John M. Burkart, MD
Scott and White Memorial Hospital
Wake Forest University Medical Center
New York, NY
Temple, TX
Michael J. Choi, MD
Jim R. Curtis, CHT, CCHT
David Bushinsky, MD
Jim Curtis & Associates
University of Rochester
Baltimore, MD
Portland, OR
Louise Clement, MS, RD, CSR, LD
Jessica Cabness, MSW, PhD
South Plains Kidney Disease Center
Klinikum Offenbach
University of South Florida
Lubbock, TX
Offenbach, Germany
Winston–Salem, NC
Rochester, NY
St. Petersburg, FL
Carolyn Cochran, RD, LD, MS, CDE
Jan Deane, RN, CNN
Mary Beth Callahan, ACSW, LCSW
Dallas Nephrology Associates
Renal Network of the Upper Midwest
Dallas, TX
Saint Paul, MN
Dallas, TX
Jean Colaneri, ACNP, MS
Andrea DeKam, LMSW
Donna Calvin, APRN, BC-FNP, CNN
Albany Medical Center Hospital
University of Michigan Dialysis
University of Illinois at Chicago
Albany, NY
Livonia, MI
Francis Delmonico, MD
Ellen Case, MSW, LGSW
Mayo Clinic
Minneapolis, MN
Boston, MA
Olympia Fields, IL
Rochester, MN
p.116
Laura Dember, MD
Paul W. Eggers, PhD
Allon Friedman, MD
Boston University School of Medicine
National Institute of Health
Indiana University School of Medicine
Boston, MA
Bethesda, MD
Carmel, IN
Christina Denman, LMSW
Karen Egloso, BSW, MSW, LSW, CNSW
Barbara Fromm, MS, RD
Collin County
Sunrise Children’s Hospital
Harborview Medical Center, University
Plano, TX
Las Vegas, NV
of Washington
Vincent W. Dennis, MD
Garabed Eknoyan, MD
Cleveland Clinic
Baylor College of Medicine
Mary Ann Fuller, RD, LD
Cleveland, OH
Houston, TX
DaVita Arlington Dialysis
Kimberly English, MSN, RN, FNP
Centers For Dialysis Care
Scott & White Sleep Disorders Clinic
Anthony Furlan, MD
Shaker Heights, OH
Temple, TX
Cleveland Clinic Cerebrovascular Center
Thomas Depner, MD
Jessica Farrell, MSW, LCSW-P
University of California, Davis
Duke University Medical Center
Mindy Gentile, MS, RD, LD
Sacramento, CA
Durham, NC
McKinney, TX
David DeWalch, MSPA, PA-C, MS, MA
Daniel I. Feig, MD, PhD
Joel Glickman, MD, FACP
American Association of Surgical Physician
Texas Children’s Hospital
Assistants, Tyler Radiology Associates
Houston, TX
Philadelphia, PA
Harvey A. Feldman, MD, FACP
Deborah Glidden, ARNP, BC, CNN
Lesley Dinwiddie, MSN, RN, FNP, CNN
Nova Southeastern University
Nephrology Associates of Central Florida, PA
Institute for Clinical Excellence,
Ft. Lauderdale, FL
Orlando, FL
Harold I. Feldman, MD, MSCE
David S. Goldfarb, MD
New York Harbor VA Medical Center/NYU
Philadelphia, PA
School of Medicine
Tyler, TX
Education and Research
Cary, NC
Bradley Dixon, MD
Veterans Affairs Medical Center and
University of Iowa
Iowa City, IA
Bart Dolmatch, MD
UT Southwestern Medical Center
Dallas, TX
Mary Anne Dooley, MD, MPH
University of North Carolina
Fredric O. Finkelstein, MD
North Bend, WA
Lake Dallas, TX
Cleveland, OH
New York, NY
Hospital of St. Raphael, Yale University
Cheri Goldstein, PA-C
New Haven, CT
Michael Flessner, MD, PhD
Dallas, TX
University of Mississippi Medical Center
Thomas Golper, MD, FASN, FACP
Jackson, MS
Nashville, TN
Chapel Hill, NC
Scott and White Hospital, Texas A&M
Thomas A. Gonwa, MD, FASN, FACP
University HSC
Mayo Clinic
Tilman Drüeke, MD
Temple, TX
Jacksonville, FL
Stanley S. Franklin, MD, FACP, FACC
UCI Heart Disease Prevention Program
Mayo Clinic Dialysis Services
Los Angeles, CA
Rochester, MN
Hôpital Necker
Paris, France
Senator Robert Duncan
Crenshaw, Dupree and Milam
Austin, TX
p.117
FACULTY
John Q. Gowan, LMSW
Rebecca Hays, MSW
Priscilla Hollander, MD
ESRD Network # 14
University of Wisconsin Hospital and Clinics
Baylor Endocrine Center
Dallas, TX
Madison, WI
Dallas, TX
Michael Grasso, MD
Mikhaelle Heald, LMSW
Norman K. Hollenberg, MD, PhD
Saint Vincents Medical Center
The Children’s Mercy Hospitals and Clinics
Brigham & Women’s Hospital
Rye, NY
Kansas City, KS
Boston, MA
Tom Greene, PhD
David J. Hellmann, MD
Jean L. Holley, MD
University of Illinois
Salt Lake City, UT
Baltimore, MD
Urbana, IL
Loic Guillevin, MD
Brenda R. Hemmelgarn, MD
Josefina Houchins, LMSW
Hopitaln Avicenne
University of Calgary
DaVita Oak Cliff Dialysis Center
Bobigny Cedex, France
Calgary, Alberta, Canada
Dallas, TX
Kay Hall, BSN, RN, CNN
Johann Herberth, MD, FASN
Tricia Howard, MHS, PA–C
DaVita, Inc.
University of Kentucky
Medical Associates of Savannah
Brentwood, TN
Lexington, KY
Savannah, GA
Lisa Hall, MSSW, LCSW
Charles Herzog, MD
Kirk Hughes, MD
The Florida ESRD Network
Hennepin County Medical Center
University of Iowa Hospitals & Clinics
Tampa, FL
Minneapolis, MN
Iowa City, IA
L. Lee Hamm, MD
Tulane Medical School
Maine Medical Center Research Institute
Fresenius Medical Services-North America
New Orleans, LA
Portland, ME
Santa Rosa, CA
Haewook Han, PhD, RD, CSR, LDN
Debbie Hinnen, ARNP, CDE, BC-ADM, FAAN
Tami Hyziewicz Case, PA–C
Tufts-New England Medical Center
Mid-America Diabetes Associates
Scott & White Hospital
North Quincy, MA
Wichita, KS
Temple, TX
Sandra Hinton, RN, BSN
Ajay Israni, MD, MS
University of Washington Medical Center
Hennepin Faculty Associates
Seattle, WA
Dallas, TX
Minneapolis, MN
John W. Hartman, MD
Tammy Ho, MD
Bertrand L. Jaber, MD, MS
Visonex, LLC
Evanston Hospital
Caritas Medical Group
Green Bay, WI
Evanston, IL
Boston, MA
Jeanette Hasse, PhD, RD, FADA, CNSD
R. Michael Hofmann, MD
Aimee Jaremowicz, RD, LD
Baylor Regional Transplant Institute
Diversified Specialty Institute (DSI)
Baylor University
Madison, WI
Chicago, IL
Dallas, TX
Ronald Hogg, MD
Arfrances Johnson, LD, RD, MS
Mary Hastings Hagar, PhD, RD, FADA
Scott and White Hospital
Liberty Dialysis
American Dietetic Association
Temple, TX
Fort Worth, TX
Jeffery Hoggard, MD
Stephanie Johnstone, LCSW, MSW
Eastern Nephrology Associates
Fresenius Medical Care-North America
Greenville, NC
San Diego, CA
Washington, DC
p.118
Debra Jordan Stephen M. Korbet, MD, FASN
Anne Liles, PharmD
DaVita North Dallas Dialysis Center
Rush University Medical Center
Auburn University
Dallas, TX
Chicago, IL
Auburn, AL
Sheila Jowsey, MD
Andrea Kostick, MSW, LISW
Robert M. Lindsay, MD
Mayo Clinic
Mayo Clinic
The University of Western Ontario and
Rochester, MN
Rochester, MN
London Health Sciences Centre
Peter Juergensen, PA-C
Csaba Kovesdy, MD, FASN
Metabolism Assoicates
Salem VA Medical Center
Robert S. Lockridge, MD
Cheshire, CT
Salem, VA
Lynchburg Nephrology Physicians, PLLC
Kamyar Kalantar–Zadeh, MD
Sumit Kumar, MD
Harbor-UCLA
Charmaine Lok, MD
Torrance, CA
Dallas, TX
Marcia Kalista Richards, MPH, RD, CNSD,
Dana Kumjian, MD
LDN
Medical Associates of Savannah
Cynthia Lord, MHS, PA-C
Pennsylvania State University
Savannah, GA
Quinnipiac University
Slatington, PA
Warren Kupin, MD
London, Ontario, Canada
Lynchburg, VA
Cheshire, CT
Judith Kari University of Miami
Elena Lucio, LMSW
Centers for Medicare & Medicaid Services
Miami, FL
Christus Santa Rosa Children’s Hospital
Baltimore, MD
Nadiya Lakhani, RD, LD
San Antonio, TX
Fresenius Medical Center
Kati Malarcher, LMSW
Genzyme Renal
Dallas, TX
Collin County Dialysis Center
Vermilion, OH
Kristin Larson, RN, ANP, GNP, CNN, MSN
Plano, TX
Rita-An Kiley, MSW
Nephrology Associates
Maggie Marek Elm Grove, WI
Salt Lake City, UT
Baylor All Saints Fort Worth
Paul Kimmel, MD
Thu H. Le, MD
George Washington University
Durham VA Medical Centers
Cathi Martin, RD, CSR
Washington, DC
Durham, NC
NutrePletion Resources
Lisa Kindy, JD
Nathan Levin, MD
Medical University of South Carolina
Renal Research Institute
Arthur J. Matas, MD
Charleston, SC
New York, NY
University of Minnesota
Alan S. Kliger, MD
Kristie Lewis, LLMSW, MSW
Hospital of St. Raphael
Henry Ford Health System, Greenfield Health
Ivan D. Maya, MD
New Haven, CT
Systems – Taylor Dialysis
Westland, MI
Birmingham, AL
ESRD Network of Texas, Inc.
Edmund J. Lewis, MD
Maureen McCarthy, MPH, RD, CSR, LD
Dallas, TX
Oregon Health & Science University
Chicago, IL
Portland, OR
Dialysis Clinic, Inc.
Julia B. Lewis, MD
William McClellan, MD
Columbia, MO
Emory University
Nashville, TN
Atlanta, GA
Bobbie Knotek, RN, BSN, CNN, CPHQ
Norma Knowles, MSW, LCSW
Forth Worth, TX
Nashville, TN
Minneapolis, MN
p.119
FACULTY
Peter McCullough, MD, MPH
Jeffery C. Metzger, MD
Donna Morton de Souza, MPH, RD
William Beaumont Hospital,
University of Texas Southwestern
Professional Nutrition Services, Inc.
Beaumont Health Center
Medical Center
Sacramento, CA
Northville, MI
Dallas, TX
Samy McFarlane, MD
Mariam Michaels, MD
West Virginia University
SUNY Downstate Kings
Howard University
Morgantown, WV
County Hospital Center
Washington, DC
Brooklyn, NY
Alvin Moss, MD
Salim Mujais, MD
Ronald Miller, MD, FACP
Astellas Pharma US
Jennifer McGuoirk, MS, RD, LDN
University of California, Irvine
McGaw Park, IL
Abbott Renal Care
Irvine, CA
Aston, PA
Mary Murphy, RN, CCTC
Phoenix Childrens Hospital
Stephanie McIntyre, RD
Advanced Renal Care, Inc.
Phoenix, AZ
Avondale, AZ
Tampa, FL
Dianne McKay, MD
Meredith Miller, RD, LD
The Scripps Research Institute
Chicago, IL
La Jolla, CA
Cleveland, OH
Patrick Murray, MD
Mohanram Narayanan, MD, FASN
Patricia M. McKevitt, MSW, ACSW, LCSW
Richard Mishler, MD
Scott and White Hospital
Arizona Kidney Disease &
Temple, TX
St. Louis, MO
Hypertension Center
Beth McQuiston, MD, MS, RD, LDN
Phoenix, AZ
Orson W. Moe, MD
Park Ridge, IL
Rajnish Mehrotra, MD, FACP, FASN
UCLA Medical Center
Torrance, CA
Ravindra Mehta, MD
University of California – San Diego
La Jolla, CA
Mark Meier, LICSW, MSW
Creative Workplace Solutions
Minneapolis, MN
University of Toronto
Joe Merighi, MSW, PhD
Boston University School of Social Work
Boston, MA
Medical Center
Dallas, TX
Sharon Moe, MD
Indiana University
Indianapolis, IN
Michele H. Mokrzycki, MD, MS
Montefiore Medical Center, Albert Einstein
College of Medicine
Bronx, NY
Marianne Moncrief,
Dallas Transplant
Dallas, TX
Anne Moore, LMSW
Texas Partnership for End of Life Care
Sugarland, TX
Nancy Nardelli, RN, CCRC
Medical City Dallas Hospital
Dallas, TX
Andrew S. Narva, MD, FACP
National Institutes of Health
Bethesda, MD
Ira Nemeth, MD
Dallas County Health and Human Services
Dallas, TX
Albany Dialysis Center
Albany, NY
Allen Nissenson, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA
Ann O’Hare, MD
University of Washington
Seattle, WA
Bruce Z. Morgenstern, MD
Phoenix Children’s Hospital
Phoenix, AZ
p.120
Edmund O’Riordan, MB, BCH, BAO, MRCPI
Lisa Pratka, LMSW
Carol Roe, RN, JD
Salford Royal Foundation Trust
Centers for Dialysis Care
Salford, Manchester
Dallas, TX
Shaker Heights, OH
Emil Paganini, MD
Megan Prescott, MSW, LCSW
Arturo R. Rolla, MD
The Cleveland Clinic Foundation
University of Colorado Hospital
Cleveland, OH
Aurora, CO
Boston, MA
Robert L. Page, PharmD, FCCP, FAHA,
Pat Preston, MS
Jamie Ross, MD
FASCP, FSGC, CGP, BCPS
Pat Preston Medical Enterprises, Inc
UC Davis
Astoria, OR
Sacramento, CA
Wajeh Qunibi, MD, FACP
University of Texas Health Science Center
University of Cincinnati
San Antonio, TX
Cincinnati, OH
Jai Radhakrishnan, MD, MR, MRCP
Bharat Sachdeva, MD
Columbia University
Louisiana State University Health
New York, NY
Science Center
Center
Aurora, CO
Joni J. Pagenkemper, MS, MA, RD, LMNT
Creighton University Medical Center
Omaha, NE
Paul M. Palevsky, MD
Pittsburgh, PA
Jodi Patterson, LMSW
McKinney Dialysis Center
McKinney, TX
Jessie Pavlinac, MS, RD, CSR, LD
Oregon Health & Science University
Portland, OR
Marc Penn, MD, PhD
Cleveland, OH
Mark A. Perazella, MD
Yale University School of Medicine
Cheshire, CT
Beth Piraino, MD
Pittsburgh, PA
Ronald Pisoni, PhD, MS
Arbor Research Collaborative
Ann Arbor, MI
Marc Pohl, MD
Cleveland, OH
Shreveport, LA
University of Michigan
Antoine Samaha, MD
Ann Arbor, MI
Kidney and Hypertension Center
Robert Reilly, MD
Cincinnati, OH
Irving, TX
Cleo Richard, RN, PhD
Madison, WI
Consultant
Eduardo Sanchez, MD, MPH
Missouri City, TX
University of Texas Health Center
Mark S. Roberts, MD, MPP
Austin, TX
University of Pittsburg School of Medicine
Paul W. Sanders, MD
Pittsburgh, PA
Birmingham VA Medical Center
Bruce Robinson, MD
Birmingham, AL
Arbor Research Collaborative
Gail Sansivero, MS, ANP
Ann Arbor, MI
Community Care Physicians
Albany, NY
Mark J. Sarnak, MD
Winston Salem, NC
Tufts-New England Medical Center
Roger Rodby, MD
Boston, MA
Mary Schira, PhD, APRN, BC, ACNP
Chicago, IL
University of Texas at Arlington School
James R. Rodrigue, PhD
of Nursing
Arlington, TX
Boston, MA
p.121
FACULTY
Kathy Schiro Harvey, MS, RD, CSR
Lesley Stevens, MD, MS, FRCPC
Michael Talamantes, MSSW, LCSW
Puget Sound Kidney Centers
Tufts – New England Medical Center
University of Colorado Hospital
Mountlake Terrace, WA
Boston, MA
Aurora, CO
Donald Schon, MD
Maria Taylor, PharmD
Arizona Kidney Disease & Hypertension
Mayo Clinic
Phoenix, AZ
Rochester, MN
Birmingham, AL
Anton Schoolwerth, MD, FAHA
Stephen C. Textor, MD
Dartmouth-Hitchcock Medical Center
University of Washington,
Mayo Clinic Foundation
Spofford, NH
Northwest Kidney Centers
Rochester, MN
Donna Secker, PhD
Seattle, WA
Ravi Thadhani, MD
The Hospital for Sick Children
Children’s Hospital and Regional
Boston, MA
Mary Ann Sevick, ScD, RN
Pittsburgh, PA
Edward Siew, MD
Nashville, TN
Edward G. Silverhardt, LCSW, LSCSW, BCD, MSW
Medical Center
Seattle, WA
Dana Sturtevant, MS, RD
Be Nourished
Portland, OR
Wadi N. Suki, MD, FACP
The Kidney Institute
Houston, TX
Charlie Thomas, LCSW, ACSW, MSW, CISW
Banner Good Samaritan Medical Center
Phoenix, AZ
Cheryl Thomas, RDH
Founder Dental Inspirations, Inc.
Galveston, TX
Kathryn Thurber-Smith, LICSW
Children’s Hospital and Regional
Sparks Dialysis Center
Phyllis Sun, RD
Medical Center
Sparks, NV
St. Elizabeth’s Medical Center
Seattle, WA
Ajay Singh, MBBS, FRCP
Brighton, MA
Trent Tipple, MD, FAAP
Brigham and Woman’s Hospital
Mary Sundell, RD, LDN, CCRP
The Research Institute at Nationwide
Boston, MA
Children’s Hospital
Nashville, TN
Columbus, OH
Duane Sunwold
Ashita Tolwani, MD, MSc
Pittsburgh, PA
Spokane Community College
Spokane, WA
Birmingham, AL
Lynda Szczech, MD, MCSE, FASN
Faith Tootell, MS, RD, CSR, FADA
Evanston, IL
Duke University School of Medicine
Satellite Healthcare Inc.
Durham, NC
Fremont, CA
Texas Renal Coalition
Paul Szczybor, PA–C
Jose Torrealba, MD
Lubbock, TX
The Franklin Square Hospital Center
University of Wisconsin – Madison
Catonsville, MD
Madison, WI
Case Western Reserve University
Harold M. Szerlip, MD, FACP, FCCP
Robert D. Toto, MD
Cleveland, OH
Medical College of Georgia
UT Southwestern Medical Center at Dallas
Augusta, GA
Dallas, TX
Glen Stanbaugh, MD
Alison Steiber, PhD, RD, LD
p.122
Michelle Trahan, MS, RD, LD
Thomas Vesely, MD, FSIR
Barbara Weis Malone, BSN, RN, MSN, CFNP
Genzyme Renal
Self-Employed
Richardson, TX
Saint Louis, MO
Sciences Center
Ronald Victor, MD
DaVita Littleton Dialysis
Steven D. Weisbord, MD, MSc, FASN
Highlands Ranch, CO
Dallas, TX
University of Pittsburgh School of Medicine
Lara Tushla, LCSW, MSW
Theodôr Vogels, MSW
Rush Presbyterian
Máxima Medical Centre
John Jason White, MD
Chicago, IL
The Netherlands
Medical College of Georgia
Tracey A. Tyus–Bailey, MSW, LMSW, ACSW
Bradley Warady, MD
Greenfield Health Systems
Children’s Mercy Hospitals and Clinics
Robert Whitlock, MSSW, LCSW, MHA
Southfield, MI
Kansas City, MO
Missouri Kidney Program
Mark Unruh, MD, MSc
Richard A. Ward, PhD
University of Louisville
Karen Wiesen, CHT, LPN, RD, LD
Pittsburgh, PA
Louisville, KY
Aris Q. Urbanis, MD
Kurt A. Wargo, PharmD, BCPS
RMS Lifeline, Inc.
University of Alabama – Birmingham
Grosse Pointe Park, MI
Huntsville, AL
Tushar Vachharajani, MD, FASN, FACP
David G. Warnock, MD
University of Alabama – Birmingham
Winston Salem, NC
Birmingham, AL
Ramiro Valdez, PhD
Sarah Washburn, MS, RD, CD
Valdez Seminars
Seattle Cancer Center Alliance
Denton, TX
Seattle, WA
Joseph P. Vande Griend, PharmD
Tiffany Washington, MSW
University of Colorado Denver
UNC Chapel Hill School of Social Work
School of Pharmacy
Chapel Hill, NC
Aurora, CO
Amy Waterman, PhD
Joseph Vassalotti, MD
Washington University in St. Louis
St. Louis, MO
New York, NY
Pat Weber, MS, RD, CDE, CSR, LDN
Miguel Vazquez, MD
Genzyme Corporation
UT–Southwestern in Dallas
Springville, AL
Dallas, TX
Matthew R. Weir, MD
Joyce Vergili, MS, RD, CDN, CDE
University of Maryland School of Medicine
Columbia-Greene Dialysis Centers
Baltimore, MD
Catskill, NY
Aurora, CO
Pittsburgh, PA
Augusta, GA
Columbia, MO
– Barnes Jewish Dialysis Center
St Louis, MO
Alan Wilkinson, MD
UCLA Medical Center
Los Angeles, CA
Wolfgang Winkelmayer, MD
Harvard Meical School
Cambridge, MA
Alexander Wiseman, MD
Sciences Center
Denver, CO
Jay B. Wish, MD
Case Western Reserve University
Cleveland, OH
Harvard Meical School
Brookline, MA
Jack Work, MD
Emory University, Dialysis Access Center
Atlanta, GA
p.123
FACULTY
Linda Wright, MHSC, MSW, RSW
University Health Network
Qingyu Wu, MD, PhD
Cleveland, OH
Steven Wu, MD
Boston, MA
Judy Yang, RD, LD
USRC/TDC–PD Clinic
Fort Worth, TX
Alexander S. Yevzlin, MD
Madison, IL
Kim Zuber, PA-C, MSPS
Metropolitan Nephrology
Alexandria, VA
Patrice Zyry, RN, BSN, CNN
Nephros, Inc.
Manalapan, NJ
w
30 East 33rd Street
New York NY 10016
www.kidney.org
www.nkfclinicalmeetings.org
p.125
Innovation
Delivering Biotechnology
Innovation to Nephrology
© 2008 Amgen. All rights reserved.
MC40657-A

April 2–6, 2008 Gaylord Texan, Dallas, Texas Spring `08 Clinical

Transcription

Similar documents

4th of july sendiks - Nehring`s Sendik`s Downer

Oct 2015 - National Kidney Foundation

map of TENKILLER Block A Lot 109

Kidneys

LT Julie Taylor-Cure Bureau of Prisons FMC Devens

MediTrim - Grand Junction`s HCG Weight Loss Clinic

CAMP INVENTION REGISTRATION INFO

AWSF 15 - Road Closure Map Flyer

Untitled - Maple Grove Raceway